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Summary 
Infectious diseases remain some of the most serious health threats facing the world. 
The immune system is equipped to initiate a rapid and specific response to foreign 
invaders of the body, with its ultimate aim being to protect an organism from injury 
and disease. Eicosanoids, including prostaglandins and leukotrienes, are a family of 
lipids that play key roles in inflammation including helping leukocytes fight infection.  
Cells of the innate immune system including tissue macrophages, neutrophils and 
sentinel dendritic cells are major contributors of local eicosanoids. In mammals an 
inflammatory insult will result in a cytokine cascade whereby tumour necrosis factor 
α (TNF-α) is released, followed by interleukin-1β (IL-1β) and then IL-6. Downstream 
of these cytokines, others are released that serve as potent chemoattractants to 
induce migration of neutrophils and macrophages to the site of infection.  
 
It is known that exposure to varying bacterial components results in a different 
profile of lipids and cytokines, and by characterising mediator signals it may be 
possible to define biomarker fingerprints predictive for early bacterial infections. To 
analyse this, a combination of a targeted lipidomic approach and cytokine 
immunoassays were employed to identify neutrophil and macrophage responses to 
individual bacterial components and the whole organism. 
 
Work in this thesis has identified potential markers of bacterial infection, such as 12-
HETE, 14-HDOHE and TNF-α, which, along with future advances, could be used to 
develop novel strategies for clinicians, nurses and primary care staff to analyse 
patients suspected of bacterial infection at the bedside. Work here provides an 
insight into how the eicosanoid and cytokine storms are generated alongside each 
other to accompany classic inflammation during specific bacterial infection. The 
ability to distinguish between species of bacteria causing infection could prove 
invaluable, reducing the time taken to establish the cause of infection, ultimately 
leading to better patient outcomes.  
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1.1 The immune system 
The immune system is an organisation of cells and molecules which have specialised 
roles in defending the host against infection (Delves & Roitt 2000). The human 
immune system develops in order to protect the host from opportunistic invasion of 
microorganisms such as bacteria, viruses, fungi and parasites. It works 
simultaneously to combat and destroy foreign pathogens entering the body, whilst 
also recognising and removing host cells that are damaged, senescent or cancerous. 
The ability of the immune system to be able to distinguish between self and non-self 
is crucial to its success and therefore the survival of the organism.         
 
1.1.1 Innate immunity during infection  
The immune system employs two branches: innate (natural) immunity and adaptive 
(acquired) immunity. Innate immunity is a non-specific cell-mediated response which 
essentially creates a rapid first line of defence against infection (Rittirsch et al. 2008).  
Adaptive immunity also possesses a cellular response alongside an antibody-
mediated (humoral) factor that culminates in a highly specific, efficient response 
(Steinke & Borish 2006). These two components act together in the clearance of 
pathogens.  
 
The innate immune system is intrinsic to the organism, and consists of all the immune 
defences that lack immunological memory (Delves & Roitt 2000). The innate immune 
system is able to target a broad spectrum of pathogenic infections as it does not 
require the production of antibodies. It is composed of a complex network of both 
cellular and molecular factors, which cooperate to counteract any invasion by 
pathogenic microorganisms. The major function of the innate immune system in 
vertebrates includes the recruitment of immune cells to the site of infection through 
the generation of chemical mediators; identification and removal of foreign invasion 
in organs, tissue, blood and lymph by specialised white blood cells, through 
phagocytosis and generation of neutrophil extracellular traps (NETs); activation of 
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the complement cascade to identify bacteria, activate cells and promote clearance 
of antibody complexes; activation of the adaptive immune system and acting as a 
chemical and physical barrier to infectious agents (chemical measures include 
clotting factors in blood and physical factors such as the skin) (Dunkelberger & Song 
2009; Parham 2015) (Figure 1.1).  
 
The cellular components of the innate immune system include the phagocytic cells 
neutrophils and macrophages, which will be discussed in this thesis. A molecular 
aspect of the innate immune response is called complement. This is a complex 
network of plasma and membrane-associated serum proteins, which work in a chain-
like manner whereby each component interacts with the next in a cascade of 
proteolytic interactions to generate subsequently active molecules (Dunkelberger & 
Song 2009). At the end, this results in the accumulation of complement components 
in the membrane of targeted cells to generate pores that kill the cell by causing lysis. 
In a process called opsonisation, certain members of the complement cascade also 
work together with cellular components and mark targeted cells (with complement 
component 3bi (C3bi)) for removal by phagocytic cells. Other complement 
components generate a chemotactic gradient (of complement component 5a(C5a)), 
which recruits phagocytic cells to the vicinity (Dunkelberger & Song 2009). In all 
instances, the resultant cell debris is swept away by the phagocytic foot soldiers of 
the innate immune system, neutrophils and macrophages. In performing these 
functions, complement provides a vital first-line barrier to invading pathogens. 
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Inflammation is an essential host defence mechanism, whereby the innate immune 
system plays a pivotal role, as it mediates the initial response and protects the body 
against pathogenic microorganisms (Russell & Schwarze 2013). Resolution of 
inflammation is an active process, where the production of counter-regulatory 
molecules such as anti-inflammatory cytokines (for example, IL-4, IL-10 and IFN-alpha), 
resolvins, lipoxins and protectins attempt to restore an immunological equilibrium, 
rendering inflammation self-limiting under normal conditions (Cohen 2002; Russell & 
Schwarze 2013).  In early infection circulating neutrophils and macrophages produce and 
respond to pro-inflammatory signals such as cytokines and lipid mediators, facilitating 
their migration to the site of inflammation and allowing them to phagocytose foreign 
pathogens (Strassheim et al. 2002; Lerman et al. 2014). Although these inflammatory 
mediators are important for the host defence, in uncontrolled conditions, damage to the 
host can result when there is an excessive and non-resolving inflammatory response 
(Lerman et al. 2014). This overzealous activity is demonstrated in sepsis for example, 
where homeostatic control declines during an inflammatory response to infection, 
leading to a pro-inflammatory, pro-coagulation state that can cause organ dysfunction 
and death (Russell & Schwarze 2013).      
 
Systemic inflammation is commonly demonstrated amongst the elderly, infants, 
immunocompromised and critically ill patients (Pugin 2012). The concept of the systemic 
inflammatory response syndrome (SIRS) was conceived by Roger C. Bone in 1991 and 
was soon incorporated into the definition of sepsis by the American College of Chest 
Physicians/Society of Critical Care Medicine (ACCP/SCCM) consensus conference (Bone 
et al. 1992a;  Bone et al. 1992c). The host response to injury is termed SIRS when there 
is an over-whelming disproportionate activation of the immune system (Pugin 2012). 
This response can be attributed to various underlying causes, besides that of infectious 
insult, including pancreatitis, ischemia, haemorrhagic shock and multiple trauma and 
tissue injury, thus, the generic term SIRS incorporates both sterile and non-sterile 
inflammation (Bone et al. 1992a; Stoppelkamp et al. 2015; Dellinger et al. 2013).  
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1.1.2 Infectious diseases 
Infectious diseases are disorders caused by pathogenic organisms. Whilst this includes 
bacteria, viruses and many types of fungi, discussion here will focus specifically on 
bacteria. They remain some of the most serious health threats facing the world. 
Successfully combating infections caused by pathogenic organisms is essential for the 
host survival (Das 2011). The immune system is equipped to initiate a rapid and specific 
response to foreign invaders of the body, with its ultimate aim being to protect an 
organism from injury and disease (Tecchio et al. 2014).   
 
The signs, symptoms and severity of the immune response vary depending on the 
organism causing the infection. The human body is equipped with an indigenous 
microbiota, which develops with the host from birth and is subject to complex interplay 
that depends on the host genome, nutrition and life-style (Nicholson et al. 2012).  
Indigenous microbiota are also a source of protection from other invading bacteria. The 
complex host-microbe and microbe-microbe interactions that exist in the body have a 
beneficial role, including the human skin microbiota and the gut microflora. For example, 
the most common clinical isolate of cutaneous microbiota on the body, Staphylococcus 
epidermidis (S. epidermidis), comprises around 90% of the aerobic resident flora (Cogen 
et al. 2008). S. epidermidis promotes cutaneous defence through elicitation of host 
immune responses. Data suggest that S. epidermidis plays a protective role by 
influencing the innate immune response of keratinocytes through toll-like receptor 
signalling (Cogen et al. 2008).  Also, the leading human pathogen Staphylococcus aureus 
(S. aureus) can result in a range of clinical diseases from skin infections to invasive life-
threatening diseases such as sepsis (Cogen et al. 2008). However, despite the usual 
classification of S. aureus as a transient pathogen it may also be considered a normal 
component of the nasal microflora and is not synonymous with infection (Cogen et al. 
2008). Like S. epidermidis, healthy individuals rarely contract invasive infections caused 
by S. aureus where they are in effect acting as commensals rather than pathogens.     
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However, the indigenous microbiota is also a potent source of opportunistic infections 
that arise when the mechanisms that normally confine the microbes to a particular site 
are disrupted (Cho & Blaser 2012). Anaerobic infections following bowel surgery, urinary 
tract infections, chronic respiratory tract infections, catheterisation, dental/gingival 
diseases, and skin conditions, such as surgical site infections and abscesses, come into 
this category. An overuse of antibiotics may disrupt the delicate balance of the 
cutaneous microflora leaving individuals susceptible to pathogens previously kept at bay 
by the existing resident and mutual microbiota. 
 
1.1.2.1 Specific bacterial infections 
1.1.2.1.1 Wounds 
The skin is the body’s largest organ and is the first defence barrier to external threat. The 
surface of the skin is not sterile and is populated with microorganisms, known as normal 
flora. Wound and skin infections represent an invasion of tissues by one or more species 
of microorganisms. The infection triggers the body’s immune system, causing 
inflammation and tissue damage. Tissue injury is followed by the sequential infiltration 
of the wound by neutrophils and macrophages (Brancato & Albina 2011). Neutrophil 
abscess formation is a critical event in the innate immune response against invading 
pathogens and is required for wound resolution and bacterial clearance (Kim et al. 2011). 
Macrophages control the cellularity of wounds through their capacity to induce 
apoptosis and phagocytose a variety of wound cells. Macrophage-targeted cells include 
neutrophils during the inflammatory phase of repair and fibroblasts and endothelial cells 
during its resolution (Brancato & Albina 2011). 
Many infections remain confined to small areas, such as scratches, and can be self-
resolving. Other infections may persist and if untreated, increase in severity and spread 
further into the body. Wounds are breaks in the skin and tissue, which may be superficial 
but also include punctures, burns or through surgical intervention. Chronic wounds are 
a major cause of morbidity, affecting more than 1% of the UK population (Edwards & 
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Harding 2004). Chronic wounds tend to occur in individuals with an increased risk of 
bacterial invasion as a result of trauma or systemic disease such as diabetes mellitus and 
rheumatoid arthritis (Edwards & Harding 2004). Methicillin-resistant Staphylococcus 
aureus (MRSA) is one of the most common causes of wound infections in both hospital 
and community settings (Patel 2007). MRSA infections can range from minor infections 
of the skin to more serious chronic wound infections, contaminated implants, 
pneumonia and sepsis (Patel 2007). The emergence of methicillin resistance is due to 
the acquisition of a transferable DNA element called staphylococcal cassette 
chromosome mec (SCCmec), a cassette (type l-V) carrying the mecA gene, coding 
penicillin-binding protein (PBP) 2a (Ma et al. 2002; Cogen et al. 2008; Foster 2004). 
Through site-specific recombination, the DNA element integrates into the genome.  
Normally, β-lactam antibiotics bind to the PBPs in the cell wall, disrupt peptidoglycan 
layer synthesis and kill the bacterium (Cogen et al. 2008). However, β-lactam antibiotics 
cannot bind to PBP2a, allowing a bacterium containing the mecA gene to survive β-
lactam killing (Foster 2004). S. aureus expresses many virulence factors (ability to cause 
disease; degree of pathogenicity) that contribute to evasion, which are both secreted, 
and cell-surface associated. These include the secretion of chemotaxis inhibitory protein 
of staphylococci (CHIPS) which binds to the formyl peptide receptor and C5a receptor on 
neutrophils, subsequently interfering with neutrophil chemotaxis (de Haas et al. 2004). 
Bacterial extracellular adhesion protein (Eap) is a novel anti-inflammatory factor that 
inhibits leukocyte recruitment by adhering to the intracellular adhesion molecule-1 on 
neutrophils (Indesmith et al. 2003). 
 
1.1.2.1.2 Urinary tract infections, meningitis and pneumonia 
Other common infections which induce inflammatory responses include urinary tract 
infections (UTIs), pneumonia and septicaemia. Escherichia coli (E. coli) represents a 
diverse organism that is normally a harmless commensal but only needs to acquire a 
combination of mobile genetic elements to become a highly adapted pathogen capable 
of causing a range of diseases, from gastroenteritis to infections of the urinary tract, 
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bloodstream and central nervous system. E. coli is the most common Gram-negative 
pathogen in patients of all ages and the most common cause of UTIs (Swami et al. 2012). 
Around 70-80% of health care-acquired infections are attributed to the use of indwelling 
catheters (Nicolle 2014). Urophathogenic E. coli (UPEC) can cause cystitis in the bladder 
and acute pyelonephritis in the kidneys (Croxen & Finlay 2010). The ability to ascend the 
urinary tract from the urethra to the bladder and kidneys reflects exceptional 
mechanisms for evading innate immunity and avoiding clearance by micturition (Croxen 
& Finlay 2010). There are several highly regulated virulence factors that contribute to 
this complex pathogenesis, including secretion of toxins, multiple pili, a polysaccharide 
capsule and biofilm formation (Croxen & Finlay 2010; Nicolle 2014). During infection, the 
resulting influx of phagocytes causes tissue damage, and UPEC attachment and invasion 
results in apoptosis and exfoliation of bladder cells (Croxen & Finlay 2010).  
The most frequent cause of Gram-negative-associated meningitis in new-borns is caused 
by neonatal meningitis E. coli (NMEC) (Croxen & Finlay 2010). Fatality rates can reach up 
to 40% and survivors are often left with severe neurological defects. NMEC is a common 
inhabitant of the gastrointestinal tract, where the bacteria must enter the bloodstream 
and cross the blood-brain barrier into the central nervous system which can lead to 
meningeal inflammation and pleocytosis of the cerebrospinal fluid (Croxen & Finlay 
2010). NMEC survival in the blood is crucial as progression of the disease is dependent 
on high bacteraemia (>103 colony-forming units per ml of blood). Virulence factors which 
help protect the bacteria from host immune defences include possession of an 
antiphagocytic capsule, invasion of macrophages and monocytes prevent apoptosis and 
chemokine release providing a niche for replication (Selvaraj & Prasadarao 2005; 
Sukumaran et al. 2004).            
 
Klebsiella pneumoniae can be carried asymptomatically by individuals in their nose, 
throat and on their skin (Doorduijn et al. 2016). Klebsiella pneumoniae is recognised as 
an important opportunistic pathogen that frequently causes UTIs and pneumonia in 
immunocompromised individuals, neonate and the elderly (Struve & Krogfelt 2003). It is 
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characteristic that most Klebsiella pneumoniae infections are preceded by colonization 
of the patients’ gastrointestinal tract, which is considered the main reservoir of 
transmission of the bacteria (Struve & Krogfelt 2003). One of the main virulence factors 
expressed by Klebsiella pneumoniae is a capsule that protects the pathogen against 
phagocytosis, antimicrobial peptides and complement-mediated lysis (Doorduijn et al. 
2016). The acquisition of antibiotic resistant genes and intrinsic resistance to several 
classes of antibiotics limits the treatment options for infections caused by Klebsiella 
pneumoniae (Doorduijn et al. 2016). There is a current global spread of Klebsiella 
Pneumoniae strains producing Extended Spectrum Beta-Lactamases (ESBLs) and 
carbapenemases (Hawkey & Jones 2009). These enzymes inactivate β-lactams, a class of 
antibiotics that forms the basis of effective treatment for Klebsiella pneumoniae-
infected patients (Doorduijn et al. 2016). As a result, the antimicrobial peptide colistin 
has been reintroduced to treat multi-drug-resistant Klebsiella pneumoniae infections. 
However, there have been reports of colistin-resistant Klebsiella pneumoniae, 
threatening the effectiveness of colistin as a last antibiotic for multi-drug resistant 
Klebsiella infections (Wang et al. 2016). 
 
1.1.2.1.3 Sepsis 
Sepsis arises when the body’s response to an infection damages its own tissues and 
organs. It is a syndrome that comprises physiological, pathological and biological 
abnormalities induced by infection (Singer et al. 2016). The septic response is an 
extremely complex chain of events involving pro- and anti-inflammatory processes, 
humoral and cellular reactions and circulating abnormalities and represents infection in 
its worst case (Limongi et al. 2016). Last revised in 2001, the sepsis definition has been 
used for the past quarter of a century, sculpting the basis of research into sepsis and 
propelling the development of its clinical recognition and management (Levy et al. 2003; 
Gotts & Matthay 2016). However, substantial advances made within the pathobiology 
(changes in organ function, immunology, cell biology, circulation, morphology and 
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biochemistry), management and epidemiology of sepsis have called for a re-evaluation 
of definitions (Singer et al. 2016).   
 
In February 2016, the European Society of Intensive Care Medicine and the SCCM 
published a new consensus definition of sepsis and related clinical criteria (Table 1.1).  
Sepsis is now defined as life-threatening organ dysfunction caused by a dysregulated 
host response to infection (Singer et al. 2016). In the United Kingdom (UK) there are an 
estimated 150,000 cases of sepsis each year, with a survival rate between 30-50%, 
resulting in 44,000 deaths; claiming more lives than breast, bowel and prostate cancer 
combined (Daniels 2009; Daniels 2011). In 2011, the Centre for Maternal and Child 
Enquiries (CMACE) found sepsis to be the commonest direct cause of maternal death in 
the UK (Cantwell et al. 2011). Alongside the mortality associated with sepsis also lies the 
social and economic impact. This life-threatening condition has a major bearing on 
healthcare resources and expenditure and fuels the need for early detection of infection.   
 
The specific species of bacteria discussed throughout section 1.1.2.1 will be employed in 
this thesis to look for initial marker profiles of infection. They were chosen as they are 
highly pathogenic and represent some of the most common causes of bacterial 
infections. Early detection of infectious diseases plays a crucial role in all treatment and 
prevention strategies. Rapid and accurate identification of the underlying agent using 
diagnostic testing is essential to select the correct control measure. 
 
1.1.2.2 Clinical diagnosis of specific infections 
Bacterial infections can be challenging to diagnose, this is because clinical presentation 
of infections from different causative agents can be similar. For example, in certain 
instances it may be difficult to differentiate viral from bacterial infections. Inflammatory 
states, such as trauma, pancreatitis, transplant rejects and vasculitis, might also have 
clinical presentation similar to that for an infection (Simon et al. 2004). Treating viral 
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illnesses or non-infective causes of inflammation with antibiotics is not only ineffective, 
but also contributes to the development of resistance (WHO, 2000), increases costs and 
adding to the risk of toxicity and allergic reactions. Studies carried out by the World 
Health Organisation (WHO) found that for every 100 respiratory infections, only 20 
required antibiotic treatment (WHO, 2000). 
The most accurate way to diagnose bacterial infection is by culture (Simon et al. 2004). 
Laboratory methods for detecting pathogens from blood cultures or wounds require 
long incubation times that do not support rapid detection and fast decisions for selecting 
the most appropriate therapeutic interventions (Wolk et al. 2009). It is now accepted 
that early recognition and therefore appropriate intervention of therapy are key to 
preventing patient deterioration, which in severe cases may lead to death (Dellinger et 
al. 2013). The significant mortality and rising economic costs of critically ill patients are 
driving research towards gaining a greater understanding into basic immunity, in turn 
creating a more effective therapeutic approach (Osuchowski et al. 2007). Diagnostic 
biomolecular markers could simplify and accelerate diagnosis, verification and timely 
correct therapy for bacterial infections. Current diagnostic markers in used are discussed 
later in this chapter. One potential target for this is through the use of immune mediators 
secreted by innate immune cells. 
 
1.1.3 White blood cells 
White blood cells (WBCs) were first divided into subpopulations based on differences in 
their morphologies by Paul Ehrlich in 1898 (Figure 1.2) (Werber 1986). Ehrlich described 
one subgroup to appear to contain multiple clustered nuclei as opposed to a single 
nucleus. However, upon further examination, he observed the appearance of nuclear 
‘lobes’, which remained connected by fine tethers and proceeded to call them ‘cells with 
polymorphous nuclei’ (Ehrlich 1898). This group of cells became the focus of much 
attention and were later renamed by the Russian scientist Ilya Mechnikov as  
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 ‘polymorphonuclear leukocytes’ (PMNLs) in 1905. PMNLs is a term that is still used to 
describe this subpopulation of WBCs. Following pioneering studies by Mechnikov came 
the discovery of macrophages and the proposal of phagocytes and phagocytosis 
(Metchnikov 1939).  
 
Although WBCs account for only 1% of blood, they are important components of the 
blood system and their impact is significant. Along with WBC, the peripheral blood 
consists of multiple cell types, including red blood cells (erythrocytes), platelets, as well 
as a liquid component known as plasma (Figure 1.3). All WBCs are derived from 
multipotent cells in the bone marrow (Figure 1.4), known as hematopoietic stem cells, 
and are stored in the blood and lymphatic tissues. Also called leukocytes, WBCs are cells 
of the immune system and are essential in the defence against infectious diseases and 
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1.1.4 Phagocytes   
Phagocytes (from the ancient Greek – phagein, meaning ‘to devour’ and kytos, meaning 
‘cell’), are a class of cells that help protect the host by engulfing any potentially 
dangerous cell debris and foreign microorganisms. Phagocytosis (from the ancient Greek 
phagein, kytos and osis meaning ‘process’), is the mechanism by which, namely 
phagocytes, internalise foreign invaders of the body within compartments known as 
phagosomes and proceed to degrade them (Metchnikov 1905; 1939; Silva & Correia-
Neves 2012). Other lower organisms also utilise phagocytosis mainly for acquisition of 
nutrients (Silva & Correia-Neves 2012).  
 
Neutrophils and macrophages are leukocytes that are collectively known as phagocytic 
cells. Vertebrates have well established phagocytic cells, which are crucial to their innate 
immune response to invading pathogens. They also represent the two innate immune 
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cell types closely linked with the extreme inflammatory response characterising severe 
sepsis (Strassheim et al. 2002).   
 
1.1.4.1 Neutrophils 
Neutrophils, also known as polymorphonuclear neutrophils (PMN) due to their multi-
shaped nuclei, are the most abundant cell type contributing approximately 40-80% of 
the WBCs in circulation (Stearns-Kurosawa et al. 2011). They are continuously generated 
in the bone marrow from the myeloid hematopoietic system (Kolaczkowska & Kubes 
2013), and are produced at around 108 cells/minute (Prince et al. 2011). Neutrophils are 
short-lived, terminally differentiated cells with a circulating half-life of 6-8 hours, hence 
their rapid rate of production (Summers et al. 2010). They are also the first line of 
defence against infection during innate immunity, often being the first leukocytes to 
move towards inflammatory lesions to perform host defence mechanisms, including 
production of reactive oxygen species (ROS), phagocytosis and neutrophil extracellular 
traps (NETs) (Waksman et al. 1990; Clark et al. 2007). When activated by a microbial or 
inflammatory stimulus, such as various cytokines and growth factors as well as bacterial 
products, their longevity increases by several fold ensuring the presence of primed 
neutrophils at the site of inflammation (Summers et al. 2010; Kolaczkowska & Kubes 
2013). 
 
Although neutrophil production is constitutive during homeostasis, an increased 
neutrophil response is often essential for host survival (Huo et al. 2017). During SIRS and 
severe sepsis, for example, there can be up to a 10-fold increase in the production of 
these immune effector cells in the bone marrow, and their recruitment into the host 
circulation (Drifte et al. 2013).      
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1.1.4.2 Macrophages  
Monocytes circulate in the blood, bone marrow and spleen (Geissmann et al. 2010).  
Under normal conditions circulating blood monocytes are short-lived, undergoing 
spontaneous apoptosis on a daily basis (Parihar et al. 2010). Upon stimulation, for 
example through infection, monocytes are rapidly recruited from the blood to the tissue 
where they differentiate into tissue macrophages (Daigneault et al. 2010). Once 
differentiated these long-lived cells (life-span ranging several days to over a week) have 
considerable plasticity, whereby the environmental cues they receive dictate their 
functional phenotype (Figure 1.5) (Daigneault et al. 2010; Leavy 2011). For example, 
when in a proinflammatory environment, macrophages are driven towards a classically 
activated M1 state, characterised by the production of pro-inflammatory cytokines (such 
as TNF-α, IL-1β, IL-6, IL-8) and are modulators of cellular behaviour. Pro-inflammatory 
cytokines can directly or indirectly regulate inflammatory reactions through adhesion 
molecules or other cytokines (Anderstam et al. 2012).  When in the presence of specific 
regulatory/anti-inflammatory cytokines (including interleukin-4 (IL-4), interleukin-13 (IL-
13)) they are termed alternatively activated M2 macrophages, which can be further 
subdivided to accommodate similarities and differences between IL-4 (M2a), immune 
complex + toll like receptor (TLR) ligands (M2b) and interleukin-10 (IL-10) (M2c) 
(Martinez & Gordon 2014; Genin et al. 2015). Macrophages not only contribute to innate 
immune responses but they also form the bridge into adaptive immunity via antigen 
processing (Daigneault et al. 2010). 
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1.1.4.3 Neutrophil and macrophage infiltration 
Inflammatory leukocytes, including neutrophils and macrophages, are equipped with 
surface receptors including a specific family of pattern recognition receptors (PRRs) 
called toll-like receptors (TLRs) (Yang et al. 2014). These transmembrane receptors 
recognise pathogen-associated molecular patterns (PAMPs), which are macromolecular 
motives from microorganisms (Schulte et al. 2013). Examples of PAMPs include 
lipopolysaccharide (LPS), which is only present in Gram-negative bacteria and a TLR4 
agonist, flagellin, which is the major component of the bacterial flagellar filament and a 
TLR5 agonist, and bacterial lipoproteins such as pam3CSK4 and FSL-1, which are TLR1/2 
and TLR6/2 agonists, respectively (Table 1.1) (Schulte et al. 2013).  Binding of the PAMPs 
to the cell surface TLRs initiates a signal transduction cascade, leading to the activation 
of nuclear factor-κB (NF-κB) and subsequent translocation into the nucleus inducing 
cytokine, chemokine, nitric oxide and lipid mediator synthesis (Clark et al. 2011; Schulte 
et al. 2013). In neutrophils and macrophages these mechanisms of defence, including 
the synthesis of a range of effector cytokines and chemokines, such as tumour necrosis 
factor (TNF) and interleukin-1, are major contributors to the pathophysiological change 
in infectious and inflammatory diseases including septic shock (Cohen 2002).   
 
Neutrophils and macrophages also biosynthesise an array of lipid mediators of 
inflammation derived from fatty acids including arachidonic acid (AA), known as 
eicosanoids and also perform other host defence mechanisms including phagocytosis, 
generation of oxygen-derived free radicals and the release of proteolytic enzyme (St-
Onge et al. 2007).    
 
PAMPs are recognised by pattern recognition receptors. Bacterial proteins are N-
formylated, and the formylated peptides activate chemoattractant formylated-peptide 
receptors (FPRs) (Zhang et al. 2010). These bacterial stimuli activate neutrophils through 
the formylated peptide receptor-1 (FPR-1) on their surface, subsequently mediating an 
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inflammatory response through the release of the immune modulators MMP-8 and IL-8 
and phosphorylation of several MAP kinase enzymes (Calfee & Matthay 2010). The 
principle ligands for FPR1 are bacterial and mitochondrial formylated peptides, which 
are actively secreted by invading pathogens or passively released from apoptotic host 
cells after tissue injury (Dorward et al. 2015).  As mentioned, TLRs respond to many 
PAMPs including the bacterial CpG DNA that stimulates TLR9. Mitochondria provide a 
link between internal and external triggers of the innate immune response, where 
mitochondrial DNA and bacterial DNA share many similar structural motifs (Calfee & 
Matthay 2010). The mitochondrial genome (mtDNA) contains the CpG DNA repeats and 
codes for formylated peptides because they have evolved from saprophytic bacteria to 
endosymbionts to organelles (Zhang et al. 2010; Taanman et al. 1999). The 
mitochondrial formyl peptides act as neutrophil chemoattractants and activators of 
related cell lines (Rabiet et al. 2005). Formylated peptides, such as the synthetic peptide 
N-formylmethionyl-leucyl-phenylalanin (fMLP, also known as fMLF), stimulates a 
bacterial challenge through G-protein-coupled receptors FPR-1 and FPRL-1, with high 
and low affinity, respectively (Zhang et al. 2010). Alternative neutrophil activating agents 
include LTB4, PAF, C5a and IL-8. 
Activation of neutrophils by G-protein-coupled receptors causes an increased 
intracellular calcium concentration ([Ca2+]i) (Hauser et al. 2000), heterologous and 
homologous G-protein-coupled receptor desensitisation (Tarlowe et al. 2003) and 
activates MAP kinases (MAPKs) (West et al. 2007). Mitochondrial damage associated 
molecular patterns from human myocytes induce human neutrophil [Ca2+]i fluexes equal 
to 1 nM fMLP (Zhang et al. 2010). During infection, pathogens target and destroy host 
tissue with the synchronised released of both bacterial- and host-derived formylated 
peptides, therefore connecting FPR1 to both the infective and sterile inflammatory 
processes (Dorward et al. 2015). 
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Pam3CSK, FSL, Zymosan. TLR1,2,6 Gram-positive bacteria (e.g S. 
aureus) 
LPS, Lipid A TLR4 Gram-negative bacteria (e.g. E. coli) 
Flagellin TLR5 Bacteria, Flagellum 
dsRNS TLR3 Virus 
ssRNA TLR7,8 Virus 
CpG DNA TLR9 Bacteria, DNA 
 
1.2 Therapeutic agents 
Antimicrobial resistance is defined as the ability of an organism to resist the action of an 
antimicrobial agent to which it was previously susceptible (Beceiro et al. 2013). 
Antibiotic resistance is an ever-increasing problem, and one of the greatest healthcare 
challenges currently faced, particularly within the intensive care unit (ICU) patient cohort 
(Fullerton et al. 2014). There are a diminishing number of antimicrobial agents that 
remain effective against common pathogens, both Gram-positive (primarily MRSA) and 
Gram-negative (Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae) 
(Harbarth et al. 2003). The World Health Organization stated that, “Antimicrobial 
resistance...threatens the effective prevention and treatment of an ever-increasing 
range of infections caused by bacteria.... A post-antibiotic era—in which common 
infections and minor injuries can kill—far from being an apocalyptic fantasy, is instead a 
very real possibility for the 21st Century.” (WHO 2014).   
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Antibiotics are available to effectively inhibit bacterial cell wall synthesis, protein 
synthesis and DNA replication, which include penicillins, tetracyclines and rifampicin 
(Neu 1992). The microbes that were once susceptible are becoming even more difficult 
to combat as treatment is compromised by the development of antibiotic-resistant 
strains of microbial pathogens (Mazel & Davies 2016). A variety of biochemical processes 
are involved to enable bacterial resistance to antibiotics, these include chromosomal 
mutations, inductive expression of latent chromosomal genes or acquisition of genetic 
material through transformation (exchange of DNA), transduction (bacteriophage), or 
conjugation by plasmids (extrachromosomal DNA) (Mazel & Davies 2016; Neu 1992).        
 
Administration of antibiotics, often to a presumed pathogen, is the single most 
important life-saving measure in diseases such as bacterial meningitis and sepsis, 
subsequently followed by supportive care (Brouwer et al. 2010; Hutchins et al. 2014). It 
is well understood that rapid, appropriate antibiotic treatment is paramount and any 
delay can reduce survival (Garnacho-Montero et al. 2006; Ferrer et al. 2009). A range of 
studies carried out on infected and septic patients showed that inappropriate 
antimicrobial therapy was a constant predictor of poor outcomes (Harbarth et al. 2003; 
Garnacho-Montero et al. 2003). One retrospective review carried out between 1989 and 
2004 of 2,700 Canadian patients admitted with septic shock found that 50% received 
effective antibiotic treatment within six hours of the onset of hypotension (Kumar et al. 
2006). Patient survival rate has been associated with nearly a 12% reduction for each 
hour antibiotic administration was delayed, after the onset of shock (Kumar et al. 2006). 
A more recent analysis in 2014 from 18,000 patients admitted with septic shock or 
severe sepsis from 165 ICUs across Europe, USA and South America, found a correlation 
in steadily increasing hospital mortality as the delay in antibiotic administration 
increased (Ferrer et al. 2014). 
 
The incidence of urinary tract infections (UTIs), skin and soft tissue infections, 
pneumonia and sepsis are amongst conditions increased due to the changing 
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epidemiology of bacterial infections (Robson & Daniels 2008). It is also due to an 
increasingly older population displaying multiple comorbidities, in turn leading to an 
increase in hospital-acquired infections (through the use of catheterisation and 
cannulation). Alongside this, is also antibiotic resistance, due to the over-prescribing of 
antibiotics or patient misuse (Dellinger et al. 2013; Greenhow et al. 2014).  
 
From this, it is evident that there is an ever-increasing need for the development of 
assays that are rapid, sensitive and specific for the identification of bloodstream 
pathogens, which will in turn allow for timely, appropriate and accurate antimicrobial 
therapy (Choi et al. 2013).   
 
1.3 Bacterial pathogens and innate immunity  
The human body contains bacteria both inside and on the surface, especially on the skin 
and the mucous membranes (Kendall & Nicolaou 2013). Many of these bacteria are 
innocuous, several are beneficial, and some are even necessary. However, other 
bacteria, which are considered as pathogens, are able to colonise, invade and damage 
the host and thus cause illness. Pathogenicity describes the ability of an agent to cause 
disease, and the pathogenic bacteria possess several factors that enable them to 
enhance their virulence (i.e., the degree of pathogenicity) (Beceiro et al. 2013). It is 
common for most pathogens to make use of a combination of two properties to cause 
disease: i) toxicity, the degree to which a substance causes harm, and ii) invasiveness, 
the ability to penetrate into the host and spread (Madigan et al. 2009). The final 
consideration that forms the balance of an infectious disease process will depend on the 
virulence or pathogenicity of the microbe alongside the host status (in relation to risk 
factors such as immune status, age, diet and stress), which determines the host 
susceptibility to infection (Beceiro et al. 2013). 
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The human host and bacteria have co-evolved over millions of years, during which 
pathogenic bacteria have altered their virulence to adapt to host defence systems 
(Beceiro et al. 2013). This contrasts with the relatively recent evolution and spread of 
antimicrobial resistance, which has occurred mainly in the last 50 years since antibiotics 
were first used. However, despite these differences, timescales of evolution of these 
processes share some common characteristics, such as the ability to survive under 
adverse conditions (host defence systems and antimicrobial therapies), the transfer of 
virulence and resistance factors between species by gene transfer, and the fact that 
antibiotic resistance is often associated with infection and therefore is also related to 
virulence (Akira et al. 2006; Beceiro et al. 2013). Other characteristics that are common 
in both virulence and resistance include the direct involvement of porins (outer 
membrane protein channels, which allow diffusion of hydrophilic molecules) (Tsai et al. 
2011), cell wall alterations (Moya et al. 2008), and two-component systems that activate 
or repress the expression of various genes (Yeung et al. 2011). 
 
Opportunistic pathogens are not able to produce infection in healthy individuals as they 
lack the necessary mechanisms of toxicity and invasiveness that enable primary 
pathogens to overcome the host immune system (Beceiro et al. 2013). However, in some 
cases such as individuals who are immunocompromised, have indwelling catheters, 
contaminated implants, hip replacements, opportunistic pathogens can produce 
infection, which can be prevented mainly with use of antimicrobial therapies.      
 
1.3.1 Toll-like receptors as pattern-recognition receptors 
Vertebrates are constantly threatened by the invasion of microorganisms. The host has 
evolved systems of immune defence to eliminate infecting pathogens in the body. As 
previously stated, the initial innate immune system recognises signature molecules of 
pathogens via PRRs. To date, several classes of PRRs including, TLRs, retinoic acid-
inducible gene (RIG)-l-like receptors and nucleotide-binding oligomerization domain 
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(NOD)-like receptor (NLRs) have been identified. PRRs possess common characteristics, 
which are i) recognition of microbial components known as PAMPs, ii) constitutive 
expression of PRRs in the host and detection of the pathogen regardless of the life-cycle 
stage, and iii) PRRs are germline-encoded, nonclonal, expressed on all cells of a given 
type and independent of immunological memory (Akira et al. 2006).  
 
The study of innate immunity in mammals amplified after the discovery of Toll and the 
role of this protein in the innate immune defence of Drosophila melanogaster (Philpott 
& Girardin 2004). It was initially identified as a gene product essential for the embryonic 
development of the fly (Anderson et al. 1985), before later being shown to play a critical 
role in the antifungal response of flies (Lemaitre et al. 1996) and then Gram-positive 
bacterial infections (Lemaitre et al. 1997). The first discovery of Toll-related proteins in 
mammals was in 1998 (Rock et al. 1998) which was rapidly followed by the 
demonstration that the mammalian TLR4 was the long-sought after signalling receptor 
in a protein complex responsible for recognition of LPS and cellular responses leading to 
this event (Poltorak et al. 1998).  
 
TLRs are transmembrane proteins with an extracellular domain which consists of 
leucine-rich repeats (LRR) and a cytoplasmic domain called the Toll/IL-1 receptor or TIR 
domain (Figure 1.6)(Kumar et al. 2009). Stimulation of the TLR ligand leads to the 
recruitment of adaptor proteins containing the TIR domain, such as myeloid 
differentiation factor 88 (MyD88), to the cytoplasmic portions of the TLRs through 
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homophilic interaction of their TIR domains (Akira et al. 2006). This triggers a 
downstream signalling cascade and drives the expression of many genes, many of which 
are involved in the proinflammatory response (Philpott & Girardin 2004). 
 
1.3.2 Bacterial recognition by TLRs 
In January 2018, the world health organisation (WHO) reported the most common 
antibiotic-resistant bacteria were Escherichia coli, Klebsiella pneumoniae, 
Staphylococcus aureus and Streptococcus pneumoniae, followed by Salmonella species 
(spp). Bacteria can be classified into two distinct groups according to the different 
staining characteristics of their cell walls, namely Gram-positive and -negative bacteria 
(Figure 1.7). The names come from the Danish physician Hans Christian Gram, who 
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developed the staining technique (Claus 1992). Gram staining involves three processes, 
staining the pathogen with a water-soluble dye called crystal violet followed by 
decolourisation and counterstaining usually with safranin. Due to differences in the 
thickness of the peptidoglycan layer in the cell membrane between Gram-positive and -
negative bacteria, Gram-positive bacteria (with a thicker peptidoglycan layer) retain the 
crystal violet stain during the decolourisation process; which uses organic solvents such 
as ethanol or acetone as the decolouriser. While the Gram-negative bacteria lose the 
crystal violet stain and are instead stained red by the counterstain safranin in the final 
staining process. Since safranin is lighter than crystal violet, it does not disturb the purple 
colour in Gram-positive cells.  
 
It is some of these unique cell wall components that act as PAMPs, which are recognised 
by individual TLRs and stimulate the immune cells. LPS, also known as endotoxin, is 
generally perceived as the most potent immunostimulant among these cell-wall 
components (Akira et al. 2006). The structure of LPS molecules vary in their phosphate 
patterns, numbers of acyl chains and fatty-acid composition within different bacteria 
(Akira et al. 2006). Lipid A is a lipid segment of LPS that is responsible for most of the 
pathogenic events associated with Gram-negative bacterial infections such as endotoxic 
shock. LPS from Gram-negative bacteria associates with LPS binding protein (LBP), 
present in the bloodstream, before subsequently binding to CD14, a 
glycosylphosphatidylinositol (GPI-linked protein expressed on the surface of phagocytes 
(Akira et al. 2006). LPS is then transferred to MD-2, which is associated with the 
extracellular portion of TLR4, followed by oligomerisation of TLR4 (Poltorak et al. 1998; 
Shimazu et al. 1999). 
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Lipoproteins and peptidoglycan (PTG) are potent immunostimulants present in both 
Gram-positive and -negative bacteria. The Gram-positive bacterial cell wall contains 
components that also stimulate the innate immune system. These bacteria do not 
contain LPS, however, they do have lipoteichoic acid (LTA) which appears to function in 
a similar manner as an immune activator (Merly & Smith 2005). TLR2 plays a major role 
in Gram-positive bacterial detection and is involved in the recognition of microbial 
components including lipoproteins, peptidoglycan and LTA (Merly & Smith 2005). TLR2 
appears to interact alongside TLR1 and TLR6 to form a collaboration, which discriminates 
between subtle changes in the lipid portions of the lipoproteins (Merly & Smith 2005; 
Akira et al. 2006).  
 
Another potent activator of the innate immune response is flagellin, the major protein 
constituent of the bacteria flagella, the motility apparatus used by both Gram-positive 
and -negative microbial pathogens (Hayashi et al. 2001). TLR5 is the receptor responsible 
for the detection of flagellin and specifically recognises the constant domain D1, which 
is comparatively conserved amongst different species (Hayashi et al. 2001).  
 
TLR9 regulates the recognition of the unmethylated 2’-deoxyribo (cytidine-phosphate-
guanosine) (CpG) DNA motifs found in bacteria and viruses (Krieg 2002). The methylated 
CpG motif does not activate mammalian innate immune cells (Akira et al. 2006). CpG-
DNA displays potent immunostimulatory activities including induction of inflammatory 
cytokines and Th1 immune responses (Akira et al. 2006). The particular DNA sequence 
that provokes an immune response varies between species (Merly & Smith 2005). As 
TLR9 resides in the endosome, the bacterial DNA must be transported to this 
intracellular compartment where the acidic and reducing conditions lead to the 
degradation of the double-stranded DNA into multiple single-stranded CpG-motif-
containing regions that subsequently interact with TLR9 (Latz et al. 2004; Ahmad-Nejad 
et al. 2002). 
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1.4 Eicosanoids  
The term ‘eicosa’ (meaning twenty in Greek) represents the number of carbon atoms in 
arachidonic acid (Cook 2005). Eicosanoids, including prostaglandins (PGs) and 
leukotrienes (LTs) are a family of lipid signalling molecules generated by all cutaneous 
cell types and contributing to homeostatic processes and inflammatory responses 
associated with injury, allergy, infection and other acute or chronic conditions (Harizi et 
al. 2008; Nicolaou 2013). The major precursor of these oxygenated compounds is the 
fatty acid derivative arachidonic acid (AA) (Cook 2005). Eicosanoids are primarily 
generated through an oxidative pathway from AA, but are also known to be produced 
through pathways from eicosapentaenoic and dihomo-γ-linolenic acids (Levin et al. 
2002; Wada et al. 2007).   
 
Innate immune cells including tissue macrophages, sentinel dendritic cells and 
neutrophils are major producers of local eicosanoids, exerting their effect in both an 
autocrine and paracrine fashion (Cook 2005; St-Onge et al. 2007). There is increasing 
evidence to suggest that eicosanoids collaborate with other signalling mediators, 
particularly cytokines and chemokines, playing a vital role in the modulation of 
physiological processes in both homeostatic and inflammatory conditions (Cook 2005; 
Stafford & Marnett 2008).    
 
The biosynthesis of eicosanoids is dependent upon the availability of free AA (Figure 1.8) 
(Harizi et al. 2008). Tissue exposure to physiological and pathological stimuli, for example 
growth factors or cytokines, causes the release of AA from the phospholipid cell 
membrane, in a Ca2+-dependant manner; catalysed by phospholipase A2 (PLA2) and it is 
subsequently converted into different eicosanoids (Harizi et al. 2008; St-Onge et al. 
2007). There are three main pathways that enzymatically metabolise AA;   
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cyclooxygenase (COXs), lipoxygenase (LOXs) and cytochrome P450 epoxygenase (Dennis 
& Norris 2015). 
 
Reactive oxygen species are generated under oxidative stress due to an imbalance 
between pro-oxidant and antioxidant states. Free-radical-induced peroxidation of AA, 
leads to the non-enzymatic formation of a family of prostaglandin-like compounds called 
isoprostanes (IsoPs) (Comporti et al. 2008). Once formed, they are cleaved by 
phospholipases and free IsoPs are released from tissues into circulation, where they are 
partially metabolised (Comporti et al. 2008). In general, IsoPs are considered as ‘gold 
standard’ biomarkers for oxidative stress and, in particular, lipid peroxidation (Comporti 
et al. 2008). IsoPs are mainly excreted in urine; several studies have shown that levels of 
IsoPs increase in certain disorders or experimental conditions such as Alzheimer’s 
disease and chronic obstructive pulmonary disease (Helmersson et al. 2009; Praticò et 
al. 2002).  
 
The COX pathway exists in two isoforms, COX-1 (encoded by a constitutively expressed 
gene) and COX-2 (encoded by an immediate early response gene), and responsible for 
the production of prostaglandins (PGs), prostacyclin and thromboxanes (TXs) (Chang et 
al. 2005). The cytochrome P450 epoxygenase pathway produces 
hydroxyeicosatetraenoic acid (HETEs) and epoxides (Harizi et al. 2008).  There are several 
LOX enzymes (5-LOX, 12-LOX, 15-LOX) that convert AA into diverse 
hydroperoxyeicosatetraenoic acids (HPETEs) and HETEs (Harizi et al. 2008). Cells are 
highly selective as to the specific eicosanoids that they synthesise, however, the 
amounts generated are altered by the activation state and the physiological conditions 
of the specific tissues in which they reside (Dennis & Norris 2015).    
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1.4.1 LOX products  
LOX are the main enzymes that generate lipid signalling molecules (Massey & Nicolaou 
2013). The first step of leukotriene (LT) biosynthesis involves the conversion of AA into 
HETEs by LOX enzymes (Harizi & Gualde 2005).  Activation of 5-LOX, in neutrophils, can 
subsequently lead to the conversion of 5-HETE into leukotriene LTA4 which is a precursor 
of LTB4, cysteinyl-LTs (CysLTs); including LTC4, LTD4 and LTE4, and lipoxins (LXs) (Bäck 
2007). The numbers denoted on the enzymes are derived by the number of the carbon 
on which the alcohol group is attached to the molecule; the products are named in the 
same way. 5-LOX, 12-LOX and 15-LOX convert AA into 5-HETEs, 12-HETEs and 15-HETEs, 
respectively (Figure 1.9a). Two separate classes of LTs are formed based on structural 
differences; firstly, cysLTs form one group based on the cysteine residue in the structure, 
secondly, LTB4 contains two hydroxyl groups instead of amino acids (Brink 2007). 5-LOX 
is expressed by neutrophils and mast cells, 12-LOX is expressed in monocytes and 
platelets and 15-LOX is expressed by macrophages under certain circumstances and 
eosinophils (Clark et al. 2011; Alanne-Kinnunen et al. 2014). 
 
Leukotrienes are potent mediators of inflammation and can initiate, amplify or dampen 
inflammatory responses (Bäck 2007). Generally, during inflammation eicosanoids will be 
present and the LOX products act as modifiers of vascular permeability (LTs), 
chemoattractants (LTB4), and induce smooth muscle cell proliferation (CysLTs) 
(Parameswaran et al. 2002, Bäck 2007).  Lipoxins (LXs) play an active role in promoting 
resolution of inflammation whereby they control entry of neutrophils to sites of 
inflammation (Schwab & Serhan 2006). 
 
The biological effects of LTB4 are primarily targeted towards inflammatory cells. LTB4 is 
a potent chemotactic agent for neutrophils and macrophages. With neutrophils, LTB4 
also increases the production of toxic oxygen species and release of granule enzymes 
and up-regulates membrane adhesion molecule expression (T Lämmermann et al 2013). 
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LTB4 stimulates action and cytokine release; on macrophages and lymphocytes, and is 




CysLTs are mediators associated with allergic inflammation; they are potent 
bronchoconstrictors, powerful inducers of vascular leakage and are important 
inflammatory mediators for asthma (Okunishi et al. 2004).  Upon exposure to a specific 
allergen, LTC4, LTD4 and LTE4 are released from the lung tissues of an asthmatic subject, 
which would suggest a pathophysiological role in immediate hypersensitivity reactions 
(Samuelsson et al. 1987).  Specifically, LTC4 and LTD4 have been shown to be potent 
inducers of airway obstruction (Holroyde et al 1981).  While LTC4 and LTD4 are very short 
lived in vivo, LTE4 is stable and the only cysLT excreted in the urine (Drazen et al 1992). 
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1.4.2 COX products 
PGs are a group of structurally related molecules that are generated by cells in response 
to stimuli, and regulate cellular growth, differentiation and homeostasis (Figure 1.9b) 
(Shibata et al. 2002). PGs are derived from fatty acids, namely AA, which is firstly 
converted into an unstable endoperoxide intermediate by cyclooxygenases and 
subsequently converted into one of several related products through the action of 
specific PG synthetases, these products include PGD2, PGE2, PGF2α, prostacyclin (PGIs) 
and thromboxane A2 (Shibata et al. 2002; Dennis & Norris 2015). PGs are physiologically 
present in body fluids, however, arachidonate metabolism is highly increased under 
several pathological conditions, including hyperthermia, infection and inflammation 
(Shibata et al. 2002).  
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1.4.3 Measuring eicosanoids 
The quantification of eicosanoids must be carefully characterised, as they are chemically 
and biologically complex lipid mediators. There is a marked interest in the development 
of high-throughput analytical methods for targeted determination of eicosanoid panels 
for clinical use (Ferreiro-Vera et al. 2011; Dennis & Norris 2015). Quantitative analysis of 
eicosanoids in biological samples calls for detection techniques that should be highly 
accurate, sensitive and specific. There are several approaches that can be used to 
determine these mediators, including immunoassays (ELISA), high-performance liquid 
chromatography-ultraviolet detection (HPLC-UV) (trienes e.g. leukotrienes (235nm) and 
dienes e.g HETE (270nm) absorb at different UV maxima due to different 
chromophores), Gas chromatography-tandem mass spectrometry (GC-MS/MS) and 
HPLC-MS/MS. ELISA is a plating technique that passively binds antibodies. However, 
eicosanoids are lipids that are poorly immunogenic and so these ELISAs are not as 
sensitive or specific as ELISAs for proteins such as cytokines (Morgan et al. 2010). The 
use of these immunoassays also carries a degree of immunological cross-reactivity 
among commercially available eicosanoid antibodies (Ferreiro-Vera et al. 2011). To 
overcome such problems, techniques such as solid-liquid transfer to an organic solvent 
for tissue and liquid-liquid or solid phase extraction (SPE) for biofluids can be used to 
isolate eicosanoids from proteins. Additionally, a chromatographic step would be 
required for individual separation of eicosanoids to avoid immunological cross-reactivity 
(Ferreiro-Vera et al. 2011).  
 
Lipidomics-based assays can be described as being ‘targeted’, where lipids to be 
monitored are known before the analysis. An example of a targeted assay is the multiple 
reaction monitoring (MRM) method described below. The shotgun approach is a 
lipidomics-based assay that is described as ‘untargeted’ and is a more exploratory, 
qualitative assessment of the lipids (Harkewicz & Dennis 2011). A mass spectral full scan 
will search new mass-to-charge ratio peaks, often used when hoping to detect novel lipid 
species.  
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HPLC with UV detection is mostly useful when dealing with a relatively large amount of 
eicosanoids that are present in a clean biological sample (containing conjugated doubles 
bonds, such as mono-, di-, or tri-hydroxy lipids from the LOX pathway) (Maskrey & 
O’Donnell 2008). Also, distinguishing isomers such as 5- and 15-HETE with UV is difficult. 
However, very specific separation can be achieved using HPLC to separate on the basis 
of retention time followed by MS analysis of the analyte, therefore, HPLC-MS/MS is a 
highly-sensitive technique (Maskrey & O’Donnell 2008). Coupling liquid chromatography 
to the mass spectrometer and employing MRM mode (see Figure 1.10 for detailed 
schematic of MRM), is highly selective and highly sensitive. If a specific molecule is 
eluting from the chromatographic column at any time during the analysis, its specified 
MRM pair can be detected and recorded (Harkewicz & Dennis 2011). The development 
of complex methods have shown that hundreds of lipid mediators, such as eicosanoids, 
can be monitored through their defined MRM pairs in a single analysis lasting only 20 
min (Harkewicz & Dennis 2011). The ever-expanding field of lipidomics has provided 
fertile ground to discover and characterise novel lipid species (Clark et al. 2011), and 
mass spectrometry will continue to play a vital role in this area.  
  
1.5 Cytokines  
Cytokines are intracellular signalling proteins (defined as >0.5kDa and <30kDa) essential 
for the activation, differentiation and control of the immune system (Hiscott & Ware 
2011; Anderstam et al. 2012). Cytokines, including interleukins, interferons, 
lymphokines, adipokines and chemokines, can work alone or in conjunction with each 
other, have multiple functions and act on several different cell types eliciting distinct 
developmental or functional effects (Hiscott & Ware 2011). Innate immune cells produce 
and release cytokines as part of a critical response to inflammation and infection in the 
body (Lacy & Stow 2011). The synthesis and release of cytokines is a carefully controlled 
and sequentially orchestrated process, which allows the immune system to function   
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appropriately (Lacy & Stow 2011). Thus, after innate immune cells have produced an 
initial cytokine cascade, mounting inflammatory or allergic responses, tight regulation 
later ensures the responses efficiently subside (Hu & Ivashkiv 2009). Proinflammatory 
cytokines also serve to generate adaptive immune responses by means of T lymphocyte 
recruitment and activation (Iwasaki & Medzhitov 2010).   
 
Residing at the frontline of defence in immunity, cells of the innate immune system 
comprising white blood cells including neutrophils, monocytes, dendritic cells, 
eosinophils, and basophils along with tissue-resident mast cells and macrophages 
control opportunistic invasion from a wide range of viral, bacterial, fungal and parasitic 
pathogens (Iwasaki & Medzhitov 2010; Lacy & Stow 2011). This is coordinated somewhat 
by the plethora of cytokines and chemokines released by the innate immune cells, which 
include TNF, IFN-γ, TGF and interleukins such as IL-1β, IL-4, IL-6, IL-10, that subsequently 
communicate with other cells and thereby direct immune responses (Lacy & Stow 2011).  
Cytokines exert their effect through a matching cell-surface receptor, for example 
tumour necrosis factor (TNF) binding protein and IL-6 receptor (IL-6R), which when 
activated, initiate a cascade of immune-related events (Anderstam et al. 2012).  
 
Complement- or immunoglobulin receptor-mediated signalling or pathogen-induced 
cellular receptors; including pattern recognition receptors such as TLRs, can directly 
evoke cytokine secretion (Hu & Ivashkiv 2009; Iwasaki & Medzhitov 2010). A highly 
potent trigger of cytokine release is the Gram-negative bacterial coat component LPS, 
which activates the cellular response through TLR4, and is the main factor for toxic shock 
syndrome and sepsis (Se et al. 2008; Lacy & Stow 2011).   
 
1.5.1 Cytokine generation in neutrophils  
Neutrophils produced a wide range of cytokines and chemokines, but despite being a 
first line defence in innate immunity, their precise intracellular locations are not known 
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and surprisingly little is known about the way in which their secretory organelles 
(azurophilic granules, specific granules, tertiary granules and secretary vesicles) 
contribute to cytokine trafficking and release (Borregaard et al. 2007; Lacy & Stow 2011). 
Upon immuno-histological examination of mature peripheral blood neutrophils it is 
suggested that TGF-α, TNF, IL-6, IL-12 and CXCL2/IL-8 are stored within peroxidase-
negative organelles, which may be specific or tertiary granules or endosomal secretary 
vesicles (azurophilic granules are peroxidase-positive) (Calafat et al. 1997; Borregaard et 
al. 2007; Lacy & Stow 2011).  Soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors (SNAREs), including vesicle-associated membrane proteins (VAMP)-2, 
VAMP-7, syntaxin-4, syntaxin-6 and synaptosome-associated protein (SNAP-23) are 
expressed in neutrophils and are involved in the regulation of trafficking and release of 
a number of these secretory organelles (Martín-Martín et al. 2000; Mollinedo et al. 2006; 
Logan et al. 2006). 
 
1.5.2 Cytokine generation in macrophages  
Macrophages, and dendritic cells (DC), do not possess the typical secretory granules seen 
in other innate immune cells such as neutrophils, eosinophils and natural killer cells (NK), 
therefore, constitutive exocytosis is the predominate mechanism for which cytokines are 
released from these cells (Figure 1.11) (Stow et al. 2009). TNF is a potent 
proinflammatory cytokine secreted by many innate immune cells, particularly activated 
macrophages, but also neutrophils, eosinophils, mast cells, DCs and NK cells, and is one 
of the most comprehensively studied pathways for cytokine release (Calafat et al. 1997; 
Shurety et al. 2000; Lacy & Stow 2011). There are varying pathways for exocytic release 
of TNF between these cell types, and in macrophages TNF is only released by constitutive 
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exocytosis after being synthesised in response to inflammatory stimuli (Shurety et al. 
2000). Other pro- and anti-inflammatory cytokines produced and secreted by 
macrophages through constitutive exocytosis include IL-6, IL-10 and IL-12 (Shurety et al. 
2000; Stow et al. 2009). The release of TNF-α from macrophages ensues within 30 
minutes of pathogen recognition, following gene transcription and RNA translation, 
establishing this mediator as an early regulator of immune response (Schulte et al. 2013). 
 
Cytokines that lack the N-terminal signal sequence required for endoplasmic reticulum 
(ER) entry, are synthesised in the cytoplasm before being released by the a cell in a non-
classic secretory pathway (Nickel 2003). Examples of such cytokines include IL-1β, IL-15, 
IL-18 and macrophage inhibitory factor, where numerous potential yet diverse routes 
for these cytokines to cross the plasma membrane and exit the cell have been proposed 
(Figure 1.12) (Nickel 2003; Lacy & Stow 2011). 
 
The potent proinflammatory cytokine IL-1β plays a crucial role in mediating 
inflammation and host responses to infection, in spite of this, its mechanism of release 
remains amongst the least understood (Eder 2009). The biologically inactive pro-
interleukin-1β (pro-IL-1β) is the precursor to IL-1β and is synthesised directly in the cell 
cytoplasm to generate mature, biologically active IL-1β by caspase-1 before being 
released directly into the extracellular environment (Eder 2009; Lacy & Stow 2011). 
However, the point of exit for IL-1β, whether it be crossing the plasma membrane 
directly or by entering or associating with intracellular membranes remains controversial 
(Eder 2009; Lacy & Stow 2011). 
 
Arrays of cytokines are released by cells of the immune system and currently play a 
pivotal role at the forefront of medicine, with a surge in popularity as targets for 
therapeutic antibodies and as causative factors in the pathogenesis of a large number of 
diseases associated with inflammation (Taylor & Feldmann 2009; Apostolaki et al. 2010). 
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The ability to elucidate stimuli that are able to induce cytokine synthesis in our cells 
can bring us greater knowledge and understanding into the pathogenesis of diseases 
in which our innate immune cells represent the first cell type to encounter and 
interact with the etiologic agent; in turn helping to identify characteristic stimuli-
specific responses of our cells (Tecchio et al. 2014).  
 
The proinflammatory cytokines, tumour necrosis factor-α (TNF-α) and the 
interleukin-1 family (including IL-1α and IL-1β), are amongst the most well-studied 
cytokines in inflammation and infectious diseases such as sepsis and meningitis and 
have also been implicated in other non-infectious diseases including atherosclerosis, 
rheumatoid arthritis and Alzheimer’s disease (Jawien 2008; Schulte et al. 2013). Both 
of these cytokines have been reported to have a link with sepsis in both humans and 
animal models. For example, administration of the bacterial endotoxin LPS showed 
increased levels of both proteins (Cannon et al. 1990; Schulte et al. 2013). The 
production of these proinflammatory cytokines by immune cells starts a continuum 
of cell stimulation, acting on target cells such as neutrophils and promoting 
macrophage differentiation and activation, ultimately prolonging their survival and 
enhancing their proinflammatory response during infection (Schulte et al. 2013).   
 
1.5.3 Measuring cytokines  
Detection of the spectrum of pro- and anti-inflammatory cytokines can be examined 
using several methods. One such method is using real-time quantitative polymerase 
chain reactions (Q-PCR). This involves the measurement of cytokine mRNA transcript 
abundance, detecting many different cytokines from a relatively small sample 
amount.   One of the main disadvantages is that the presence of RNA does not always 
accurately reflect protein levels. For example, secretion of some cytokines (such as 
IL-4 and IL-10) is partially regulated at the translational level, where others are 
regulated post-translationally (such as IL-1 and IL-18) (Amsen et al. 2009). Another 
disadvantage of RNA-based detection of cytokines is that identification of cellular 
sources of the cytokines requires isolation of different cell types, which may be 
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difficult in some instances. Also, although PCR is sensitive, if there are only small 
numbers of cells present in tissue samples that generate the cytokines of interest, 
the limit of detection may not be reached (Amsen et al. 2009).  
The presence of cytokines can also be determined by enzyme-linked immunosorbent 
assays (ELISAs). This method allows detection of secreted cytokines at the protein 
level. ELISAs are commonly chosen for their accuracy and sensitivity of detection. 
They possess the ability to specifically detect a protein within a protein network in 
comparison to high-performance liquid chromatography (HPLC) (Aly et al. 2011). 
High specificity is ensured for the detection of the target analyte as each assay is 
tested for cross-reactivity and interference with a panel of analyte-related molecules 
(R&D DuoSet ELISA development systems). A sandwich immunoassay is used to 
detect sample antigen between two layers of antibodies (capture and detection 
antibodies) and enables the quantification of cytokine secretion in cell supernatant. 
Sandwich ELISAs are preferred over competitive ELISAs as they result in less variable 
results. A plate reader is then used to measure the absorbance of the plate wells to 
determine the presence and quantity of antigen. A disadvantage to using ELISAs is 
that sufficient quantities of tissue fluids or supernatant are not always easily 
obtained. This coupled with cellular consumption of cytokines means that actual 
cytokine levels may be underestimated. 
 
1.6 Biomarker isolation and identification 
Biomarkers are characteristic biological molecules that provide independent 
diagnostic or prognostic value by reflecting normal or diseased states within the body 
(Stearns-Kurosawa et al. 2011). Such molecules can be detected and measured, for 
example, in blood, tissue or urine, and represent a marker of a biological process 
commonly used to diagnose disease and guide therapies (Stearns-Kurosawa et al. 
2011). 
The inflammatory response is complex, paving the way for the development of a 
biomarker approach towards accurate diagnosis for patients with bacterial 
infections. A key element in the survival rate of severe infections, such as meningitis 
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and sepsis, is early therapy. This being the case, a biomarker should reduce the time 
taken to confirm a diagnosis, distinguish between an infectious and non-infectious 
origin of inflammation, discriminate between viral and bacterial infections and 
evaluate a suitable control for the infection (Kobeissi & Zanotti-Cavazzoni 2010). 
 
As mentioned above, antibiotic resistance is a major public healthcare challenge and 
strategies to promote a judicious use of antibiotics is urgently needed. The use of 
empiric broad-spectrum antibiotics is frequently initiated in critically ill patients 
presenting with systemic inflammation due to the time-consuming diagnostic 
challenges. Often a prolonged course of antibiotics is administered despite the 
absence of microbiological data supporting diagnosis of bacterial infection. 
 
Several studies have evaluated various diagnostic biomarkers of systemic bacterial 
infection including ferritin, haptoglobin, interleukin 6, C-reactive protein (CRP) and 
procalcitonin (PCT) (Harbarth et al. 2001; Garnacho-Montero et al. 2014; Meynaar et 
al. 2011).   
Currently there are diagnostic tests that can identify between bacterial and viral 
pathogens and therefore improve distinction between bacterial and viral infection. 
The most well studied biomarkers are PCT and CRP. These markers represent the 
most promising results to date as clinical markers for the diagnosis of bacterial 
infection (Han et al. 2015). However, their sensitivity and specificity are still 
questioned (Hausfater et al. 2002). PCT is normally secreted by the C cells of the 
thyroid in response to hyper-calcaemia, and is the pre-hormone of calcitonin (Simon 
et al. 2004). Under normal conditions, negligible serum PCT concentrations are 
detected (Whicher et al. 2001). It is believed that PCT is produced by the liver and 
peripheral blood mononuclear cells, and modulated by LPS and proinflammatory 
cytokines (Hausfater et al. 2002). Despite its lack of specificity, CRP level 
measurements are frequently used to differentiate diagnosis of bacterial infection 
(Hausfater et al. 2002). CRP is an acute-phase reactant that is synthesised by the liver, 
mainly in response to IL-6, which is produced not only during infection but also in 
many types of inflammation (Ridker 2003). It binds to polysaccharides in pathogens, 
activating the classic complement pathway (Simon et al. 2004). Overall, it has been 
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observed that PCT levels were more accurate markers for bacterial infection than 
were CRP levels, both when differentiating bacterial infections from non-infective 
causes of inflammation and when differentiating bacterial infections from viral 
infections (Simon et al. 2004).   
 
While severe bacterial infections typically trigger the production of multiple 
mediators such as eicosanoids, cytokines and other inflammatory proteins, 
surprisingly, few studies have assessed the utility of a combination of biomarkers in 
the diagnosis of bacterial infection (Han et al. 2015). The use of multiple biomarkers 
will undoubtedly provide a more accurate strategy to diagnose bacterial infection. In 
addition, in the case of critically ill patients where timely administration of empiric 
broad-spectrum antibiotics significantly reduces mortality, the greatest clinical 
advantage of biomarker signatures may be to support clinical decisions to 
discontinue antibiotics when no bacterial infection is identified. There are initial 
efforts into potential biomarker algorithms to identify patients with suspected sepsis 
at very low likelihood of bacterial infection (Han et al. 2015). Studies aiming to 
identify potential markers of infection could contribute to the development of 
specific biomarker algorithms and further enhance and refined their accuracy. 
 
Early identification of bacterial infection is still challenging for clinicians. The most 
precise way to diagnose bacterial infections is through blood cultures, which can take 
several days and are often inconclusive. The effort to determine if biomarkers can 
differentiate between bacterial pathogens would prove to be an invaluable practice. 
Using potential eicosanoid and cytokine readouts as biomarkers for bacterial 
infection could allow for faster administration of targeted antibiotics at the earliest 
opportunity, increasing positive long-term patient outcomes. Current practice uses 
broad-spectrum antibiotics to a presumed pathogen, which increases resistance and 
therefore reduces scope for treatment. The identification of profile markers explicitly 
for species-specific bacterial infections, that can be generated at the bedside as an 
on-the-spot system would be invaluable to assist in current medical practice. 
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1.7 Aims  
This study aims to determine the nature of the relationship between bacterial species 
and eicosanoid and cytokine signalling in the early stages of infection with the host. 
It is hoped that further understanding of the eicosanoid and cytokine profiling during 
specific bacterial infections will identify biomarker fingerprints that could be used as 
early predictors of specific bacterial infections.     
 
It is hypothesised that the profile of the eicosanoid and cytokine responses 
generated during bacterial infections varies depending on the nature of the bacterial 
pathogen.  
 
The primary aims of the work presented in this thesis are: 
1. To investigate the eicosanoid and cytokine response of neutrophils and 
macrophages when exposed to individual bacterial components. 
2. To develop an infection model for live bacterial exposure to phagocytic cells. 
3. To establish the relationship between bacterial strain and eicosanoid and 
cytokine signalling following infection, with a view to determining early 
profiles of infection.
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2. General methods 
The materials and methods defined in this section are non-specific and are relevant 
to the results presented in multiple chapters of this thesis. Detailed descriptions of 
the specific materials and methods for individual chapters will be given at the start 
of each chapter. 
 
2.1 Chemicals 
Unless stated otherwise, all chemicals used for the experiments described were 
purchased from Sigma-Aldrich Company Ltd (Poole, Dorset, UK), and all solvents used 
for the experiments described were purchased from Fisher Scientifics UK Ltd 
(Loughborough, Leicestershire, UK). 
 
2.2 General buffers and solutions 
All buffers were made from dry chemicals on the bench for the purpose of human 
neutrophil isolation and were filter sterilised by passing the buffer through a 0.2 
micron syringe filter (Corning) in a tissue culture hood and were stored frozen at -
20°C. 
 
2.2.1 Preparation of phosphate buffered saline (PBS)  
One Dulbecco’s PBS (no calcium, no magnesium) tablet (Gibco) added to 100mL 
double-distilled H2O, pH 7.4. Note: one tablet dissolved in 200mL water yields 0.01M 
phosphate buffer, 0.0027M KCl and 0.137M NaCl.      
 
2.2.2 Preparation of citrate PBS 
2.8% citrate (w/v); 2.8g sodium citrate tribasic in 100mL PBS, pH 7.3.  0.4% citrate 
(w/v); 0.4g sodium citrate tribasic in 100mL PBS, pH 7.3. 
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2.2.3 Preparation of hypotonic saline, 0.2%  
0.2g NaCl in 100mL double-distilled H2O. 
 
2.2.4 Preparation of hypertonic saline, 1.6% 
1.6g NaCl in 100 mL double-distilled H2O. 
 
2.2.5 Preparation of Krebs (Ca2+ free) 
Hepes buffered Krebs [50mM HEPES, 100mM NaCl, 5mM KCl, 1mM NaH2PO4, 2mM 
glucose] was prepared and adjusted to pH 7.4 with NaOH. The buffer was filter 
sterilised and stored at -20°C.      
 
2.3 Reagents  
Eicosanoid analytes and deuterated internal standards used from Cayman Chemical 
(Michigan, USA) Human and Mouse TLR1-9 Agonist Kit, a set of known agonists for 
human and mouse TLR1 to TLR9, were purchased from InvivoGen.  
 
Human TLR agonist kit (tlrl-kit1hw; InvivoGen, Toulouse, France). All descriptions are 
taken from the product information sheet for this product. 
 
TLR1-9 Agonist Kit Content: 
• Pam3CSK4 - TLR1/2 agonist 
Pam3CSK4 is a synthetic tripalmitoylated lipopeptide that mimics the acylated amino 
terminus of bacterial lipoproteins. Pam3CysSerLys4 (Pam3CSK4) is a potent activator 
of the proinflammatory transcription factor NF-kB. Recognition of Pam3CSK4 is 
mediated by TLR2 which cooperates with TLR1 through their cytoplasmic domain to 
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• HKLM – Heat-Killed Listeria monocytogenes - TLR2 agonist  
HKLM is a freeze-dried heat-killed preparation of Listeria monocytogenes (LM), a 
facultative intracellular Gram-positive bacterium. Infection with LM induces a strong 
nonspecific response characterized by the secretion of proinflammatory cytokines 
such as TNF-α. This response is mediated by TLR2. Stimulation with HKLM induces 
immediate activation of NF-kB and the production of proinflammatory cytokines. 
 
• Poly (I:C) - TLR3 agonist  
Poly(I:C) is a synthetic analogue of double-stranded RNA (dsRNA), a molecular 
pattern associated with viral infection.  
 
• Escherichia coli K12 Lipopolysaccharide (LPS) - TLR4 agonist 
Lipopolysaccharide (LPS), the major structural component of the outer wall of Gram-
negative bacteria, is a potent activator of the immune system. LPS recognition is 
mediated by TLR4 which forms a complex with MD2 and CD14 leading the production 
of proinflammatory cytokines such as TNF-α through the MyD88 pathway. LPS 
signalling also involves a MyD88-independent cascade that mediates the expression 
of IFN-inducible genes via the adaptor TRIF. 
 
• Salmonella typhimurium Flagellin - TLR5 agonist  
Flagellin is the major component of the bacterial flagellar filament, which confers 
motility on a wide range of bacterial species. Flagellin is a potent stimulator of innate 
immune responses in a number of eukaryotic cells and organisms, including both 
mammals and plants. In mammals, flagellin is recognized by TLR5 and triggers 
defence responses both systemically and at epithelial surfaces. Flagellin induces the 
activation of NF-kB and the production of cytokines and nitric oxide depending on 
the nature of the TLR5 signalling complex.  
 
• FSL-1 - TLR6/2 agonist 
FSL-1 (Pam2CGDPKHPKSF) is a synthetic lipoprotein that represents the N-terminal 
part of the 44-kDa lipoprotein LP44 of Mycoplasma salivarium. The framework 
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structure of FSL-1 is the same as that of MALP-2, a Mycoplasma fermentans derived 
lipopeptide (LP), but they differ in the amino acid sequence and length of the peptide 
portion. FSL-1 is recognized by TLR2 and TLR6 inducing a MyD88-dependent 
signalling cascade that leads to the activation of NF-kB and the production of 
proinflammatory cytokines.  
 
• Imiquimod - TLR7 agonist  
Imiquimod (R837), an imidazoquinoline amine analogue to guanosine, is an immune 
response modifier with potent indirect antiviral activity. Imiquimod is an approved 
treatment for external genital warts caused by human papillomavirus infection.  
 
• ssRNA40 - TLR8 agonist 
ssRNA40 is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide 
containing a GU-rich sequence15. ssRNA40 is complexed with the cationic lipid 
LyoVecTM (ratio 1:2), to protect it from degradation and facilitate its uptake, and 
lyophilized to generate ssRNA40/LyoVec. When complexed to cationic lipids, ssRNA 
can substitute for viral RNAs in inducing TNF-α and IFN-α production in peripheral 
blood mononuclear cells.  
 
• ODN2006- TLR9 agonist 
CpG ODNs are synthetic oligonucleotides containing unmethylated CpG 
dinucleotides in particular sequence contexts that induce strong immunostimulatory 
effects through the activation of TLR9. Two types of CpG ODNs have been described. 
Type A (or D) ODNs preferentially activate plasmacytoid dendritic cells (pDC) to 
produce IFN-α, whereas type B (or K) ODNs induce the proliferation of B cells and the 
secretion of IgM and IL-6. 
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TLR1-9 Agonist Kit Content: 
• Pam3CSK4 -TLR1/2 agonist  
• HKLM – Heat-Killed Listeria monocytogenes - TLR2 agonist 
• Poly (I:C) - TLR3 agonist  
• Escherichia coli K12 Lipopolysaccharide (LPS) - TLR4 agonist 
• Salmonella typhimurium Flagellin - TLR5 agonist  
• FSL-1 - TLR6/2 agonist 
• Imiquimod - TLR7 agonist 
• ODN1826 - TLR9 agonist  
CpG dinucleotides in particular sequence contexts that induce strong 
immunostimulatory effects through the activation of TLR9. ODN1826 is the optimal 
motif to induce the proliferation of B cells. 
 
2.4 Isolation of human neutrophils from peripheral blood 
Whole blood was taken by venepuncture from the antecubital fossa, from healthy 
volunteers free from non-steroidal anti-inflammatory drugs for at least fourteen 
days.  Clinical supplies (needles etc.) were obtained from clinical sterile stores (Cardiff 
School of Pharmacy and Pharmaceutical Sciences, SPPS). Ethical permission for all 
donations was obtained from the local research ethics committee (SPPS) (1314-19), 
and all human participants gave written informed consent. Human neutrophils were 
isolated using the methods described by Thomas and colleagues (Thomas et al. 
2014). Briefly, blood was drawn through a 21-gauge butterfly needle directly into a 
syringe containing 2.8% citrate PBS and Hetasep (Stemcell Technologies) at a 
blood:citrate:Hetasep ratio of 10:2:2. The erythrocytes were allowed to sediment at 
room temperature for 35-50 minutes and the upper plasma layer removed and under 
laid with Lymphoprep (Stemcell Technologies) at a plasma Lymphoprep ratio of 2:1. 
This was centrifuged at 800 g for 20 minutes at 4°C (Heraeus, Megafuge-40R 
centrifuge). The monocytic cells at the interface were removed and discarded along 
with all the remaining plasma and Lymphoprep and the pelleted cells were recovered 
with 0.4% citrate PBS and transferred to a clean centrifuge tube. This was then 
centrifuged at 400g for 5 minutes at 4°C. The supernatant was discarded, and the red 
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blood cells were lysed by hypotonic shock.  The cells were re-suspended in hypotonic 
saline solution (ice-cold 0.2% saline) before restoring osmolality after 35-50 seconds 
(by addition of an equal volume of ice cold 1.6% saline) after which the solution was 
centrifuged at 400 g for 5 minutes at 4°C.  The hypotonic shock procedure was 
repeated until no further red colour was visible (typically 3 cycles). The final pellet 
was re-suspended in Krebs buffer and the neutrophils were diluted to a 
concentration of 1x107 neutrophils per mL (the concentration was measured by 
trypan blue exclusion using a haemocytometer under an inverted microscope).  
 
2.4.1 Neutrophil activation 
Human neutrophils were isolated as per section 2.5.1 and used at 0.5ml of 0.5 × 106 
cells/ml.  The cells were incubated for 5 minutes at 37°C before the addition of 100 
µl of activating agents’ calcium ionophore A23187 (10µM final concentration) or 
fMLP (1µM final concentration) combined with 2.5 mM CaCl2 and 1.25 mM MgCl2 for 
between 2 minutes and 60 minutes. Activating agents were prepared as per Table 
2.1. 
 
Table 2.1 Activating agent preparations. 
Agonist mix Krebs (µl) Agonist (µl) MgCl2 (µl) CaCl2 (µl) 
MgCl2 + CaCl2 (untreated) 900 - 50 50 
Calcium Ionophore A23187 875 25 50 50 
fMLP 895 5 50 50 
 
When neutrophils were exposed to TLR agonists, the cells were pre-incubated with 
agonists for 30 minutes at 37°C prior to the addition of 100 µl of the fMLP preparation 
for a further 2 minutes.  
 
Following incubation, 500 μl samples for cytokine analysis were transferred into a 
fresh eppendorf tube and frozen at -80°C until required. 
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2.5 Preparation of eicosanoid standard curve 
Internal standard (IS) was prepared by diluting 12-HETE-d8 stock to 1 ng/μl with 
methanol (MeOH). 20 pg/μl of the standard was then mixed with 980 μl of MeOH. 
The analyte mix was prepared as per Table 2.2 and the final volume was made up to 
300 μl with MeOH. 
 
Table 2.2 Internal standard and analyte dilutions.  
  Stock Stock 
concentration  
Add 
IS: 12-HETE-d8 25μg in 250μl 100ng/μl  20μl of 100ng/μl to get 1ng/μl (in 980μl MeOH) 
Analytes:       
5-HETE 100μg in 1ml 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
8-HETE 25μg in 250μl 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
11-HETE 25μg in 250μl 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
12-HETE 250μg in 2.5ml 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
15-HETE 25μg in 250μl 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
PGE2 1mg/ml 1mg/ml 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
PGD2 1mg/ml 1mg/ml 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
LTB4 25μg in 250μl 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
LTE4 25μg in 250μl 100ng/μl 6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
TxB2 1mg/ml   6μl of 100ng/μl to get 2ng/μl final (in 300μl) 
 
To create the standard curve the analyte mix was diluted as per Table 2.3. 100 μl of 
the IS mix was added to 100 μl of each analyte dilution. 10 μl of each dilution was 
then injected onto the column to create the standard curve. 
  
Table 2.3 Standard curve preparation. 




1 Original analyte mix (6μl each with 240μl MeOH) 2ng/μl 1ng/μl 10ng 
2 150μl of (1) with 150μl MeOH 1pg/μl 0.5pg/μl 5ng 
3 60μl of (2) with 240μl MeOH 0.2ng/μl 0.1ng/μl 1ng 
4 150μl of (3) with 150μl MeOH 0.1ng/μl 50pg/μl 500pg 
5 60μl of (4) with 240μl MeOH 20pg/μl 10pg/μl 100pg 
6 150μl of (5) with 150μl MeOH 10pg/μl 5pg/μl 50pg 
7 60μl of (6) with 240μl MeOH 2pg/μl 1pg/μl 10pg 
8 150μl of (7) with 150μl MeOH 0.5pg/μl 0.5pg/μl 5pg 
9 60μl of (8) with 240μl MeOH 0.2pg/μl 0.1pg/μl 1pg 
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2.6 Extraction of lipids with acidified hexane: isopropanol  
Following treatment, lipids were extracted immediately from the supernatant using 
the extraction methods described by Thomas and colleagues (Thomas et al. 2014). 
For quantitation 5 μl of an internal standard was added to the cells. The internal 
standard is known amounts of compound added and detected in all samples, which 
allow the signal from the unknown analyte to be quantified when compared to the 
signal from the standard.  
 
Lipids were extracted by adding a solvent mixture (1M acetic acid, propan-2-ol, 
hexane; 2:20:30; vol/vol/vol) at a ratio of 2.5 mL solvent mixture per millilitre of 
supernatant and vortexing for 1 minute. A further 2.5 mL of hexane was added 
followed by vortexing and centrifugation at 300g for 5 minutes at 4°C.  Lipids were 
carefully recovered from the upper hexane layer and transferred into a clean glass 
tube. The lipids were then re-extracted from the lower layer by the addition of 2.5 
mL of hexane, vortexing and centrifuging at 300 g for 5 minutes at 4°C. The upper 
hexane layer was recovered and combined with the first hexane layer. The samples 
were dried using nitrogen gas evaporation, dissolved in methanol (MeOH), and 
stored at -80°C before analysis by HPLC/MS/MS.  
 
2.7 Solid phase extraction 
2.7.1 Sample preparation 
The cells were analysed for intracellular eicosanoid generation. Cell samples 
underwent prior lipid extraction as described in section 2.6. The 100 μl sample 
(resuspended in MeOH) was added to 1700 μl of HPLC grade water and 
supplemented with 200 μl of MeOH to bring the total volume of MeOH to 15% by 
volume. 45 μl of acetic acid was then added to the sample mixture. Internal standard 
was added during the hexane-lipid extraction. 
The media were analysed for extracellular eicosanoid release. After stimulation 1 mL 
of media was removed from the cell sample, 700 μl of HPLC grade water was added 
followed by 300 μl of MeOH to bring the total volume of MeOH to 15% by volume. 
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45 μl of acetic acid was then added to the sample mixture and 10 μl internal standard.  




Eicosanoids were extracted using Sep-Pak Vac 6cc (500mg) tC18 cartridges (Waters, 
UK; WAT036790) Columns were washed with 12 mL of MeOH and then 6 mL of HPLC 
grade water with 0.25% acetic acid. After applying the sample, the columns were 
washed with 10 mL of water followed by 6 mL of hexane.  Columns were then allowed 
to dry for 20 minutes. Samples were eluted with 8 mL of methyl formate and then 
dried under vacuum at 30°C, before being dissolved in 100 μl of MeOH. Samples were 
stored at -80°C before analysis by HPLC/MS/MS. 
 
2.8 MultiQuant software 
MultiQuant software was used for mass spectrometry integration and quantitation 




2.9 Cytokine concentration determination 
2.9.1 Enzyme-linked immunosorbent assay 
A DuoSet enzyme-linked immunosorbent assay (ELISA) development system (R&D 
Systems Europe, Ltd. Abingdon, UK) was used to measure the secretion of natural 
pro-inflammatory cytokines (IL-1β, TNFα, IL-6 and IL-8). The ELISA was performed as 
described by the manufacturers’ guidelines. Typically, a 96-well plate (Greiner, 
Austria) was coated with 4 μg/mL of the capture antibody, sealed and incubated 
overnight at room temperature. The plate was aspirated/washed with wash buffer 
(PBST, 0.05% Tween®20 in PBS), inverted and blotted. Wells of the plate were then 
blocked with reagent diluent (RD, 1% BSA in 1xPBS), for a minimum of 1-hour at room 
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temperature. Aspiration of the plate was repeated before samples and standards 
were added. Samples were retrieved from -80°C storage and allowed to thaw on ice.  
Standards were tested using a seven-point standard curve, using 2-fold serial 
dilutions from the highest concentration provided (dilute using RD). A negative 
control (RD) was also included and the plate was incubated at room temperature for 
2-hours. The plate was aspirated and blotted before adding 200 ng/mL of biotin 
labelled detection antibody in RD and subsequently incubated at room temperature 
for 2-hours. Aspiration of the plate was repeated, before adding enzyme-labelled 
streptavidin horseradish-peroxidase, diluted 1:40, to each well. The plate was 
incubated at room temperature, in the dark for 20 minutes, before the final 
aspiration. Enzyme-substrate solution (20 mg o-phenylenediamine dihydrochloride 
(OPD) and 20 μl 30% H2O2 in 0.1M citric acid and 0.2M phosphate) was added to each 
well and further incubated in the dark for 20-minutes at room temperature before 
the stop solution (2.5M H2SO4) was added. The optical density of each well was 
determined immediately, using a microwell reader set to 490 nm (Tecan, Infinite 
F50). 
 
2.10 Statistical analysis  
In Chapters 3 and 4 data were analysed using a one-way ANOVA and Chapters 5 and 
6 data were analysed using a two-way ANOVA. When a significant main effect was 
reported a post-hoc Tukey analysis with Bonferroni corrections was used to detect 
individual group differences. Prior to carrying out the ANOVAs a test for normal 
distribution of data (Shapiro-Wilk; Tukey box-plots) were carried out. If data violated 
these tests the data were transformed by square root and transformed data were 
used for analysis. Where data remained not normally distributed following 
transformation or when data were unable to be transformed due to 0 values within 
the data set a non-parametric equivalent of the one-way ANOVA, Kruskal-Wallis test 
was used to determine main effects with Dunn’s non-parametric comparison with 
Bonferroni corrections for post-hoc analysis to compare individual differences.




3 Identification of 5-HETE and proinflammatory 
cytokines from isolated human neutrophils 
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3.1 Introduction 
As previously discussed in Chapter 1, the ability for the host to recognise microbial 
pathogens is an essential element for the innate immune response. Cells of the 
innate immune system express various receptors both extracellularly and 
intracellularly, with the potential to directly recognise microbial or endogenous 
signals. Neutrophils express a large number of cell surface receptors as well as 
providing rapid deployment and effector functions of the innate immune response 
to infection. As part of their response they are able to generate immune-modulating 
signals, the composition of which is dependent on the nature of the pathogen. To do 
this the cell is equipped with a range of reporter systems, which recognise and 
respond to an extensive repertoire of pathogen-associated molecular patterns 
(PAMPs) (Prince et al. 2011). The system focussed upon in this body of work is 
comprised of toll-like receptors (TLRs), which were formerly discussed in Chapter 1.   
 
Chapter 1 also discusses the necessity for rapid differentiation between bacterial 
aetiology of infection for a decision on empirical antibiotic treatment. It has 
previously been shown that primary human neutrophils possess bacterial toll-like 
receptors which generate proinflammatory cytokines, and have the ability to 
produce lipid mediators in response to bacterial components (Clark et al. 2011). For 
these reasons, primary human neutrophils provide a good model to investigate the 
relationship between lipid and cytokine generation under agonist-activated 
conditions, in addition to the fact that neutrophils are the predominate immune cell 
in human blood and are typically the first leukocyte recruited to the site of trauma 
or infection. 
 
The focus of this research was to employ a targeted lipidomic approach to show that 
isolated human neutrophils generate 5-lipoxygenase (5-LOX) lipids, as discussed in 
Chapter 1, when activated with bacterial products. At the time, the most established 
technique in the Cardiff Lipidomic Group, School of Medicine, employed a Q-Trap 
mass spectrometer instrument (Applied Biosystems 4000) operating in multiple 
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reaction-monitoring (MRM) mode and is considered to be one of the most sensitive 
systems available. It is important to highlight that during the course of this PhD study 
and in keeping with the fast-moving developments within the lipidomics field, 
Chapters 5-6 show how technical and methodological aspects of the targeted 
lipidomics approach have been further enhanced. Nonetheless, techniques used in 
this chapter were optimised at the time of study.  
 
The aim of this chapter was to determine whether different TLR agonists initiate 
distinct lipid and cytokine profiles, which could be used as a robust indicator of the 
early innate immune response to bacterial infection. An earlier study by Clark and 
colleagues found that human neutrophils, when exposed to various agonists 
including TLR binding agents, generated the eicosanoid 5-HETE (Clark et al. 2011). 
The results of this study indicated that the profile of 5-HETE eicosanoids varied in 
response to different classes of pathogens. Chapter 3 takes this approach a stage 
further by employing the whole array of bacterial TLR agonists to look at neutrophil 
responses and determine any variation between components. 
A further aim is to characterise the profile of cytokines and eicosanoids produced by 
human neutrophils following exposure to bacterial TLR agonists with a view to 
determining which play a key role in early inflammatory signalling.   
3.1.1 Specific aims 
The specific aims of the work in this chapter are therefore: 
 
1. To examine the effects of calcium ionophore A23187 (non-receptor agonist) and 
bacterial peptide N-formylmethionyl-leucyl-phenylalanin (fMLP) (receptor-based 
agonist) on isolated human neutrophils. 
2. To establish mass spectrometry detection of neutrophil 5-HETE formation.  
3. To determine the contribution of toll-like receptor agonist priming of isolated 
neutrophils on cytokine and eicosanoid signalling. 
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3.2 Specific material and methods  
3.2.1 Isolation and activation of human neutrophils  
Human neutrophils were isolated from a healthy donor, as previously described in 
Chapter 2 section 2.4, resuspended in a small volume of Ca2+-free Krebs buffer, 
counted and kept on ice.  Neutrophils (1.5x105 cells) were incubated for 5 minutes at 
37°C before the addition of the activating agents calcium ionophore (A23187; 10 µM) 
or fMLP (1 µM) followed by 2.5 mM CaCl2 and 1.25 mM MgCl2 for between 2 minutes 
and 60 minutes.        
 
When priming agents were used (Table 3.1) (InvivoGen, tlrl-kit1hw) neutrophils 
(1.5x105 cells) were pre-incubated for 30 minutes at 37°C in the presence of the TLR 
agonists, before the addition of the activating reagent fMLP (1 µM), 2.5 mM CaCl2 
and 1.25 mM MgCl2 for a further 2 minutes. Following incubation, deuterated 
internal standard, 12HETEd8 (5 ng/mL) (Cayman Chemicals, 334570), was added to 
all samples before subsequent lipid extraction, as described in Chapter 2, section 2.6.   
For cytokine analysis, isolated human neutrophils (1.5x105 cells) were primed 
separately with the six bacterial TLR agonist for 30 minutes at 37°C before being 
stimulated with fMLP (1 μM) for 4 hours (times points were indicated during 
optimisation). Samples were transferred into fresh Eppendorf tubes and frozen at -
80°C until required. 
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3.2.2 Reverse-phase LC/MS/MS of lipids 
The dried lipid extract was separated using liquid chromatography (LC)-MS/MS.  
Samples were separated on a C18 Spherisorb ODS2 HPLC Column (5 μm, 150 x 4.6 
mm; Waters, Hertfordshire, UK), at a gradient of 50 to 90% mobile phase B over 15 
minutes. Mobile phases A and B were made up of solvent mixtures water, 
acetonitrile, acetic acid at a ratio of 75:25:0.1; v/v/v and methanol, acetonitrile, 
acetic acid at a ratio of 60:40:0.1; v/v/v, respectively.   Samples were injected with 
an auto-sampler and the sample chamber temperature was set at 4°C.  The injection 
volume was 10μL with a flow rate of 1mL/minute. Electrospray mass spectra were 
obtained on a Q-Trap instrument (Applied Biosystems 4000 Q-Trap; Cardiff School of 
Medicine, Lipidomics Group) operating in the negative mode.  Products were 
analysed in the multiple-reaction monitoring (MRM) mode transitions from the 
parent ion (m/z 319) to the daughter ion 115 (5-HETE [M-H]-) every 0.60 seconds. 
The area under the curve for the parent ion to the 115 ion was integrated and 
normalised to the internal standard for 5-HETE. For quantification of the lipid, a 
standard curve was generated with purified 12-HETE. The limit of detection of the 
internal standard was determined to be 5 pg.   
 
3.2.3 Enzyme-linked immunosorbent assay for cytokines 
Double antibody sandwich enzyme-linked immunosorbent assays (ELISAs) were used 
to measure the protein concentration generated by isolated neutrophils. The analysis 
was performed using R&D systems Human DuoSet ELISA kits to quantify the 
concentration of four proinflammatory analytes; IL-1β (DY201), IL-6 (DY206), IL-8 
(DY208) and TNF-α (DY210). The minimal detection concentrations (pg/mL) are as 
follows: IL-1β; 3.9, IL-6; 9.4, IL-8; 31.2, and TNF-α; 15.6. The ELISA kits were used with 
an ancillary reagent pack (R&D systems, DY008) to allow for uniform application of 
reagents, according to the manufacturer’s instructions. The amount of cytokine was 
calculated using a standard curve generated from a known amount of the analyte 
provided with the kit.  
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3.2.4 Statistical analysis 
Statistical analysis was carried out as described in Chapter 2, section 2.10. 
 
Both the 5-HETE and cytokine responses to each TLR agonist came from the isolated 
neutrophils of one individual donor. Due to the large variation between donor 
responses, data were normalised where values were expressed as a mean 
percentage of the untreated (where the untreated value was 0 a value of 0.01 was 
given). Data were expressed on a log scale to enable identification of any patterns 
and allow comparison and statistical analysis between donors. Normalising data 
allows the comparison of values in a way that eliminates the effects of certain outside 
influences.       
 
3.3 Results 
3.3.1 Time course of 5-HETE expression 
3.3.1.1 Responses of calcium ionophore A23187-activated neutrophils  
Calcium ionophore A23187 (10 μM) was employed as a known chemical activation 
agent to confirm 5-HETE generation from human neutrophils isolated from fresh 
peripheral blood (Figure 3.1)(Clark et al. 2011). As can be seen from Figure 3.1A, 
precursor LC/MS/MS identified that exposure to calcium ionophore A23187 for 2 
minutes stimulated the production of 5-HETE (~47 ng/106cells). The level of 5-HETE 
expression then reduced to 18 and 15 ng/106cells over the time course of 15 and 60 
minutes, respectively. 
 
3.3.1.2 Responses of fMLP activated neutrophils 
After confirming 5-HETE generation with calcium ionophore A23187, the next 
consideration was to corroborate that 5-HETE could be generated and detected 
when neutrophils were stimulated with the well-characterised formylated bacterial  
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peptide, fMLP (1 μM) over time (Clark et al. 2011). fMLP activation of isolated 
neutrophils from the same donor for 2, 15 and 60 minutes also showed a similar 
response to calcium ionophore A23187, where the most substantial formation of 5-
HETE was after 2 minutes of incubation generating ~ 28 ng/106cells, followed by a 
rapid decline to < 5 ng/106cells at 15 minutes and undetectable levels at 60 minutes 
(Figure 3.1B). The level of expression was also of a similar order of magnitude to that 
seen from ionophore-activated cells. These results are consistent with those 
previously published by Clark et al., 2011. For this reason, and because the focus was 
on bacterial generation of inflammatory mediators, in all subsequent experiments, 
bacterial peptide fMLP was used as the agonist for neutrophil activation at a time 
point of 2 minutes. 
3.3.2 Neutrophil exposure to TLR bacterial agonists 
3.3.2.1 Gram-positive TLR1/2 agonist Pam3CSK4  
Normalised data for 5-HETE production showed that priming of human neutrophils 
with Gram-positive lipoprotein Pam3CSK4 resulted in no significant increase upon 
subsequent activation with fMLP compared to the fMLP control (P>0.05) (Figure 
3.2A). Both fMLP treated neutrophils with and without Pam3CSK4 were significantly 
increased compared to untreated and Pam3CSK4 treated cells alone (P’s < 0.001). 
Treatment of neutrophils with Pam3CSK4 in the absence of fMLP induced a small 
production of 5-HETE, 12-fold lower than levels seen when they were combined 
(P<0.001) (Figure 3.2A). 
Normalised data indicate stimulation of human neutrophils with Pam3CSK4 alone 
resulted in the generation of TNF-α, IL-1β and IL-8. Although not significant (P>0.05), 
TNF-α and IL-8 showed an apparent 6 and 0.5-fold increase, respectively, when 
neutrophils were primed with Pam3CSK4 with the addition of fMLP, compared to the 
agonist alone (Figure 3.3Ai, Aiii). This additive effect was not seen for IL-1β (Figure 
3.3Aii). fMLP-treated neutrophils showed no significant cytokine production. IL-6 was 
below the limit of detection. 
Individual donor responses to the agonist are shown for information (Figure 3.2B-
3.3Bi-iii).  
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3.3.2.2 Gram-positive TLR2 agonist heat-killed Listeria monocytogenes (HKLM) 
Normalised data for 5-HETE production showed priming of human neutrophils with 
Gram-positive agonist HKLM had no significant increase when activated with fMLP 
compared to the fMLP control (P>0.05) (Figure 3.4A). HKLM-treated neutrophils 
showed minor production of 5-HETE, over 150-fold less than that seen when 
subsequently activated with fMLP (Figure 3.4A). 
 
Normalised data showed that HKLM induced TNF-α and IL-8 generation from 
neutrophils, which, although not significant, had an apparent 1-fold increase when 
the agonist was combined with fMLP, for both cytokines (P>0.05) (Figure 3.5Ai, Aiii). 
HKLM stimulated generation of IL-1β, which was shown to decrease > 6-fold when 
treatment was combined with fMLP (Figure 3.5Aii). fMLP-treated neutrophils did not 
induce TNF-α or IL-1β production (Figure 3.5Ai-ii) but produced IL-8 at a 0.5-fold 
decrease compared to the agonist alone (P>0.05) (Figure 3.5Aiii). IL-6 was below the 
limit of detection.            
Individual donor responses to the agonist are shown for information (Figure 3.4B-
3.5Bi-iii).     
 
3.3.2.3 Gram-negative TLR4 agonist lipopolysaccharide (LPS) 
Normalised data for 5-HETE production showed that priming of human neutrophils 
with Gram-negative agonist LPS followed by activation with fMLP resulted in a non-
significant, 0.25-fold increase compared to the fMLP control (P>0.05) (Figure 3.6A). 
LPS alone did not generate 5-HETE. 
When data were normalised, neutrophils exposed to LPS showed TNF-α generation, 
which had an apparent 3-fold decrease with the addition of fMLP (Figure 3.7Ai). LPS 
alone also stimulated IL-1β generation; the agonist combined with fMLP and fMLP 
alone did not show any significant response (P>0.05) (Figure 3.7Aii). IL-8 was 
generated in response to LPS, fMLP and the combined treatment. There was no 
significant difference shown   
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between any of these conditions for cytokine generation (P>0.05). IL-6 was below 
the limit of detection.            
Individual donor responses to the agonist are shown for information (Figure 3.6B-
3.7Bi-iii).     
 
3.3.2.4 Gram-negative TLR5 agonist Flagellin 
Although not significant, normalised data for 5-HETE production indicated that 
priming of neutrophils with Salmonella typhimurium flagellin followed by fMLP 
activation showed an inhibitory effect of ~ 0.3-fold, compared to fMLP alone (P>0.05) 
(Figure 3.8A). The agonist alone did not generate any significant 5-HETE compared to 
the untreated neutrophils (P>0.05). fMLP alone (P<0.01) and fMLP combined with 
flagellin (P<0.05) showed a significant increase in 5-HETE generation compared to 
untreated neutrophils and neutrophils exposed to flagellin alone.  
 
For cytokines, normalised data showed that, flagellin induced TNF-α generation from 
neutrophils; levels remained the same with the addition of fMLP (Figure 3.9Ai). fMLP 
alone did not generate TNF-α. There was no significant difference shown between 
any of the conditions for cytokine generation of TNF-α (P>0.05). Flagellin stimulated 
the generation of IL-8, where levels showed a non-significant 0.8-fold apparent 
increase compared to fMLP alone and a significant 2-fold increase compared to 
flagellin combined with fMLP (Figure 3.9Aii). Neutrophils primed with flagellin before 
fMLP activation showed a significant increase in IL-8 generation compared to 
neutrophils alone (P<0.01). IL-1β and IL-6 were below the limit of detection.            
Individual donor responses to the agonist are shown for information (Figure 3.8B-
3.9Bi-iii).      
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3.3.2.5 Gram-positive TLR6/2 agonist FSL 
Normalised data for 5-HETE production showed that priming of human neutrophils 
with Gram-positive Mycoplasma salivarium lipoprotein FSL had no significant 
increase upon subsequent activation with fMLP compared to the fMLP control 
(P>0.05) (Figure 3.10A). Treatment of neutrophils with FSL alone induced a small 
production of 5-HETE, > 35-fold lower than levels seen when combined with fMLP 
(Figure 3.10A). Neutrophils exposed to fMLP alone and FSL combined with fMLP 
showed a significant increase in 5-HETE generation compared to untreated 
neutrophils and neutrophils exposed to the agonist alone (P’s<0.0001).  
When data were normalised, neutrophils exposed to FSL showed TNF-α generation, 
which had a 2-fold increase with the addition of fMLP (Figure 3.11Ai). fMLP alone did 
not produce TNF-α.  FSL also induced IL-8, which showed a > 1-fold apparent increase 
when the agonist was combined with fMLP (Figure 3.11Aii). fMLP induced IL-8 
generation. There was no significant difference shown between any of these 
conditions for cytokine generation (P>0.05). IL-1β and IL-6 were below the limit of 
detection.            
Individual donor responses to the agonist are shown for information (Figure 3.10B-
3.11Bi-iii). 
 
3.3.2.6 Gram-negative and Gram-positive TLR9 agonist ODN      
Although non-significant, normalised data for 5-HETE production showed that 
priming of human neutrophils with intracellular Gram-positive and -negative 
oligonucleotide ODN followed by fMLP activation showed an apparent inhibitory 
effect of ~ 0.3-fold, compared to fMLP alone (Figure 3.12A). The agonist combined 
with fMLP generated 5-HETE with an apparent ~ 17-fold increase compared to the 
agonist alone, this increase was not significant (P>0.05) (Figure 3.12A). The agonist 
combined with fMLP did show a significant increase (P<0.05) in 5-HETE generation 
when compared to the neutrophils alone. fMLP treated neutrophils generated 5-  
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HETE, which was significantly increased compared to the neutrophils alone and the 
neutrophils exposed to the agonist alone (P’s<0.05).    
 
Normalised data indicate, stimulation of human neutrophils with ODN alone 
generated of TNF-α, IL-8 and IL-6. Although not significant, TNF-α, IL-8 and IL-6 
showed an apparent 1, 2.5 and 7-fold increase, respectively, when neutrophils were 
primed with ODN with the addition of fMLP, compared to the agonist alone (P>0.05) 
(Figure 3.13Ai-iii). fMLP-treated neutrophils showed no significant cytokine 
production (P>0.05). IL-1β was below the limit of detection. 
Individual donor responses to the agonist are shown for information (Figure 3.12B-
3.13Bi-iii).  
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3.4 Discussion 
Work presented in this chapter describes the effect of individual bacterial TLR 
agonists on freshly isolated human neutrophils. The first series of experiments used 
a targeted lipidomics approach to compare the ability of calcium ionophore A23187 
and fMLP to stimulate the production of the eicosanoid 5-HETE. 
 
It has been shown previously, in vitro, that neutrophil 5-HETE is generated via the 
FPR1 receptor by the bacterial peptide fMLP (Clark et al. 2011). In the preliminary 
time course experiment the most substantial production of 5-HETE, by the isolated 
neutrophils, occurred following a 2 minute incubation in the presence of either the 
positive control, calcium ionophore, or fMLP. This rapid rate of formation could be 
suggestive of an autocrine mode of action, which is consistent with the observations 
seen by Clark et al., 2011. It cannot be determined from these data if the peak of 
formation is before 2 minutes, or whether levels are already declining by this point.  
Further experiments could investigate this by sampling at shorter time points. The 
level of 5-HETE expression reduced over the time course of 15 and 60 minutes, 
respectively, suggesting possible metabolism of 5-HETE over time. 
For all subsequent experiments the bacterial peptide fMLP was used, to stimulate 
cells for 2 minutes, as it is able to activate all the classic functional activities of 
leukocytes, and acts independently to the TLR system (Pan et al. 2000).  
 
3.4.1 Human neutrophil generation and detection of 5-HETE 
Once the optimal time point of neutrophil activation was established, experiments 
then went on to analyse the generation of 5-HETE by isolated human neutrophils 
when primed with a comprehensive set of bacterial TLR agonists. TLR signalling is an 
important factor in host defence, playing a crucial role against a wide range of 
microorganisms (Bauer 2008).   
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Neutrophils have a wide array of effects in response to cell receptor TLR ligation, 
including cytokine production, priming, receptor expression and phagocytosis 
(Hayashi et al. 2003). The most studied TLRs are TLR2 and TLR4, mediating responses 
to Gram-positive and Gram-negative bacteria, respectively. TLR2 creates a 
heterodimer with TLR1 to detect triacylated peptides (Pam3CSK4) or TLR6 to detect 
diacylated peptides (FSL), whereas TLR4 recognises the lipid A component of 
lipopolysaccharide (LPS) (Prince et al. 2011).  
TLR5 recognises bacterial flagellin while TLR9 which is an intracellular receptor 
response to bacterial DNA  (ODN) which contains short sequences of non-methylated 
CpG dinucleotides that are at least 20-fold more common in bacterial than vertebrate 
DNA (Hayashi et al. 2001; Jozsef et al. 2006).  
 
The most meaningful comparisons made within this body of work are between the 
neutrophils primed with the TLR agonist then activated with fMLP or exposed to 
fMLP alone. This is because it carries the most biological relevance, mimicking what 
would happen during infection as the host would be exposed to multiple pathogen 
derived signals. It was observed that there were no significant differences in 5-HETE 
production between these groups for any of the TLR agonists. This indicates that 5-
HETE generation does not vary depending on the nature of the bacterial agonist, 
however, there may be several contributing factors.    
 
Work here indicated that treatment of isolated neutrophils with Escherichia coli K12 
LPS alone (TLR4 agonist), failed to stimulate the production of detectable 5-HETE. It 
may be the case that LPS alone does not prime human neutrophils (Hayashi et al. 
2003; Kurt-jones et al. 2002). Commercially available LPS contains a significant 
amount of bacterial lipopeptide, a known TLR2 agonist and thus should be viewed as 
a dual TLR2 and TLR4 agonist (Hayashi et al. 2003). However, this is not the case for 
the LPS employed in this study as ultra-pure LPS was used. 
It is known that treatment with the immune modulator granulocyte-macrophage 
colony-stimulating factor (GM-CSF) primes neutrophils to response to LPS (Kurt-
Jones et al. 2002).  Kurt-Jones et al., also described the synergistic effect of GM-CSF 
treatment prior to TLR2 stimulation, indicating that TLR2 expression was also 
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increased after GM-CSF treatment. This finding supports the fact that in this study 
neutrophils exposed to TLR1/2 agonist Pam2CSK4 showed little to no 5-HETE 
formation in response to the agonist alone. This lack of expression seen after 
treatment with the agonists alone was seen across all TLR agonists. This could 
indicate that cells may need pre-treatment with an immune modulator, such as GM-
CSF, to increase receptor expression and induce an eicosanoid response to all 
bacterial agonists. It has been suggested by Hallett & Lloyds that priming is a 
laboratory artefact. However, they go on to discuss that in a physiological situation 
it is hard to envisage neutrophils being directly exposed to an activating stimulus at 
a high concentration without first being  exposed to a lower concentration (Hallett & 
Lloyds 1995). Therefore, transition from resting to activated may possibly proceed 
via an intermediate primed state.    
 
In vitro, priming with either Gram-negative LPS or Gram-positive Pam3CSK4, HKLM 
and FSL before subsequent fMLP activation showed a slight additive effect in terms 
of 5-HETE production when data were normalised, although not significant. This 
suggests that additional bacterial factors could enhance 5-HETE generation, in 
response to these TLRs. Clark et al., showed that levels of 5-LOX lipids generated in 
vitro and in vivo were remarkably similar, suggesting that 5-LOX-derived lipids will 
occur in response to Gram-positive and -negative organisms, stimulated by bacterial 
factors and thus is probably a common response to acute infection.  
 
In contrast to the other agonists, when data were normalised, both the fixed 
concentrations of TLR5 flagellin and TLR9 ODN showed a non-significant decrease in 
fMLP-dependent formation of 5-HETE.  This suggests that the concentration of the 
agonists employed may need to be increased to look at the dose response of these 
cells when exposed to the agonists, or that the exposure time for these specific 
agonists may need to be extended to see a greater response. It is also possible that 
the neutrophil cell type requires a co-stimulation for activation of the cell response, 
or synergy between TLRs for activation to be increased (Kurt-jones et al. 2002; Clark 
et al. 2011).  
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3.4.2 Human neutrophil generation of proinflammatory cytokines 
In conjunction with 5-HETE formation, I also examined the ability of isolated human 
neutrophils to produce the following proinflammatory cytokines, TNF-α, IL-1β, IL-6 
and IL-8, when exposed to the bacterial TLR agonists. In contrast to 5-HETE, it was 
seen that cytokine generation was not fMLP-dependent. Cytokine production 
showed a more consistent response between donors compared to lipid generation. 
It is unknown whether this response would mirror physiology as to date there are no   
published studies comparing cytokine and lipid profiles generated from human 
donors. However, the responses suggest that there may be potential to use both 
mediators as a double marker of infection, using cytokine expression as a well-
characterised initial readout followed by the possibility to confirm microbial species 
with HETE formation. 
 
The proinflammatory cytokines TNF-α and IL-1β are two of the most potent cytokines  
implicated in infectious and non-infectious diseases (Schulte et al. 2013). They both 
amplify the inflammatory cascade, in a autocrine and paracrine manner, by activating 
macrophages to secrete other inflammatory cytokines (IL-6 and IL-8), lipid mediators 
and reactive oxygen species (Schulte et al. 2013).  The minimal levels of TNF-α and 
IL-1β seen with Pam3CSK4 generation may imply that agonist concentrations need 
to be increased to look at a dose response of the cells to agonist exposure. However, 
HKLM was used at its maximal working concentration (InvivoGen, tlrl-kit1hw) and is 
unlikely to induce a greater TNF-α response. As previously suggested it is also 
possible that the neutrophil cell type requires a co-stimulation for activation of the 
cell response (Clark et al. 2011), or that the number of neutrophils employed in our 
studies need to be increased. Neutrophils primed with Pam3CSK4 before being 
stimulated with fMLP showed an increased production of TNF-α but this was not 
shown to be significant. fMLP alone was not able to stimulate TNF-α formation which 
is consistent with findings that showed a relatively high concentration of fMLP (1 
μM), matching that employed in this study, suppresses the production of TNF-α 
(Divisio 1998). Although it has been reported that saturation of responsiveness of the 
FPR1 fMLP receptor occurs at low concentrations of fMLP (Zigmond et al. 1982), it 
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has been shown that the regulation of many significant biological functions of 
neutrophils requires high concentrations of the formyl peptide (Elbim et al. 1993; 
Tomhave et al. 1994), thus justifying the dose employed.          
 
The TLR agonists LPS (TLR4), flagellin (TLR5) and FSL (TLR6/2) also showed low 
induction levels of TNF-α. Flagellin and FSL had no detectable generation of IL-1β. It 
has been shown that in some cases various TLRs work synergistically to produce a 
response, this could be the case, for example, with Gram-negative LPS and flagellin 
(Mizel et al. 2003). As previously mentioned, it may also be plausible that working 
concentrations of the agonists need to be increased to enable us to see a greater 
response. Even though formylated peptides are well known proinflammatory 
molecules, primed neutrophils with LPS showed little to no formation of TNF-α when 
exposed to fMLP. It must also be taken into account that activated neutrophils also 
secrete many direct inhibitors, for example, the release of superoxide anions and/or 
lysosomal proteases that could affect the biological activity of TNF-α (Divisio 1998). 
 
The intracellular TLR9 agonist ODN failed to produce detectable levels of TNF-α. This 
could be explained by evidence that has shown TLRs to interact in synergy or in a 
sequential fashion to amplify an innate immune response (Bhan et al. 2007).  
Although minimal, ODN was the only TLR agonist seen to generate the 
proinflammatory cytokine IL-6.  This cytokine has a variety of biological functions, the 
main one being to mediate an acute phase response to inflammatory stimuli 
characterised by an induced fever, leucocytosis and release of hepatic acute phase 
proteins such as C-reactive protein (Schulte et al. 2013).  
It has been speculated that low level of expression could be due to the purity of the 
isolated neutrophils, where high purity neutrophils (>99%) release detectable, but 
considerably less, IL-6 than standard neutrophil preparations (~5% contaminating 
cells) (Jozsef et al. 2006). However, the method of isolation used in this study 
provides the standard neutrophil preparation. 
It may also be the case that the number of neutrophils used for TLR exposure needs 
to be increased to be able to detect higher levels, however, this would be difficult as 
individual donors produced varying amounts of neutrophils. Another possibility is 
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that the time point of formation differs between cytokines, for example one study 
showed that flagellin (TLR5) induced IL-6 production where levels peaked at 2-hours 
exposure and had declined by 4 hours (Hayashi et al. 2001).  
 
The proinflammatory cytokine IL-8 was found to be secreted in abundant quantities 
by isolated human neutrophils stimulated with all bacterial TLR agonists. In all cases 
the agonists alone were able to generate the production of IL-8.  This was also the 
case when neutrophils were exposed to fMLP without the TLR agonist, which 
corroborates finding that indicate fMLP is a potent inducer of IL-8 release in human 
neutrophils (Hidalgo et al. 2015).  Four of the 6 bacterial agonists, Pam3CSK4, HKLM, 
Flagellin and FSL, showed an increased generation of IL-8 when neutrophils were 
primed prior to treatment with fMLP. This could indicate a possible synergy between 
TLR priming and fMLP activation, as it has been reported that the addition of fMLP 
increases NADPH oxidase activity and reactive oxygen species production, which 
favour the activation of the NF-kB transduction pathway involved in IL-8 release by 
neutrophils (Hidalgo et al. 2015). Normalised data showed that the Gram-positive 
ligands, Pam3CSK4, HKLM and FSL showed similar responses in terms of stimulating 
IL-8 generation compared to the other TLRs, which supports other findings that there 
is no difference between TLR ligands inducing release of IL-8 (Hilda & Das 2016).   
 
3.4.3 Variability of neutrophil responses from different donors  
This body of work proposes many factors that should be taken into consideration 
when interpreting the data. These include the diverse range of responses seen from 
individual donors following exposure of their neutrophils to TLR agonists. A 
retrospective power calculation was carried out to show how many donors would be 
needed in order to obtain significant results (TLR + fMLP Vs. fMLP). Based on the data 
collected in this chapter, and presuming donors are representative of the population, 
the study would require a sample size of 724 donors to achieve a power of 80% to 
declare that the conditions have significantly different means (i.e. a two sided p-value 
of less than 0.05) (Dhand & Khatkar 2014). With such a limited group of donors it is 
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also not possible to speculate whether any outliers within the donor responses (e.g. 
as seen with pam3CSK4) are in fact extreme outliers or are a genuine member of the 
population. This indicates that, as the donor cohort was extremely small, a much 
larger data set would need to be carried out to allow for the diverse variation 
between donors in a population and enable more significant comparisons between 
responses. This is an important point as the human race is outbred and thus 
observing a wide range of responses would be expected. The challenge in terms of 
predicting infection is determining which response is outside the ‘normal’ range. 
 
Due to the ethics of the study presented in this chapter no information about the 
donors, such as gender and age, can be disclosed. Donors within this study were 
considered to be ‘healthy donors’. This meant that they had not consumed alcohol 
within 12 hours of their morning blood draw and not taken non-steroidal anti-
inflammatory drugs as they are known to inhibit the arachidonic acid cascade (Meirer 
et al. 2014). Donors were also required to have no known health conditions or 
diseases. For example, an individual with unstable asthma or someone who had 
suffered a recent asthmatic attack may present with elements of an infection, 
meaning that an inflammatory immune response would already be triggered (Lin et 
al. 2014). However, any possible underlying unknown conditions could have had an 
impact on their immune response. 
 
Another factor to be considered is the varied ethnicities presented within an 
undefined donor population. This has been seen to demonstrate different 
characteristics, for example, people of African descent have been observed to have 
a reduced neutrophil count compared to individuals of European ancestry (Reich et 
al. 2009). Other influences to consider include age, gender, diet and lifestyle, which 
are all know to have an effect on the immune system function (Nakanishi et al. 2004; 
Oertelt-Prigione 2012). These factors further indicate the need for a larger donor 
pool within a defined population and could all be reasons for the diverse variation 
seen within donor responses in this body of work. 
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3.5 Conclusion  
Work in this chapter observed that primary neutrophil exposure to bacterial TLR 
agonists stimulated the generation of the eicosanoid 5-HETE and proinflammatory 
cytokines. The TLR agonist results indicate that components derived from different 
bacteria had varying effects on the neutrophil 5-LOX pathway. This supports the idea 
that it may be possible to use LOX (or other eicosanoids) as an indicator of the 
presence of bacteria during an acute inflammatory response. This work also observes 
that all the TLR agonists explored in this study were able to induce neutrophils to 
secrete cytokines, and supports the concept that neutrophils form a link between 
innate and adaptive immune systems as cytokines are mediators between various 
immune cells during an immune response. 
 
The response of primary human neutrophils was examined as they play a central role 
in the human immune response to infection.  Although primary neutrophils have a 
limited lifespan, they do offer a number of advantages over a cell line, specifically, 
that they are more cost-effective compared to using a cell line; they carry a lower 
risk of gene mutations; and are isolated directly from the tissue and therefore 
resemble primary tissue characteristic and the capture the genetic diversity of 
individual donors thus increasing their biological relevance (Welser-Alves 2015).  
 
Indeed, it is this diversity and the wide range of “normal” responses generated by 
the human race that represents the principal challenge when seeking to identify a 
specific response indicative of bacterial infection. 
  
To be able to get a real understanding of the biological readouts seen in this chapter 
a much larger cohort of donors would need to be analysed to allow for the variability 
seen within a population.  A further issue which arose during this chapter of study 
was the unpredictable quantity of neutrophils isolated from the peripheral blood of 
individual donors, which in some cases was too low to support planned experiments. 
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These issues coupled with the need to markedly increase the donor pool to account 
for the natural variation within the population lead us to investigate the feasibility of 
employing a human immortalised cell line THP-1 to characterise the responses to 
individual TLR agonists (Chapter 4).




4 Detecting the production of 15-HETE and 
proinflammatory cytokines by human THP-1 
monocyte derived macrophages  
  
   94 
4.1 Introduction 
There are numerous methods used to study macrophages in vitro, with the most 
common being either the use of primary peripheral blood mononuclear cells (PBMCs) 
or monocyte cell lines with standardised degrees of differentiation. As demonstrated 
in Chapter 3 primary cells are highly variable, which is why monocyte cell line 
populations are frequently used as models. As previously mentioned, when isolated 
from human whole blood donations, cells are limited in numbers. This, coupled with 
the fact that primary tissue macrophages cannot be readily expanded ex vivo, limits 
use of these primary cells when needed in protocols requiring large numbers of cells 
(Daigneault et al. 2010).  It is also important to produce a standardised population of 
cells due to the wide variation in responses seen in primary cells, as demonstrated in 
Chapter 3. The use of cell lines are advantageous as they present a homogeneous 
genetic background which reduces the variability in cell phenotype. However, it is 
important to note differences in their differentiated state can lead to variations in 
cell responses and therefore experiments may not always accurately predict the 
behaviour of differentiated tissue macrophages (Daigneault et al. 2010; Lund et al. 
2016). Cell lines are also very sensitive to good culture conditions, and in some cases 
can undergo differentiation as a result of inconsistencies within their culture 
conditions, which can subsequently affect the outcome of the study (Aldo et al. 
2012).        
 
A possible model system for neutrophils is the human leukaemia cell line HL-60, 
which can be stimulated with agents such as dimethyl sulfoxide (DMSO) to 
differentiate into neutrophil-like cells (Hauert et al. 2002). However, conflicting data 
suggest that these differentiated cells are limited in their capacity to respond to 
stimuli such as formylated peptides, which also activate neutrophils, as seen in 
Chapter 3 (Mangelsdorf et al. 1984). There are several examples of monocytic cell 
lines, which include human U937, HL-60 or THP-1 (Aldo et al. 2012) and mouse RAW 
264.7 cells (Schrimpe & Wright 2009). Human THP-1 cells are the most widely 
employed to investigate the function and expression of primary human macrophages 
during disease (Lund et al. 2016). THP-1 cells are a human monocytic leukaemia-
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derived cell line, acquired from the peripheral blood of a one-year-old male with 
acute monocytic leukaemia (ECACC 2016). These cells are differentiated into 
monocyte-derived macrophages using phorbol 12-myristate 13-acetate (PMA), and 
are accepted as a model to study immune response because of the similarities in 
their responses, which closely resemble those of primary human macrophages 
(Chanput et al. 2010; Lund et al. 2016). 
 
It has been reported that expression of 15-lipoxygenase (15-LOX) and 
proinflammatory markers have been used to look at correlations during ischemic 
heart disease and atherosclerosis; cells employed included isolated human 
peripheral blood monocytes and subsequent cell culture into macrophages, isolated 
human carotid plaque macrophages and differentiated THP-1 cells (Magnusson et al. 
2012; Wuest et al. 2012; Hultén et al. 2010; Danielsson et al. 2008). Literature has 
also shown that overexpression of 15-LOX in THP-1 monocyte-derived macrophages 
generates 15-HETE when infected with recombinant adenoviral vectors (Danielsson 
et al. 2008). These studies show that macrophages have been seen to generate 
markers of non-infectious and infectious disease. The major advantages of using THP-
1 cells over primary cells is their homogeneous genetic background which abolishes 
donor variability, and they are easily accessible and obtained without contamination 
with other blood components (Schildberger et al. 2013). Therefore, this readily 
available cell line will be employed in this body of work, with the appreciation that 
extrapolation of the results for in vivo settings will be with care.   
 
This chapter proposed to establish a growing culture of human THP-1 monocyte cells, 
which could be differentiated into monocyte-derived macrophages, and used as a 
standardised population of cells to produce readouts in response to bacterial 
treatment. Initial experiments aimed to use a lipidomic approach, described in 
Chapter 3, to show that differentiated human THP-1 cells generate 15-lipoxygenase 
(15-LOX) derived lipids, when activated with the stimuli calcium ionophore A23187 
and fMLP. As detailed in Chapter 1, calcium ionophore A23187 promotes calcium 
mobilisation and subsequent translocation of the enzyme, 15-LOX, to the inner 
membrane surface, and is a commonly use stimulus for the generation of these lipids 
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in human and animal macrophages (Hammond & O’Donnell 2012). The potent 
formylated chemotactic peptide, fMLP, is similar in structure to oligopeptide 
products of bacterial metabolism (Holian & Daniele 1981). Both neutrophils and 
macrophages are known to display the specific formyl peptide receptor for fMLP, 
allowing cells to respond to infection/inflammation (Shrivastava 2007).  
 
As discussed in Chapter 1, innate immune cells produce and release an array of 
cytokines in response to inflammation and infection in the body, and modulation of 
this inflammatory signalling during systemic infection has been considered a possible 
means to improve survival (Osuchowski et al. 2006; Lacy & Stow 2011). Activated 
monocytes, macrophages and neutrophils generate cytokines, chemokines, cell 
surface receptor/adhesion proteins and other molecules as part of an immune 
response essential to host defence during bacterial infection (Z. K. Pan et al. 2000). 
As previously discussed, proinflammatory cytokines, including interleukin-1beta (IL-
1β), interleukin-8, interleukin-6 and tumour necrosis factor (TNF), are some of the 
most well studied proteins that regulate inflammation (Anderstam et al. 2012). 
Techniques will be employed to confirm cytokine generation alongside eicosanoids.  
 
4.1.1 Aims of this chapter  
The first aim of the work reported in this chapter was to use a lipidomic approach to 
determine whether the human monocytic THP-1 cell line generated 15-lipoxygenase 
(15-LOX) lipids, when differentiated into THP-1 monocyte-derived macrophages and 
thus allow me to use these cells as an in vitro model for macrophage bacterial 
response. The second aim was to confirm the production of selected 
proinflammatory cytokines from differentiated THP-1 cells, in response to LPS 
stimulation.    
 
The objectives were:  
1. To establish a growing culture of human THP-1 monocyte cells and 
successfully differentiate them into THP-1 monocyte-derived macrophages. 
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2. To examine the effects of calcium ionophore A23187, using mass 
spectrometry detection of THP-1 macrophage 15-HETE formation.  
3. To use ELISAs to analyse the cell supernatant after stimulation to detect 
proinflammatory cytokine generation.  
 
4.2  Specific materials and methods  
4.2.1 Human monocyte THP-1 cell culture 
The cell line was purchased from Public Health England’s European Collection of 
Authenticated Cell Cultures (ECACC 88081201). Sigma-Aldrich Company Ltd 
(Gillingham, Dorset, UK) supplied all cell culture reagents unless otherwise stated.   
 
THP-1 cells were maintained in RPMI-1640 supplemented with heat-inactivated 
foetal calf serum (FCS; 10% v/v) and 2mM L-glutamine (ThermoFisher Scientifics, 
Gibco 25030-081) (referred to hereafter as THP-1 media). The cells were grown in a 
humidified incubator at 37°C in the presence of 5% CO2.  
 
4.2.1.1 Revival of stock THP-1 cells from liquid nitrogen storage 
Cells were removed from liquid nitrogen storage and placed on ice to allow gentle 
thawing.  Routine culture media (RMPI-1640 with 10% heat-treated FCS and 2mM L-
glutamine) was added to the cells and centrifuged at 300g for 5 minutes. The 
supernatant was removed, and the cells were re-suspended in fresh culture media 
before being transferred to a T-25 cell culture flask (Sigma-Aldrich).  The flask was 
stood upright and incubated at 37°C in the presence of 5% CO2.        
4.2.2 Human monocyte THP-1 cell differentiation 
To optimise differentiation, cells were exposed to varying concentrations of phorbol 
12-myristate 13-acetate (PMA) ranging from 0.5-100 μmol/L over a time course of 
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24-72 hours (stock PMA was dissolved in dimethyl sulfoxide (DMSO)).  Optimisation 
showed that exposing the cells to 0.5 μmol/L PMA for both 24 and 48 hours had the 
best rate of differentiation. Differentiation was determined by adherence. For all 
subsequent experiments THP-1 cells were differentiated in accordance with these 
findings. 
 
For differentiation into a macrophage phenotype, THP-1 cells (used at 5 x 105 
cells/0.5mL) were incubated for 24 and 48 hours with PMA (0.5 µmol/L) in a 24 well 
tissue culture plate (Corning).  After 24-hours non-adherent cells were removed by 
gently washing the cells in fresh THP-1 media when looking for cytokine secretion or 
RPMI-1640 media alone when looking for eicosanoid generation. Adherent cells were 
incubated and allowed to recover in the appropriate fresh THP-1 media or RPMI-
1640 for a further 30 minutes prior to use.  
 
4.2.3 THP-1 cell fluorescent staining and microscopy 
THP-1 cells (2.5x105) were grown in glass bottom dishes (MatTek, ThermoFisher 
Scientifics), either untreated or PMA-treated (0.5 µmol/L) (as above) for both 24 and 
48-hours. Cells were washed and re-suspended in phenol red-free RPMI 1640, 10% 
FCS-HI, 1% L-glutamine. Hoechst 33342 (ThermoFisher Scientifics) nucleic acid stain 
is a semi-permeant counter stain that emits blue fluorescence when bound to 
dsDNA.  Hoechst was prepared by diluting the stock solution 1:10,000 in media.  
Sufficient staining solution was added to cover the cells (~ 1mL) and incubated (37°C, 
5% CO2) for 5-10 minutes, protected from light.  The Hoechst was subsequently 
removed from the cells by washing them in fresh media. Non-differentiated THP-1 
cells were spun at 150g for 3 minutes as they are non-adherent. The cells were then 
counter stained with CellMask™ Orange (Life Technologies, C10045), which is a 
plasma membrane stain that allows a fast and uniform labelling of the plasma 
membrane for standard fluorescence microscopy. Stock was diluted 1:10,000 in 
media and 1 mL was added to the cells before being incubated for a further 3 
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minutes.  Cell were then washed again with fresh media and replaced with 
approximately 1 mL media and incubated.      
 
Fluorescent images were acquired using a Leica DMIRB inverted microscope 
equipped with a 40x oil objective (Cardiff School of Pharmacy). Ultraviolet (UV) light 
was used to activate the Hoechst (excitation wavelength 360 nm), which emits blue 
fluorescence between a wavelength of 460 to 490 nm. Green light was used to 
activate the CellMask™ Orange (excitation wavelength 554 nm), which emits orange 
fluorescence 567 nm. Fluorescent images were detected using Alexa 350 spectrum 
to identify the nucleus and Cy5-666 spectrum to identify the plasma membrane.  
Differential interference contrast (DIC) microscopy was performed using a Leica 
DMIRB inverted microscope equipped with 10x objective and using the brightfield 
mode with a “Ph1” setting on the phase selector ring. 
 
4.2.4 Generation and identification of 15-HETE 
To generate 15-HETE from these cells, subsequent to differentiation, THP-1 
monocyte-derived macrophages were stimulated with either calcium ionophore 
(A23187; 10 µM) or fMLP (1 µM) and 2.5mM CaCl2 and 1.25mM MgCl2 for 2, 15 or 60 
minutes. Samples for 15-HETE analysis were then extracted using lipid hexane 
extraction described in Chapter 2, section 2.6. Reverse-phase LC/MS/MS of lipids was 
then carried out to identify generation of 15-HETE. The specific method used is the 
same as that described in Chapter 3 section 3.1.3, however, to quantify the 
detections of 15-HETE the MRM transition used was 319-219. 
 
4.2.5 Generation and identification of proinflammatory cytokines 
Enzyme-linked immunosorbent assays (ELISAs) were used to determine any cytokine 
expression from differentiated THP-1 monocyte-derived macrophages in response to 
different stimuli. Differentiated cells were incubated with fMLP (1 µM) and calcium 
ionophore A23187 (10 µM) over a 60 minutes time course to confirm the production 
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of proinflammatory cytokines. Following incubation, cell-free supernatants were 
transferred into fresh Eppendorf tubes for subsequent cytokine analysis.  Cytokine 
analysis was carried out using the R&D Systems Human DuoSet ELISAs described in 
Chapter 3, section 3.1.4.  
 
Cytokine secretion was also identified following E. coli K12 lipopolysaccharide (LPS) 
activation. THP-1 cells were differentiated for 24 hours with PMA (0.5 µmol/L), cells 
were washed in RPMI-1640 before being exposed to varying concentrations of LPS 
(1, 10, 100 ng/mL) for 0, 1, 4 and 24 hours.  Samples were analysed for cytokine 
production using ELISAs as previously described. 
 
To determine cytokine secretion under basal conditions, THP-1 cells were 
differentiated with PMA (0.5 µmol/L) for 24 hours.  Cells were subsequently washed 
in fresh media and the supernatant was collected over a time course of 4 hours. 
Samples were analysed as above. 
 
4.2.6 Statistical analysis 
Statistical analysis was carried out as described in Chapter 2, section 2.10. 
 
4.3 Results  
4.3.1 Optimisation of THP-1 cell differentiation 
A standardised human monocyte cell line (THP-1) was employed to characterise the 
eicosanoid and cytokine response of different bacterial agonists. Human THP-1 
monocyte cells were cultured as previously described. Originally, cells were 
differentiated using methods provided in Connon et al. 2003.  In this protocol, cells 
were incubated (37°C) for 3 hours in the presence of PMA (0.5 μmol/L) to allow for 
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cell differentiation.  However, it was found that after this period of time most cells 
had not adhered to the plate therefore indicating a lack of cell differentiation.   
 
Optimisation indicated that THP-1 cells plated in 24-well plates at 0.5 x 106 cells/well 
with 0.5 μmol/L PMA and incubated for 24 and 48 hours were the optimum 
conditions for cell differentiation. Cell adherence was indicative of differentiation. 
Following incubation, cell supernatant containing PMA was removed and cells were 
washed in RPMI-1640 media alone and allowed to recover for 30 minutes at 37°C. 
When analysing the generation of eicosanoids, cells were washed in RPMI-1640 
media alone, as culture media with foetal calf serum contains high levels of all 
hydroxyicosatetraenoic acids (HETE), which were not seen in RMPI-1640 alone 
(Figure 4.1). Therefore, for all subsequent experiments activation of the cells was 
done in RPMI-1640 alone.  
 
4.3.2 PMA-Induced differentiation of THP-1 monocyte into macrophages  
THP-1 cells were differentiated into macrophages by the treatment with 0.5 μmol/L 
PMA for 24 hours. The treatment induced the typical features of macrophages, 
represented by cell adhesion, spread morphology, increased granularity and irregular 
nucleus shape, as detected by brightfield and fluorescent microscopy (Figure 4.2). 
Differentiation of monocytes into macrophages show an association with a reduction 
on the nucleocytoplasmic ratio due to an increase in cytoplasmic volume  
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(Daigneault et al. 2010). Undifferentiated cells are spherical in shape (Figure 4.2 Ai) 
with an average diameter of 16 µm (Chitra et al. 2014). As expected, differentiated 
THP-1 monocyte-derived macrophages increased their cytoplasmic volume to an 
average of diameter of 24 µm (Figure 4.2 A-Bii-iii) compared to THP-1 monocytes 
(Figure 4.2 A-Bi). PMA treatment also enhances the adherence and granularity of the 
THP-1 cells with monocyte-derived macrophages displaying an amoeboid and 
granular morphology (Figure 4.2 Aii-iii) relative to untreated cells (Figure 4.2 Ai). 
Through observation there appears to be increased granularity, which results from 
an increase in certain membrane bound organelles (Daigneault et al. 2010). 
Macrophage differentiation also induces an irregular nucleus shape (Figure 4.2 Cii-iii) 
compared to monocyte cells (Figure 4.2 Ci).      
 
4.3.3 Basal levels of cytokine expression in differentiated THP-1 cells  
The basal line status of the culture, prior to any stimulation, is a critical factor to 
establish for the differentiated cell response. THP-1 cell cytokine secretion after 
differentiation with PMA (0.5 mol/L) over a time course of 4 hours demonstrated 
basal levels of each proinflammatory cytokine TNF-α, IL-1β, IL-8 and IL-6 (Figure 4.3). 
A similar pattern of increased secretion over time was shown across all proteins, 
between 0 and 4 hours. Cytokine secretion typically increased over time, with the 
highest seen at 4 hours. This increase was significantly different for TNF-α, IL-1β and 
IL-8 at 2 and 4 hours compared to time 0, (P<0.05, P<0.05 and P<0.0001, 
respectively). Concentrations of IL-8 were considerably enhanced, reaching ~2500 
pg/mL at 4 hours, which indicates a 7 and 24-fold increase compared to TNF-α and 
IL-1β, respectively. IL-6 displayed the lowest levels of generation peaking at ~15 
pg/mL. IL-6 had no significant increased at any point compared to time 0, (P>0.05). 
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4.3.4 Human THP-1 cell generation and identification of 15-HETE eicosanoid 
The 24 and 48 hour differentiated cells were stimulated with the positive control 
calcium ionophore A23187 (10 μM) agonist, which is routinely used to induce 
expression in macrophages (Wilson et al. 1993), at 37°C for 2, 15 and 60 minutes. 
This narrow time course was used as an initial look at eicosanoid formation as 
previous data, in Chapter 3, showed rapid eicosanoid generation from human 
neutrophils at 2 minutes. Deuterated internal standard 12HETEd8 (5ng/mL) was 
added to all samples followed by lipid extraction as described in Chapter 2, section 
2.6. 
 
In time course studies of activated THP-1 monocyte-derived macrophages; 24 and 48 
hour cell differentiation predominantly showed minimal (~0.01 ng/106cells) 15-HETE 
formation when cells were incubated with calcium ionophore A23187 for 2, 15 and 
60 minutes (Figure 4.4). Cells differentiated for 24 hours showed a >100-fold increase 
in 15-HETE generation (~1.7 ng/106cells) after 15 minute treatment with calcium 
ionophore A23187 compared to the other times points. Cells differentiated for 48 
hours showed an 8-fold increase (~0.09 ng/106cells) at 2 minutes. However, no 
significant generation of 15-HETE was seen with the positive control calcium 
ionophore A23187 (P > 0.05).   
 
To confirm cell activation, 24 hour differentiated THP-1 cells were exposed to 
agonists previously seen in studies to generate cytokines, calcium ionophore A23187 
(10 μM) and fMLP (1 μM) (Wilson et al. 1993; Shrivastava 2007), in the presence of 
Ca2+ (2.5 mM) and Mg 2+ (1.25 mM) for 2, 15 and 60 minutes. Aliquots of supernatant 
were assessed for cytokine generation (Figure 4.5).           
 
Differentiated control THP-1 cells were shown to generate all four proinflammatory 
cytokines; TNF-α, IL-1β, IL-8 and IL-6 (Figure 4.5). THP-1 macrophages exposed to 
each agonist showed no increase in generation of TNF-α at 2 or 15 minutes compared   
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to the untreated cells, at ~20 pg/mL. The fMLP treated cells and untreated THP-1 
cells showed a proportionate increased to ~50 pg/mL in TNF-α at 60 minutes. 
Although not significant, calcium ionophore A23187 induced increased expression of 
both TNF-α (~125 pg/mL) and IL-1β (~320 pg/mL) at 60 minutes compared to both 
untreated and fMLP treated cells (P>0.05). Low levels of IL-1β expression were 
apparent at 2 and 15 minutes with all treatments, with levels between 20-30 pg/mL. 
THP-1 macrophages showed the highest generation of IL-8 compared to all other 
cytokines. IL-8 generation was comparable for all treatments over time at 2 and 15 
minutes (~400 pg/mL). However, IL-8 was seen to increase 2-fold for untreated and 
fMLP treated cells at 60 minutes but remained unaltered in the presence of calcium 
ionophore A23187.  Minimal basal levels of IL-6 were seen in untreated cells over 
time (~3 pg/mL). fMLP and calcium ionophore A23187 had no major effect on IL-6 
production. 
 
4.3.5 THP-1 cell expression after LPS treatment                         
As cytokine expression is usually seen under longer exposure times than those 
previously described in section 4.3.4 (Daigneault et al. 2010), a longer time course 
was carried out over 24 hours. Here, I wanted to confirm cytokine expression under 
a longer time course of exposure and determine whether varying concentrations of 
LPS (1, 10 and 100 ng/mL) had an effect on the generation of cytokines in 
differentiated THP-1 monocyte-derived macrophages.  
    
Treatment with 100 ng/mL LPS, at 24 hours, showed the biggest generation of 
cytokines (Figure 4.6). Cells treated with 1ng/mL LPS showed the same cytokine 
response as the untreated cells. Cell exposure to 10 and 100 ng/mL LPS showed 
increased TNF-α and IL-1β generation compared to the untreated cells at 4 and 24 
hours. TNF-α increased more than 2-fold from ~1300 pg/mL at 4 hours to 24 hours, 
when cells were exposed to 100 ng/mL LPS. IL-1β generation showed a similar 
pattern of generation to TNF-α, with levels peaking at ~1700 pg/mL when cells were   
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exposed to 100 ng/mL LPS for 24 hours. THP-1 cells showed moderate production of 
IL-6 with the most substantial increase being 500 pg/mL seen at 24-hours with 100 
ng/mL LPS, which was 4-fold bigger than that seen at 4 hours. IL-8 had the biggest 
generation amongst the selected cytokines with levels reaching ~8000 pg/mL at 24 
hours.  At 4 hours exposure, untreated and 1 and 10 ng/mL LPS treated cells all 
showed about the same generation of IL-8 at ~2900 pg/mL. However, at 24 hours IL-
8 expression reached its highest levels of ~8000 pg/mL but was consistent across all 
treatments.   
 
4.4 Discussion 
The first aim of this chapter was to use a lipidomic approach to determine whether 
the human monocytic THP-1 cell line generated 15-LOX lipids, when differentiated 
into THP-1 monocyte-derived macrophages and thus allow me to use these cells as 
an in vitro model for macrophage bacterial response. The second aim was to confirm 
the production of selected proinflammatory cytokines from differentiated THP-1 
cells, in response to LPS stimulation. 
 
4.4.1 The effect of culture conditions on THP-1 cells  
Initial experiments aimed to establish a growing culture of human THP-1 monocyte 
cells, which could be differentiated into monocyte-derived macrophages, and used 
as a standardised population of cells to produce readouts of lipid and cytokines in 
response to bacterial treatment.   
 
4.4.1.1 Identification of the presence of lipids in culture medium  
Foetal calf serum (FCS) is the sterile serum obtained from the clotted blood of a 
bovine foetus.  It contains numerous factors that are needed for the survival and 
proliferation of mammalian cells in culture. Therefore, it was important to establish 
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the composition of the media used to culture the cells before looking for lipid 
generation as they may already be present. It was identified that full serum media 
contained increased levels of HETEs compared to RPMI-1640 alone. This is because 
coagulated blood contains oxidised lipids.  When clotting occurs activated platelets 
and leukocytes rapidly produce oxidised lipids through the enzymatic action of 
lipoxygenase (Sarah N. Lauder et al. 2017).  Data confirmed that THP-1 media 
containing FCS showed an array of oxidised lipids compared to RPMI-1640 alone, 
subsequent agonist exposure was carried out using RPMI-1640 alone.   
 
4.4.1.2 Cell differentiation with phorbol myristate acetate  
PMA is a phorbol ester, a class of tumour promoting compounds that can influence 
cell maturation and promote cell surface expression of numerous antigens 
characteristic of human mononuclear phagocytes (Nolfo & Rankin 1990). PMA is one 
of the most common reagents used to induce THP-1 monocyte differentiation into 
macrophage-like cells. To confirm that PMA induced differentiation, microscopy 
images were taken of THP-1 monocytes and 24 and 48 hour PMA-differentiated cells. 
As expected, untreated THP-1 cells were non-adherent, spherical cells. Treatment 
with PMA showed the typical hallmarks of macrophages, including cell adherence, 
which were consistent with that seen by Gatto et al., 2017. The phenotype of cells 
has been seen to vary between studies under PMA stimulations, but this can be 
attributed to concentration of PMA used or time of incubations (Aldo et al. 2012).  
Therefore, to minimise this, for all subsequent data cell differentiation was kept 
consistent at 24 hour PMA treatment.  
 
THP-1 cells were differentiated in the presence of 0.5 μmol/L PMA.  This 
concentration of PMA was previously seen to differentiate THP-1 cells by Connon et 
al., 2003, although a lower concentration than that reported by others  (Danielsson 
et al. 2008; Daigneault et al. 2010; Gatto et al. 2017). As previously mentioned, 
microscopy images at 24 and 48 hours showed the expected attributes of a 
macrophage-like cell. Using a lower concentration of PMA was more appropriate, as 
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it has been shown that the use of increased concentrations of PMA (16-540 nM) for 
THP-1 cell differentiation can be too high, leading to unusually expressed genes 
during the differentiation process and highly upregulated genes appear to 
overwhelm the effect of stimuli on the THP-1 macrophages (Park et al. 2007). Even 
though the THP-1 cell line is a widely accepted model for observing macrophage 
functions and responses to external stimulation in vitro, there is no current 
standardised protocol for the differentiation of THP-1 monocytes to macrophages 
using PMA (Lund et al. 2016). Here, PMA-induced differentiation of THP-1 monocyte 
cells into a macrophage phenotype was represented by cell adhesion and also 
confirmed through brightfield and fluorescent microscopy, which showed a 
characteristic spread in morphology and irregular nucleus shapes (Gatto et al. 2017).           
 
4.4.1.3 Establishing the baseline status of the THP-1 culture  
Next, I analysed the supernatant of PMA-treated THP-1 cells and determined the 
cytokine profile. Cytokine production may be induced through treatment with PMA, 
therefore it was important to establish a baseline level of expression over time of the 
PMA-differentiated cells, prior to any stimulation. This study found that PMA treated 
THP-1 cells did generate cytokines.  It is not clear if THP-1 monocytes elicit this effect 
as they were not tested here, but published data suggests that treatment with PMA 
enhances the THP-1 cell cytokine profile compared to those without PMA treatment 
(Aldo et al. 2012). Data indicated a similar pattern of cytokine secretion that typically 
increased over time, with the highest levels seen at 4-hours. TNF-α, IL-1β and IL-8 all 
showed a significant increase in generation at 2 and 4-hours compared to time 0. 
Concentrations of IL-8 were considerably enhanced compared to the other responses 
and IL-6 displayed the lowest levels of generation.  These levels were consistent with 
those found by Aldo et al. 2012. The increase in baseline expression levels are 
comparable between samples as cell culture conditions were kept consistent 
throughout.  
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4.4.2 THP-1 monocyte-derived macrophage 15-HETE generation 
The initial time course looked at the optimal time point of cell differentiation for 
subsequent 15-HETE generation. Primary experiments indicated that 24 and 48 hours 
displayed the best time point for THP-1 cell differentiation in the presence of 0.5 
μmol/L PMA.   
  
Once optimum differentiation was established cells were treated to confirm 
induction of 15-HETE formation. Data indicated that THP-1 monocyte-derived 
macrophages generated low levels (<0.2 ng/106cells) of 15-HETE, when challenged 
with the positive control calcium ionophore A23187 and analysed using sensitive 
LC/MS/MS over a time course of 60 minutes. Calcium ionophore A23187 is a 
carboxylic acid antibiotic, which bypasses receptor-ligand interactions and selectively 
increases the permeability of cell membranes to calcium, in turn activating cells for 
the release of numerous mediators, including lipids (Nolfo & Rankin 1990).  The time 
course of 60 minutes was used as previous data in chapter 3, along with that shown 
by Morgan et al., 2009 and Clark et al., 2011, indicated rapid production of lipids 
upon cell stimulation. The most substantial amount of 15-HETE was formed after 24-
hour differentiation with PMA, at 15 minutes exposure to calcium ionophore 
A23187. 
 
It has previously been shown that PMA-treated THP-1 cells did not release 
leukotrienes, which are downstream products of 15-HETE metabolism, in response 
to 5 µM calcium ionophore A23187 for 30 minutes (Nolfo & Rankin 1990). This could 
suggest a possible dose response to the stimuli, as results in this chapter of work 
indicate that increasing the concertation of calcium ionophore A23187 to 10 µM did 
stimulate cells to produce eicosanoids, although in much smaller quantities than 
what would be expected for a positive control.  The anticipated quantity of lipid 
generated by calcium ionophore A23187 would be similar to that shown by Morgan 
et al., 2009, who demonstrated the formation of 12-HETE by murine macrophages in 
response to 10 µM A23187 to reach 12 ng/106 cells after 15 minutes stimulation. This 
value indicates a 59-fold increase compared to the THP-1 lipid generation, in 
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response to calcium ionophore A23187, seen in this chapter. Calcium ionophore 
A23187 stimulus is routinely used in experimental conditions as a positive control to 
assess the maximal quantities of eicosanoids released from white blood cells, which 
is why it was selected to establish the overall capacity of THP-1 macrophages to 
release 15-HETE. It could be a possibility that 15-LOX expression may be enhanced 
upon interleukin-4 (IL-4) stimulation of the cells before agonist treatment (Wuest et 
al. 2012; Lauder et al. 2017). However, it might be the case that larger quantities of 
15-LOX derived lipids can only be seen from THP-1 cells engineered to over express 
15-LOX (Danielsson et al. 2008).    
 
To confirm that the lack of 15-HETE generation, in the cells and supernatant together, 
was real and not due to a lack of activation, the next step was to assess the cell 
supernatant, under the same conditions, for proinflammatory cytokine generation.    
 
4.4.2.1 THP-1 cell confirmation of activation 
The human THP-1 monocyte cell line has been widely used to study the immune 
response of monocytes and monocyte-derived macrophages due to the similarity in 
responses when compared to peripheral blood mononuclear cells (Seshadri et al. 
2007; Chanput et al. 2010; Wang et al. 2012). To confirm THP-1 cell activation by 
calcium ionophore A23187 and receptor mediated fMLP, supernatants were also 
analysed for cytokine generation. Exposing 24 hour differentiated THP-1 monocyte-
derived macrophages to the non-physiological calcium ionophore A23178 and the 
bacterial peptide fMLP for 2, 15 and 60 minutes showed that there was an increase 
in TNF-α and IL-1β following treatment with calcium ionophore A23187 in 
comparison to untreated and fMLP-treated cells at 60 minutes. This finding suggests 
that an increase in intracellular calcium is one mechanism by which the TNF-α and IL-
1β genes can be activated.  
The lack of cytokine generation seen by fMLP could be because cytokines are 
produced over a longer time of exposure to treatment, as indicated by Pan et al. who 
showed that fMLP resulted in a time-dependent production of IL-1β with a notable 
   116 
increase in secretion detected after 60 minutes stimulation. Although not significant, 
IL-1β secretion by macrophages in this study showed the most substantial increase. 
IL-1β is one of the main pathological mediators of inflammatory disease, and during 
microbial infection, blood monocytes and tissue macrophages serves as major 
producers of IL-1β (Z. K. Pan et al. 2000). IL-8 was the most generated cytokine and 
also indicated, at 60 minutes, the pattern seen in IL-6. These findings were also 
shown by Wilson et al. who indicated that calcium ionophore A23187 induced IL-8 
gene expression and protein secretion in THP-1 cells.  
 
The time course of activation showed clear generation of all cytokines in response to 
both untreated and treated cells.  These data confirm that 24 hour differentiated 
THP-1 cells do release detectable levels of the proinflammatory cytokine when 
stimulated with calcium ionophore A23187, as expected, and therefore had been 
activated when looking for 15-HETE generation, thus proving that the lack of 15-HETE 
is a real result.  
 
However, as 60 minutes was the longest time point in this experiment, the effect of 
calcium ionophore A23187 and fMLP on cytokine generation after this time is 
unknown.  This time course was used as an initial study to confirm cell activation 
during lipid analysis, and a previous study had shown detectable cytokine levels 
between 0 and 60 minutes (Z. K. Pan et al. 2000).  The time course of exposure for 
the THP-1 cells could be increased to give an additional indication of the pattern of 
release over 24 hours. Although not the aim here, increasing the time point of 
incubation with stimuli will correlate with the literature, which has shown human 
monocytes and monocyte-derived macrophages as well as THP-1 cells being exposed 
to various bacterial components for up to 30-hours (Seshadri et al. 2007; Chanput et 
al. 2010; Daigneault et al. 2010).  Therefore, it was thought appropriate to examine 
the cytokine generation of the THP-1 macrophage-like cells over a longer time 
course, in response to a well-known bacterial agonist E. coli K12 lipopolysaccharide 
(LPS).        
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4.4.3 Assessment of the proinflammatory response of differentiated THP-1 cells 
following LPS stimulation 
To confirm activation of alternative pathways, cells were exposed to varying 
concentrations of the toll-like receptor (TLR) agonist LPS over a 24 hour time course.  
Concentrations of LPS used were taken from those described in other studies (Park 
et al. 2007; Lund et al. 2016), making data comparable and allowing further 
confirmation that the cells were behaving as expected in terms of proinflammatory 
response, therefore indicating the lack of 15-HETE generation to be true.  
 
The binding of the TLR4 ligand LPS to macrophages activates a plethora of signalling 
cascades.  As would be expected the biggest increase was seen across all cytokines 
when cells were challenged with 100 ng/mL LPS for 24 hours. These data are 
consistent with findings demonstrating THP-1 macrophages respond to varying 
concentrations of proinflammatory stimulation (Park et al. 2007). Interestingly, TNF-
α showed the biggest increase after 24 hours treatment with 100 ng/mL LPS 
compared to 4 hours. This was not consistent with Lund et al. who stated that TNF 
secretion levels were maximal at 4 hours post stimulation with LPS. However, 
findings in this chapter were consistent with those of Park et al. who showed 
increased protein concentrations, notably TNF, after 24 hour LPS treatment. This 
work confirmed that THP-1 cells were behaving as expected when differentiated into 
macrophage-like cells, and further indicates the lack of 15-HETE to be a real result.      
Due to time pressures, it was not possible to carry out a lipid extraction and 
LC/MS/MS analysis of LPS stimulated cells to check for any 15-HETE generation. 
However, published data has seen that LPS stimulates cyclooxygenase (COX) 
induction but not LOX (Pfau et al. 2000).   
 
4.5 Conclusions 
There are numerous advantages to be seen from employing a cell line, such as THP-
1, compared to using primary cells, namely having a homogeneous genetic 
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background minimises the degree of variability that can be seen in the cell 
phenotype.  
 
This chapter of results indicate that PMA differentiated THP-1 monocyte-derived 
macrophages  do not generate sufficient levels (>12 ng/106 cells, Morgan et al. 2009) 
of the eicosanoid 15-HETE through the 15-lipoxygenase-enzyme pathway when 
exposed to the positive control calcium ionophore A23187. Though, they can be 
induced to generate the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IL-6, in 
response to calcium ionophore A23187 and LPS. 
The absence of sufficient 15-HETE generation by THP-1 monocyte-derived 
macrophages supports the idea that this standardised cell line cannot be used as a 
suitable human macrophage cell model to look at human cell eicosanoid responses 
to bacterial infection. Also, despite the wide acceptance of this cell line as a suitable 
model for looking at macrophage function and responses, as previously mentioned, 
the lack of a standard protocol for cell differentiation, would make it difficult to 
compare results between studies (Lund et al. 2016). However, the use of a cell line 
does reduce variability and enables a larger quantity of cells to be obtained and used 
over a shorter time frame.   
 
For these reasons, an alternative murine cell line was employed based on RAW 264.7 
macrophages which have been genetically engineered with the 12/15-LOX pathways. 
This cell line, which was developed by Professor Valerie O’Donnell’s Lipidomics Group 
at Cardiff University, has been extensively characterised and is known to generate 
eicosanoids in response to stimuli, therefore representing a suitable model for future 
studies as described in the next chapter.




5 Detecting eicosanoids and proinflammatory 
cytokines generated by 12/15-LOX transfected 
RAW 264.7 murine macrophages   
   120 
5.1 Introduction 
Chapter 1 describes how macrophages contribute to innate immunity through 
methods which include phagocytosis, secretion of inflammatory mediators,  antigen 
processing and presentation to cells of the adaptive immune system (Sigola et al. 
2016). Macrophages are a major source of lipid and protein mediators, and respond 
to a variety of stimuli by generating various eicosanoids and cytokines (Norris & 
Dennis 2014; Berghaus et al. 2010).  
 
As described in Chapter 4, multiple monocyte-lineage cell lines are available, 
including the murine macrophage-like RAW 264.7 cell line. Notably, these cell lines 
display fundamental differences compared to primary cells, due to their continuous 
growth in culture resulting in permanent alterations in their genes. These alterations 
may have an effect on the signalling cascades activated by microbial ligands (Hartley 
et al. 2008). A comparison of murine models and humans also presents additional 
obvious differences in comparative disease pathology and healing, together with 
physiology and anatomy (e.g., bone, skin and blood), which must be taken into 
account (Chamberlain et al. 2009). However, factors including cost effectiveness and 
abundant gene variants mean that murine models are often employed in survey and 
pre-clinical studies as a first step in the transition between in vitro models and pre-
clinical trials (Chamberlain et al. 2009). The increased prevalence of the murine 
model in pre-clinical in vivo studies has led to the widespread use of murine cells as 
in vitro models (Nieves & Moreno 2006; Vigo et al. 2005). This is significant as the use 
of the same species for both in vivo and in vitro work allows for the use of identical 
reagents and permits comparisons of the data.  
 
The RAW 264.7 murine macrophage cell line, the most commonly used mouse 
macrophage cell line in medical research (Hartley et al. 2008), was established from 
a tumour induced by Abelson murine leukaemia virus and has been used in numerous 
studies as a model of primary macrophages (Buczynski et al. 2007; Lee et al. 2016; 
Berghaus et al. 2010). RAW 264.7 macrophages have been shown to express bacterial 
TLR1, TLR2, TLR4, TLR5 and TLR6 on their surface, in addition to the intracellular 
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expression of bacterial TLR9 (Applequist et al. 2002). This cell line would have been 
ideal for my studies; however, native RAW 264.7 macrophages do not possess the 
relevant enzymes to make LOX-derived lipids.            
 
The work reported in this chapter was carried out in collaboration with Professor 
Valerie O’Donnell’s Lipidomics Group, Cardiff School of Medicine. RAW 264.7 murine 
macrophages had been transfected with a vector containing the 12/15-LOX gene. 
This overexpression allows the cells to generate 12/15-LOX lipids, which could 
potentially be enhanced upon stimulation and thus mimicking macrophages in vivo, 
making the cells an excellent model for the proposed study (paper in preparation). 
These cells also carry the ampicillin resistant gene as well as a puromycin resistant 
gene to make them a stable cell line. The cells carrying this 12/15-LOX vector will be 
referred to as RAW 264.7 ALOX macrophages. The RAW 264.7 Control macrophages 
will refer to cells that have also been transfected and are ampicillin and puromycin 
resistant, but the vector does not have the 12/15-LOX gene.      
 
The Lipidomics Group have also developed a robust liquid chromatography/tandem 
mass spectrometry method that can identify and quantitate 110 different 
eicosanoids and fatty acids in a single analysis (paper in preparation). This method 
was applied to the TLR agonist-stimulated and non-stimulated transfected RAW 
264.7 macrophages. It was proposed that if an initial profile could be established in 
response to the TLR agonists, these cells would then be employed to determine 
profiles in response to whole, live bacteria as they would activate multiple TLRs at 
once.  
 
5.1.1 Aims and objectives 
The first aim of this chapter was to employ a targeted lipidomic approach to profile 
the basal eicosanoid content of the transfected RAW 264.7 ALOX macrophages 
compared to the RAW 264.7 Control macrophages. Previous work carried out by 
Buczynski et al., 2007 and Lee et al., 2016 described how liquid-chromatography-
   122 
MS/MS profiles of eicosanoids produced by native RAW 264.7 macrophages varied 
when treated with various agonists, including TLRs. Therefore, work presented in this 
chapter exposes RAW 264.7 Control and ALOX macrophages to the whole array of 
individual bacterial TLR agonists. This was to confirm that the transfected ALOX 
macrophages generated the lipids of interest.  
The second aim of this chapter was to demonstrate whether individual bacterial TLR 
agonists induced varying responses, in terms of their eicosanoid and 
proinflammatory cytokines generation, in RAW 264.7 ALOX macrophages with a view 
to determining which TLR agonists play a key role in early inflammatory signalling.   
 
The specific objectives of the work in this chapter are therefore: 
1. Confirm the distinct eicosanoid profile generated by RAW 264.7 Control 
and ALOX macrophages. 
2. Establish mass spectrometry detection of RAW 264.7 ALOX macrophage 
eicosanoid formation. 
3. Determine the response to TLR agonist treatment.   
4. Compare the cytokine and eicosanoid signalling when exposed to 
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5.2 Specific materials and methods  
The work presented in this chapter was carried out in Professor Valerie O’Donnell’s 
laboratory, Cardiff Lipidomics Group, Division of Infection and Immunity, School of 
Medicine by myself.  
 
5.2.1 Construction of recombinant ALOX plasmid and optimisation of transgene 
expression 
Murine RAW 264.7 macrophages were transfected with pMXs-IRES-Puro retroviral 
plasmid, with (RAW 264.7 ALOX macrophages) and without (RAW 264.7 Control 
macrophages) the 12/15-LOX gene, using standard cloning techniques (Sambrook et 
al. 1989) by Dr Victoria Tyrell, Cardiff Lipidomics Group. The plasmid contains both 
the ampicillin resistance gene (Ampr) and puromycin resistance gene (Puror). 
Transfection of the RAW 264.7 macrophages was carried out prior to the start of my 
project and were fully characterised by Professor Valerie O’Donnell’s Lipidomics 
Group.    
 
5.2.2 Transfected murine RAW 264.7 macrophage culture 
Transfected macrophages were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with-heat inactivated foetal calf serum (FCS; 10% v/v), 
penicillin-streptomycin-glutamine (1% v/v) and puromycin dihydrochloride (150 µl/ 
500 mL DMEM) (referred to hereafter as RAW media). The cells were grown in a 
humidified incubator at 37°C in the presence of 5% CO2.  
 
5.2.2.1 Revival of stock macrophages from liquid nitrogen storage 
Cells were removed from liquid nitrogen storage and placed on ice to allow gentle 
thawing.  Routine RAW media was added to the cells and centrifuged at 300g for 5 
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minutes. The supernatant was removed, and the cells were re-suspended in fresh 
RAW media before being transferred to a T-25 cell culture flask (Sigma-Aldrich). The 
cells were incubated overnight at 37°C in the presence of 5% CO2.        
 
5.2.3 Comparison of basal eicosanoid expression in RAW 264.7 Control and ALOX 
macrophages 
To establish any basal levels of eicosanoids generated by both the RAW 264.7 Control 
and ALOX macrophages, cells were seeded in 6-well plates and left untreated at 37°C 
for 1 hour (5x106 cells/well) and 24 hours (4x106 cell/well) in RPMI-1640 alone. RAW 
media was not used as it contained FCS, which contains oxidised lipids as seen in 
Chapter 4. Cells and supernatant were collected separately. Following incubation, 
both cell and supernatant samples had deuterated internal standard mix added (5 µl 
of 1 ng/µl stock), prepared as detailed in Appendix I. The cell samples went through 
lipid extraction (described in Chapter 2, section 2.6). Subsequently, all samples (cells 
and supernatant) underwent solid phase extraction (SPE) as described in Chapter 2 
section 2.7.   
 
5.2.4 RAW 264.7 ALOX macrophage exposure to bacterial agonists 
The RAW 264.7 ALOX murine macrophages were plated in 6-well culture plates with 
4 mL of RAW media (5 x 106 cells/well for 30 minute exposure, 4 x 106 cells/well for 
24 hour exposure), and allowed to adhere overnight.  Once adhered, the RAW media 
was replaced with 1 or 4 mL RPMI-1640 alone, for the 30 minute and 24 hour time 
points respectively, and stimulated with the bacterial toll-like receptor (TLR) agonists 
(InvivoGen, tlrl-kit1mw). The bacterial TLR agonists used were TLR1/2 Pam3SCK4, 
TLR2 heat-killed Listeria monocytogenes (HKLM), TLR4 E. coli K12 lipopolysaccharide 
(LPS), TLR5 Salmonella typhimurium flagellin, TLR6/2 FSL, and TLR9 synthetic ODN 
1826. Agonists were added at the doses shown in Table 5.1. Cells were incubated at 
37°C in a humidified 5% CO2 atmosphere for either 30 minutes or 24 hours (these 
time points were optimised previously by characterisation of the cells in Professor 
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Valerie O’Donnell’s Lipidomics Group). Cells and supernatant underwent subsequent 




5.2.5 Lipidomic profiling of fatty acids and eicosanoids  
The lipid extract was separated using liquid chromatography (LC)-MS/MS.  Samples 
were separated on a ZORBAX RRHD Eclipse Plus C18 column (1.8 μm, 150 x 2.1 mm; 
Agilent, UK), at a solvent gradient shown in Table 5.2 over 22 minutes. Solvent A was 
made up of 5% solvent B, water, glacial acetic acid at a ratio of 5:95:0.1; v/v/v. Solvent 
B was made up of the solvent mixture acetonitrile, methanol, acetic acid at a ratio of 
80:15:0.1; v/v/v. Samples were injected with an auto-sampler and the sample 
chamber temperature was set at 4°C. The injection volume was 5 μl with a flow rate 
of 1 mL/minute. Electrospray mass spectra were obtained on a Q-Trap instrument 
(Applied Biosystems 6500 Q-Trap; Cardiff School of Medicine, Lipidomics Group) 
operating in the negative mode. Products were analysed using targeted multiple-
reaction monitoring (MRM) mode transitions from the parent ions to the daughter 
ions every 0.60 seconds, scanning for 110 eicosanoids and fatty acids. The area under 
the curve for the parent ion to the daughter ion was integrated and normalised to 
the corresponding deuterated internal standard for that analyte. For quantification 
of the lipid, a standard curve was generated with purified lipids as described in 
Appendix ll. The limit of detection of the internal standard was determined to be 5 
pg. 
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5.2.5.1 Heatmap correlation  
Heatmaps were generated using the pheatmap package in R Studio using hierarchical 
clustering to group similar lipids. Data were first normalised to the mean of the 
unstimulated control values for each lipid. Lipids were colour-coded according to 
their lipid groups. 
 
5.2.6 Proinflammatory cytokine analysis  
Double antibody sandwich enzyme-linked immunosorbent assay (ELISA) was used to 
measure cytokine concentrations. The analysis was performed using R&D systems 
Mouse DuoSet ELISA kits to quantify the concentration of three proinflammatory 
analytes; IL-1β (DY401), IL-6 (DY406) and TNF-α (DY410). The minimal detection 
concentrations were as follows: IL-1β; 15.6 pg/mL, IL-6; 15.6 pg/mL and TNF-α; 31.2 
pg/mL. The ELISA kits were used with an ancillary reagent pack (R&D systems, DY008) 
according to the manufacturer’s instructions. The amount of cytokine was calculated 
using a standard curve generated from a known amount of the analyte provided with 
the kit.           
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5.3 Results  
5.3.1 Baseline profiling in RAW 264.7 Control and ALOX macrophages  
5.3.1.1 Basal eicosanoid expression in RAW 264.7 ALOX macrophages 
Out of the 110 analyte transitions, 30 were detected, using this method, across the 
untreated samples and are displayed in the heatmap (Figure 5.1). All subsequent 
analysis will only discuss lipids that showed the greatest difference between 
untreated and activated cells, out of the 30 that were detected (Table 5.3). In the 
heatmaps, an increase in abundance, compared to other lipids detected, is denoted 
in red, whereas a decrease in abundance is denoted in blue. Deeper tones indicate 
greater differences, with comparisons for individual lipids made across samples. 
Where the enzymes responsible for synthesising the lipid were known, lipids were 
labelled as being derived from their specific pathways. 
 
5.3.1.1.1 Basal generation of eicosanoids in RAW 264.7 Control and ALOX 
macrophages  
The highest abundance of eicosanoids were generated intracellularly at 1 hour for 
both RAW 264.7 Control and ALOX macrophages (Figure 5.1). RAW 264.7 Control 
macrophages generated mainly COX-derived lipids. Whereas, the RAW 264.7 ALOX 
macrophages generated 12/15-LOX-derived lipids, which are not detected in Control 
macrophages.  
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At 1 hour untreated Control macrophages displayed higher levels of lipids generated 
by the COX pathway, compared to ALOX macrophages (Figure 5.1). These 
compounds include COX-derived prostaglandin D1 (PGD1) (69 vs 30 pg/106cells), 
prostaglandin D2 (PGD2) (955 vs 662 pg/106cells), and prostaglandin E3 (PGE3) (5 vs 0 
pg/106cells).  
Lipids generated were mainly seen intracellularly and not extracellularly (Figure 5.1). 
The only lipids seen at 1 hour in the supernatant, for both cell types, were 9(10)-
EpOME (between 51-63 pg/106cells) and 12(13)-EpOME (between 161-193 
pg/106cells), generated from the CYP450 pathway. 
 
Quantification of intracellular 12-HETE and PGD2 eicosanoids generated by RAW 
264.7 Control and ALOX macrophages at 1 hour is shown in Figure 5.2. ALOX 
macrophages showed generation of 12/15-LOX-derived lipids compared to Control 
macrophages (Figure 5.1). Detection of 12-HETE generated by RAW 264.7 Control 
and ALOX macrophages at 1 and 24 hours is shown in Figure 5.3A. ALOX macrophages 
showed a significant increase (P<0.001) in intracellular 12/15-LOX-derived 12-HETE 
(800 pg/106cells) compared to Control macrophages. 12-HETE was not detected in 
Control macrophages. Extracellular 12-HETE was not detected in the supernatant 
from both Control and ALOX macrophages. 
 
Detection of PGD2 generated by RAW 264.7 Control and ALOX macrophages at 1 and 
24 hours is shown in Figure 5.3B. Both Control and ALOX macrophages generated 
COX-derived PGD2. Higher levels of PGD2 were detected intracellularly for both 
Control (938 pg/106cells) and ALOX (537 pg/106cells) macrophages, compared to 
extracellular detection which showed 17 and 125 pg/106cells, respectively. There 
were no statistically significance observations between any of the groups in this data 
set (P>0.05).     
 
Additionally, the oxidation metabolite PGF2α was only identified in Control cell 
supernatant at 24 hours (86 pg/106cells). Untreated macrophages showed a lower   
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abundance of eicosanoids were generated at 24 hours (Figure 5.1). COX and CYP450-
derived lipids including 15-deoxy-12,14-PGJ2 (20-57 pg/106cells), 17,18-DiHETE (2-15 
pg/106cells) and 8,9-DHET (5-11 pg/106cells) were the only metabolites identified in 
the supernatant of both cell types after 24 hours; basal levels were higher in the 
Control macrophages compared to the ALOX macrophages (Figure 5.1).       
 
All subsequent data presented in this chapter represents an n of 1, therefore, no 
statistical analysis could be carried out to indicate any significant differences 
between the TLR agonists.   
 
5.3.1.2 Cytokine generation from RAW 264.7 Control and ALOX macrophages 
Untreated RAW 264.7 Control and ALOX macrophages had levels of TNF-α of 84 and 
129 pg/106cells, respectively (Figure 5.4A).  Levels of IL-6 were below the limit of 
detection in untreated RAW 264.7 Control and ALOX macrophages (Figure 5.4B). 
Unexpectedly, upon stimulation, the cytokine generation between the two cell types 
was not similar (Figure 5.4). Treatment with each agonist lead to higher cytokine 
generation in ALOX macrophages over the Control macrophages. IL-1β was below 
the limit of detection. 
 
All subsequent experiments were carried out using RAW 264.7 ALOX macrophages 
as they are a suitable model for looking at both eicosanoids and cytokines. Even 
though differences in cytokine levels were observed between the two cell lines it has 
previously been reported that native RAW 264.7 macrophages, stimulated with LPS 
and Pam3CSK4 gave similar levels of TNF-α to RAW 264.7 ALOX macrophages, 
suggesting that the transfection with the 12/15-LOX gene did not alter the cytokine 
generation from the RAW 264.7 ALOX cells (Berghaus et al., 2010). Therefore, the 
RAW 264.7 macrophages were considered an appropriate model as they are a closer 
representation of in vivo macrophages.  
   134 
   135 
5.3.2 Eicosanoid generation from RAW 264.7 ALOX macrophages during bacterial 
toll-like receptor activation 
Out of the 110 eicosanoid and fatty acid transitions, (as described in Appendix lll) 39 
were within detectable limits of the mass spectrometer across the samples, when 
exposed to TLR agonists (Figure 5.5). Untreated cells provided a baseline of lipid 
mediators generated by RAW 264.7 ALOX macrophages (Figure 5.5A).  All subsequent 
analysis will only comment on lipids that showed the highest abundance out of the 
39 that were detected (Table 5.4). 
 
5.3.2.1 Gram-positive TLR1/2 agonist Pam3CSK4  
Treatment with the TLR1/2 agonist, Pam3CSK4, showed a higher abundance of lipids 
intracellularly at 24 hours compared to 30 minutes (Figure 5.5B). 12/15-LOX derived 
lipids, including 12-HETE, 15-HETE and 12-HEPE, were only detected intracellularly at 
369, 76 and 62 pg/106cells, respectively. Negligible amounts of lipid were expressed 
extracellularly by the cells at 30 minutes. Only COX- and CYP450-derived lipids, such 
as thromboxane B2, 8-iso PGE2, PGD2, 8,9, DHET and 17,18-DiHETE were seen 
extracellularly at 24 hours, showing levels of 83, 349, 27,172, 39 and 104 pg/106cells, 
respectively.       
 
5.3.2.2 Gram-positive TLR2 agonist heat-killed Listeria monocytogenes (HKLM) 
Treatment with the TLR2 agonist, HKLM, showed the highest abundance of lipids 
both intracellularly and extracellularly at 24 hours (Figure 5.5C) compared to other 
TLR responses. Most 12/15-LOX derived lipids were detected intracellularly, 
including 12-HETE, 15-HETE and 15-HETrE showing levels of 396, 89 and 33 
pg/106cells, respectively. Negligible amounts of lipid were expressed extracellularly 
by the cells at 30 minutes.  Lipids detected extracellularly at 24 hours included   
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CYP450-derived 9(10)-EpOME (49 pg/106cells) and 12(13)-EpOME (236 pg/106cells) 
and COX-derived PGD2 (41,627 pg/106cell). 
 
5.3.2.3 Gram-negative TLR4 agonist lipopolysaccharide (LPS) 
Cell exposure to the TLR4 agonist, LPS, showed the majority of lipids were generated 
intracellularly (Figure 5.5D). 12/15-LOX derived lipids were only detected 
intracellularly, including 12-HETE (354 pg/106cells) at 30 minutes. Negligible amounts 
of lipid were expressed extracellularly by the cells at 30 minutes. Only COX- and 
CYP450-derived lipids, including PGD2, 8-iso PGE2, 9(10)-EpOME and 12(13)-EpOME, 
were seen extracellularly at 24 hours showing levels of 19,728, 257, 17 and 77 
pg/106cells, respectively.  
 
5.3.2.4 Gram-negative TLR5 agonist Flagellin 
The TLR5 agonist, flagellin, showed that the majority of lipids were generated 
intracellularly (Figure 5.5E). 12/15-LOX-derived lipids, including 12-HETE and 15-
HETE were only detected intracellularly at levels of 494 and 103 pg/106cells, 
respectively. Only COX- and CYP450-derived lipids were seen extracellularly at 24 
hours, these included PGD1 (165 pg/106cells), PGD2 (5,746 pg/106cells), 17,18-DiHETE 
(169 pg/106cells) and 9(10)-EpOME (15 pg/106cells). Treatment with flagellin also 
showed the lowest abundance of lipids extracellularly compared to other TLR 
responses. 
 
5.3.2.5 Gram-positive TLR6/2 agonist FSL 
The heatmap shows that treatment with FSL (TLR6/2 agonist) had the highest 
abundance of lipids intracellularly at 30 minutes (Figure 5.5F), compared to other 
lipid responses. 12/15-LOX-derived lipids, including 12-HETE, 15-HETE and 15-HETrE 
were only detected intracellularly at levels of 1081, 179, 65 pg/106cells. Negligible 
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amounts of lipid were expressed extracellularly by the cells at 30 minutes. Only COX- 
and CYP450-derived lipids were seen extracellularly at 24 hours, these included PGD1 
(878 pg/106cells), PGD2 (26,953 pg/106cells) and 15-deoxy-12,14 PGJ2 (10,477 
pg/106cells), and 9(10)-EpOME (12 pg/106cells).  
 
5.3.2.6 Gram- positive and -negative TLR9 agonist ODN 
Treatment with TLR9, ODN, show the lowest abundance of lipids extracellularly 
compared to other TLR responses (Figure 5.5G). 12/15-LOX-derived lipids, including 
12-HETE, 15-HETE and 12-HEPE, were only detected intracellularly at levels of 480, 
125 and 63 pg/106cells, respectively. Negligible amounts of lipid were expressed 
extracellularly by the cells at 30 minutes. Only COX- and CYP450-derived lipids were 
seen extracellularly at 24 hours, these included PGD2 (20,687 pg/106cells), 8,9-DHET 
(88 pg/106cells), 8-iso PGE2 (334 pg/106cells) and PGF2α (4,132 pg/106cells). 
 
5.3.2.7 Comparisons between responses to TLR agonists for selected lipids 
The majority of the lipids generated were detected intracellularly. This was the case 
for 15-HETE, 12-HETE and its downstream metabolite 6-trans LTB4 generation. All 
agonists did not generate higher amounts of 12/15-LOX-derived 12-HETE production 
over untreated levels (296 pg/106cells) at 30 minutes cell analysis, except FSL TLR6/2 
agonist (~1100 pg/106cells) (Figure 5.6A).  
15-HETE showed the same pattern of response at 30 minutes in the cells but with an 
~3-fold decrease in generation compared to 12-HETE (Figure 5.6B). Intracellular 15-
HETE production remained constant at 24 hours.    
 
The potential side product of the COX oxidation of arachidonic acid, 11-HETE, was 
detected intracellularly at 24 hours (Figure 5.6C). All TLR agonist treatments showed   
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the same levels of 11-HETE generation as seen with 15-HETE generation at 30 
minutes, but levels were approximately 20-fold higher compared to the control levels 
of 11-HETE (~44 pg/106cells) at 24 hours.  
Another COX derived lipid, PGB2, was also detected intracellularly and indicated an 
apparent increase in generation in response to TLR6/2 FSL (1066 pg/106cells) at 30 
minutes, compared to all other TLR agonist treatments, which generated levels less 
than half of this value (Figure 5.6D).    
 
There were higher levels of COX-derived lipids in the supernatant after 24 hours 
exposure to the TLR agonists, these included PGD1, PGD2, PGF2α, 13, 14-dihydro-15-
keto PGD2 and 15-deoxy-12, 14-PGJ2 (Figure 5.5B-G). The most abundant eicosanoid 
generated was PGD2. Gram-positive HKLM showed the most intense abundance of 
the COX-derived eicosanoids, namely PGD2, which was expressed at 41,627 
pg/106cells (Figure 5.5C, 5.6E). Gram-positive Pam3CSK4 and FSL showed levels at 
27,172 and 26,953 pg/106cells respectively, whereas Gram-negative LPS and Flagellin 
generated lower amounts at 19,577 and 5,746 pg/106cells, respectively. Intracellular 
Gram-negative TLR9, ODN, showed levels similar to LPS. The downstream metabolite 
of PGD2, 13, 14-dihydro-15-keto PGD2, showed the same pattern of expression for 
each TLR agonist but with over 3-fold lower levels generated compared to PGD2 
(Figure 5.6F).  
 
Looking at the heatmap (Figure 5.5) there are consistent patterns of lipid expression 
between all TLR agonists. Interestingly, 30 minutes showed the highest abundance 
of 12/15-LOX-derived lipids inside the cells and levels were not detectable at 24 
hours in the supernatant. Whilst, at 24 hours, mainly COX-derived lipids were the 
highest generated lipids in the extracellular supernatant. 
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5.3.3 Bacterial toll-like receptor induction of proinflammatory cytokines from RAW 
264.7 ALOX macrophage 
RAW 264.7 ALOX macrophage generated the proinflammatory cytokines TNF-α and 
IL-6 (Figure 5.7). IL-6 was seen to be TLR agonist-dependant as negligible amounts 
were detected in untreated cells. TNF-α was generated in higher amounts compared 
to IL-6, however, the pattern of expression was similar in response to each TLR 
agonist. IL-1β was below the limit of detection (data not shown).           
 
5.3.3.1 TNF-α generation 
Gram-negative TLR4 agonist LPS induced the highest level of TNF-α (25,032 pg/mL), 
whereas, Gram-negative TLR5 agonist Flagellin showed the lowest level of TNF-α 
(5,935 pg/mL) (Figure 5.7A).  Gram-positive TLR6/2 agonist FSL and Gram-negative 
TLR9 agonist ODN generated similar levels of TNF-α (21,834 and 20,469 pg/mL, 
respectively) (Figure 5.7A). The Gram-positive TLR1/2 agonist Pam3CSK4 and TLR2 
agonist HKLM showed slightly lower levels at 18,425 and 14,187 pg/mL, respectively 
(Figure 5.7A).  
 
5.3.3.2 IL-6 generation 
Gram-negative TLR4 agonist LPS again induced the highest level of IL-6 (14,099 
pg/mL), whereas, Gram-negative TLR5 agonist Flagellin showed the lowest level of 
IL-6 (324 pg/mL) (Figure 5.7B).  Gram-positive agonists TLR1/2 PAM3CSK4 and TLR6/2 
agonist FSL and generated similar levels of IL-6 (6,287 and 7678 pg/mL, respectively) 
(Figure 5.7B). The Gram-positive TLR2 agonist HKLM and Gram-negative TLR9 agonist 
ODN showed slightly lower levels at 4841 and 2,983 pg/mL, respectively (Figure 
5.7B).   
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5.4 Discussion 
The work in this chapter represents the first ever measure of lipids and cytokines 
generated from the 12/15-LOX transfected RAW 264.7 murine macrophages exposed 
to an array of bacterial TLR agonists. The initial aim in this body of work was to 
employ a targeted lipidomic approach to profile the basal eicosanoid content of the 
12/15-LOX transfected RAW 264.7 ALOX macrophages compared to the RAW 264.7 
Control macrophages. The next aim of this chapter was to characterise the 
generation of lipids and cytokines by RAW 264.7 ALOX macrophages when exposed 
to individual TLR agonists, to determine any varying responses between agonists. 
 
5.4.1 Comparison of baseline expression between RAW 264.7 Control and ALOX 
macrophages  
Work carried out by Buczynski et al., 2007, described how RAW 264.7 murine 
macrophages were stimulated with 16 different agonists of TLRs, G protein-coupled 
receptors and purinergic receptors. This study showed that 15 different eicosanoids 
were prodcued through the COX and 5-LOX pathway and were detected either 
intracellularly or in the media following stimulation with the agonist. No significant 
differences were seen in the COX metabolite profiles of RAW 264.7 macrophages 
exposed to the agonists and only agonists capable of creating a sustained Ca2+ influx 
were capable of activating the 5-LOX pathway in these cells; this didn’t include TLR 
agonists for the lipids looked at in this paper (Buczynski et al. 2007).          
 
The first part of the work carried out in this chapter evaluated the basal eicosanoid 
profile in RAW 264.7 Control and ALOX macrophages. 12-HETE and 15-HETE are 
synthesised by 12-LOX and 15-LOX, respectively, from arachidonic acid (AA).  The 
enzyme 12/15-LOX generates different isoforms of lipids depending on the species. 
In man, 12/15-LOX will generate 15-HETE whereas in mice it generates 12-HETE. 
Therefore, in work carried out with the RAW 264.7 ALOX murine macrophages 12/15-
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LOX activity was measured as formation of 12-HETE. Several prostaglandins (PGs), 
such as PGD2, PGE2 and PGF2α, are synthesised by COX.  
 
Results here showed the RAW 264.7 Control macrophages, containing the empty 
vector, had basal levels of COX-derived lipids without the presence of any 12/15-LOX 
products. These findings were also demonstrated by Buczynski et al. 2007, who 
showed unstimulated RAW 264.7 cells did not generate 15-HETE but did produced 
COX-derived PGs. Buczynski et al. showed PGD2 to have the highest abundance 
compared to other lipids, which was also the case for the RAW 264.7 Control 
macrophages here.  
Comparing the findings from Buczynski et al. 2007 to the work carried out in this 
chapter confirms that the RAW 264.7 cells carrying the empty vector remain 
unaltered in terms of their lipid generation as they behave the same as the standard 
RAW 264.7 cell line. This is important as it demonstrates that insertion of the empty 
vector itself does not interfere with the lipid generation of the cells when compared 
to the original RAW 264.7 cells.  
 
Analysis of the lipids detected from the RAW 264.7 ALOX macrophages confirmed 
that these cells significantly upregulated the generation of 12/15-LOX-derived lipids 
compared to the RAW 264.7 Control macrophages, where no 12/15-LOX-derived 
lipids were detected. These findings are important as they confirm that the 
transfected RAW 264.7 Control macrophages with the empty vector and the RAW 
264.7 ALOX macrophages carrying the 12/15-LOX gene remain unaltered in terms of 
their natural lipid generation, as they behave the same as the standard RAW 264.7 
cell line.  
 
5.4.2 Comparison of proinflammatory cytokine generation between RAW 264.7 
Control and ALOX macrophages 
An initial comparison of the cytokine profile of both the RAW 264.7 Control and ALOX 
macrophages was established. It was predicted that these cells would generate the 
   146 
same cytokine profile as each other because the transfection shouldn’t alter the 
cytokine production. Data indicated that the RAW 264.7 Control macrophages 
generated cytokine levels that were between 50-100-fold less than those seen by the 
RAW 264.7 ALOX macrophages, when exposed to the TLR agonists. However, one 
study showed that treatment of native RAW 264.7 cells with the TLR1/2 agonist 
Pam3CSK4 and the TLR4 agonist LPS generated ~6000 pg/mL and ~14,000 pg/mL 
TNF-α, respectively (Berghaus et al. 2010). These levels are almost 100-fold greater 
than those seen from the RAW 264.7 Control cells. A possible explanation for the 
difference seen between the RAW 264.7 Control and ALOX cells may be that the LOX 
products generated by the RAW 264.7 ALOX macrophages could upregulate cytokine 
production compared to the RAW 264.7 Control cells (Professor Valerie O’Donnell, 
personal communication). As this data set is a n of 1, with 3 replicates it would need 
to be repeated to make further conclusions. 
 
Both cell types generated TNF-α and IL-6. The proinflammatory cytokine IL-1β was 
below the limit of detection, this finding matched that seen by Merly & Smith, 2005, 
who showed that upon stimulation RAW 264.7 macrophages did not generate levels 
of  IL-1β detectable by ELISA.  IL-8 was not tested for in this data set as mice do not 
carry the IL-8 gene (Asfaha et al. 2013).  
 
Once it was confirmed that the RAW 264.7 ALOX macrophages generated 12/15-LOX 
derived-lipids, the next step was to expose these cells to bacterial TLR agonists and 
establish any patterns in their responses.       
 
5.4.3 RAW 264.7 ALOX macrophage lipid profiling  
As previously described in Chapter 1, macrophages express a large number of distinct 
TLRs, which when stimulated activate cytosolic phospholipase A2 (cPLA2) to liberate 
AA from membrane phospholipids and generate an eicosanoid response by distinctly 
different pathways (Buczynski et al. 2007). By employing an array of bacterial stimuli, 
it was anticipated that the macrophages would generate a number of different 
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eicosanoid profiles that could indicate the presence of agonist-specific responses. 
This hypothesis was tested by stimulating the RAW 264.7 ALOX macrophages with 6 
different bacterial agonists targeting TLRs.  
 
Of the 110 eicosanoid and fatty acid transitions, 39 were detectable from the RAW 
264.7 ALOX cells. It was found that, for most of the lipids produced, the same 
eicosanoid profile was generated for the 6 bacterial agonists tested. This profile was 
dominated by COX products, with PGD2 produced in greatest amount and its 
dehydration products 15d PGJ2 and 15d PGD2 also seen. These results seen in the 
RAW 264.7 ALOX cells are consistent with those demonstrated by Buczynski et al. 
2007, who found that 14 of the 16 agonists used, which included TLRs, to stimulate 
RAW 264.7 cells generated the same eicosanoid profile. Buczynski et al. 2007, also 
confirmed that out of the 60 lipids they scanned for, the COX-derived PGD2 and its 
metabolites generated the highest levels.  
For long term stimulation (24 hours) of RAW 264.7 ALOX cells with the TLR4 agonist 
LPS, the observation of increased COX products is also consistent with finding by Lee 
et al. 2016, who showed that levels of COX-dervied lipids dramatically increase over 
this time period, whereas 5-LOX activity was impaired by subsequent nitric oxide 
production. 
 
When comparing the cell responses to the TLRs on the heatmap it could be observed 
that TLR2 HKLM and TLR6/2 FSL displayed a more intense abundance of lipids 
compared to the other TLRs, however, when looking at the actual amounts 
generated these data didn’t appear to be suggestive of any substantial differences. 
The uniformity of the eicosanoid profile in response to these TLR agonists was 
particularly striking as it has been shown that macrophages obtained from in vivo 
sources yield different and unexpected eicosanoid profiles, which was demonstarted 
by studies that modulate diet (Trebino et al. 2005; Wang et al. 2006). Furthermore, 
another study (Ragolia et al. 2005), which compared human atherosclerotic plaques, 
identified that macrophages in unstable plaques have significantly higher levels of 
PGE2 and PGD2  synthase than stable plaque macrophages. The notable difference 
between the in vivo macrophages and the RAW 264.7 cells is that the differentiation 
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process occurs in different enviroments. Also, the eicosanoid profile generated 
between human and mouse models are not directly comparable.  
 
As described in Chapter 1, eicosanoids are produced rapidly after the initiation of 
inflammation. They are subsequently released by the cell to act in an autocrine or 
paracrine manor. During these studies, eicosanoid levels both inside and outside the 
cell were examined. One finding that was apparent was the elevated intracellular 
eicosanoid levels compared to the extracellular environment. For example, 12-HETE 
and 15-HETE were only detected intracellularly and surprisingly not detected 
extracellularly. It is possible that the RAW 264.7 ALOX macrophages retain these 
lipids inside the cell as they are not part of their normal processing and therefore lack 
the dedicated export pathways.  
 
Increased intracellular levels of eicosanoids were also confirmed by the observations 
of Balsinde and colleagues (Balsinde et al. 1995) who saw increases in intracellular 
AA-derived lipids following [3H]AA labelling of phospholipids and stimulation of 
P388D1 murine macrophages. This increase was also seen by Buczynski et al. 2007 
who reported the AA inside RAW 264.7 cells was ~4 times greater than the amount 
detected outside. This could be due to immortalised cells being different to primary 
macrophages as they undergo manipulation altering original characteristics and 
functions so that they proliferate indefinitely.  
 
Interestingly, results in this chapter show that increased levels of COX-derived 
prostaglandins and their metabolites were mainly detected extracellularly after 24 
hour agonist exposure to the RAW 264.7 ALOX cells.  As previously mentioned, this 
could be due to the increased COX expression over time when exposed to stimuli 
(Lee et al. 2016). It may also be the case that as these cells characteristically have the 
COX enzyme, they also possess the correct machinery to facilitate transport out of 
the cell.   
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5.4.4 Cytokine generation following toll-like receptor stimulation of RAW 264.7 
ALOX macrophage 
TLR activation initiates multiple changes in the cell, which include the induction of 
gene expression, changes in protein levels and changes in protein phosphorylation 
levels (Buczynski et al. 2007). As well as looking at the changes in eicosanoid release 
when the RAW 264.7 ALOX macrophages were activated by six bacterial TLR agonists, 
I also examined the induction of proinflammatory cytokines after 24 hour treatment. 
 
The RAW 264.7 ALOX macrophages generated similar levels of TNF-α to those seen 
by Berghaus et al. 2010, who exposed RAW 264.7 cells to the TLR4 agonist LPS and 
the TLR1/2 agonist Pam3CSK4.  
Flagellin is the natural ligand of TLR5 and resulted in the lowest generation of both 
cytokines. It has been seen that treatment of RAW 264.7 cells with flagellin does not 
change the protein levels of the receptor (Palazzo et al. 2008) and therefore ceases 
to promote the expression of the specific receptor, dampening the response 
compared to the other TLRs. It has also been shown that the RAW 264.7 macrophage 
cell line expresses similar TLR transcripts with the exception of TLR5, which was down 
regulated in comparison (Applequist et al. 2002). It could also be possible that TLRs 
work in synergy to generate a response, as it has been shown that RAW 264.7 cells 
present higher levels of the TLR4 receptor when treated with the TLR9 ligand ODN 
(Palazzo et al. 2008). Therefore, there are a number of reasons why flagellin induced 
the lowest abundance of cytokines.  
No major difference was seen in the cytokine generation when the RAW 264.7 ALOX 
macrophages were exposed to individual TLR agonists. However, experiments would 
need to be repeated in order to draw any further conclusions.   
 
5.5 Conclusion  
Using this novel RAW 264.7 transfected cell line enabled me to generate an initial 
profile of mediator expression when cells were exposed to different bacterial TLR 
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agonists.  No major differences were seen in the lipid and cytokine generation within 
this data set when the RAW 264.7 ALOX cells were exposed to individual TLR agonists. 
Therefore, it was not possible to identify profiles for individual TLR agonists.  
 
Individual TLR agonists were used to look for initial differences in lipid and cytokine 
profiles. However, during an infection multiple TLR agonists would be present. This 
further supports the idea of using whole bacteria, which contain multiple TLR 
agonists, and looking at the responses generated by the RAW 264.7 ALOX 
macrophages.    
 
This body of work confirmed that the RAW 264.7 ALOX macrophages were a 
functional cell line able to generate 12/15-LOX-derived lipids. It may be the case that 
carrying out further experiments using different combinations of TLR agonists would 
demonstrate any synergistic effects between agonists, which may give rise to distinct 
patterns within the lipid and cytokine profiles. However, the number of possible 
combinations which could be investigated was very large and might still not show 
differences. Therefore, I decided to expose these cells to whole, live bacteria. This 
would enable me to see whether the profile of lipids and eicosanoids varied in 
response to whole bacteria as opposed to individual components, as would be the 
case during bacterial infection thus creating more pathophysiologically relevant 
conditions.   




6 Detecting eicosanoids and proinflammatory 
cytokines generated by RAW 264.7 ALOX 
macrophages upon stimulation with whole bacteria 
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6.1 Introduction 
Chapter 5 confirmed the ability of RAW 264.7 ALOX macrophages to produce 
detectable levels of eicosanoids and cytokines following exposure to individual 
bacterial TLR agonists. These cells were employed in this chapter to characterise the 
innate immune response to different classes of bacterial pathogen with a view to 
identifying specific responses that could potentially be used as diagnostic 
fingerprints.   
 
As described in Chapter 1, the host defence against invading pathogens is mediated 
by the acute inflammatory response (Russell & Schwarze 2013). This response 
depends upon the innate immune recognition of unique molecules emanating from 
the bacteria (Gioannini & Weiss 2007). Chapter 1 explains how the inflammatory 
response couples the detection of these specific molecules to physiological 
alterations that characterise acute inflammation (Beutler et al. 2006). It is important 
that the inflammatory response includes fast recognition and mounts a response 
shortly after invasion of small amounts of bacteria, due to the potentially rapid 
extracellular proliferation of certain invading organisms (Gioannini & Weiss 2007). 
This action should materialise well before antigen-specific immune recognition of the 
invading pathogen has developed. 
 
Chapter 1 also explains how macrophages play an important role in controlling 
bacterial infection since they are one of the earliest components of the host defence 
systems to be activated (Daigneault et al. 2010). The outcome of the interaction 
between bacteria and macrophages (i.e., survive or destroyed) contributes to 
determining whether the infected host will eventually develop the disease associated 
with the bacteria, along with other host factors, microbial characteristics and 
timeliness of administration of appropriate antimicrobial therapy (Jin et al. 2010; 
Simor et al. 2016).  
 
There is a significant variety of bacteria causing infections, including opportunistic 
and hospital-acquired microorganisms. Chapter 1 details the difference between 
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these Gram-positive and Gram-negative bacteria. Some of the most frequently 
isolated bacteria that commonly cause infection include Gram-positive 
Staphylococcus aureus (S. aureus) and Gram-negative Escherichia coli (E. coli) and 
Klebsiella pneumoniae (Klebsiella) (Ramachandran 2014).  
 
Gram-positive S. aureus, in particular methicillin-resistant S. aureus (MRSA), remains 
one of the most prevalent bacterial pathogens worldwide (Bal et al. 2017). The past 
decade has seen a decrease in health-care-associated MRSA infections worldwide, 
but despite this, MRSA bloodstream infections continue to be associated with 
substantial morbidity and mortality, prolonged hospital stays and excess healthcare 
costs (Köck et al. 2010; Gastmeier et al. 2012; Simor et al. 2016). It was also initially 
thought that Gram-negative organisms were the major cause of bacterial sepsis, 
however, it has been shown that it is Gram-positive bacteria, such as S. aureus, that 
are the most common cause (Martin et al. 2003). The significance and pathogenic 
nature of Gram-positive MRSA make this resistant bacterium an excellent choice to 
employ when establishing an in vitro model of bacterial infection. 
 
The most common Gram-negative infectious bacteria in patients of all ages is E. coli 
(Uzodi et al. 2017). E. coli is the leading cause of urinary tract infections (UTI) in 
children and bacteremia and meningitis in infants (Mackenzie 2014; Edlin et al. 2013; 
Greenhow et al. 2014). A major concern is the emergence of antimicrobial resistance 
in E. coli. Globally, there is an increased incidence of antimicrobial-resistant E. coli 
infections, which contribute to poor patient outcomes, and increased healthcare 
costs (Swami et al. 2012; Uzodi et al. 2017). These multi-drug resistant strains are a 
significant health threat as they have proliferated faster than the development of 
new antibiotics, ultimately leading to a lack of therapeutic agents to treat these 
highly resistant strains (Swami et al. 2012; Uzodi et al. 2017).  
 
As well as E. coli, the Gram-negative bacteria Klebsiella pneumoniae (Klebsiella) is 
also a leading cause of serious infection in neonates, neutropenic cancer patients and 
other patients with underlying diseases (Kim et al. 2002). Klebsiella is an acute cause 
of infections in multiorgan systems, and is the third most commonly isolated 
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bacterium from the blood of sepsis patients (Huang et al. 2013). Incidence of 
hypervirulent Klebsiella has risen worldwide over the past few decades and it has 
been deemed the next superbug (Shon et al. 2013; Zhang et al. 2016). These strains 
have the capacity to cause severe and metastatic infections in young and healthy 
individuals, such as pyogenic liver abscesses and endophthalmitis and are even more 
antibiotic-resistant than E. coli (Kim et al. 2002; Zhang et al. 2016).             
 
The bacteria employed in this chapter of work were Gram-positive MRSA, Gram-
negative E. coli and Gram-negative Klebsiella. The strains of bacteria were carefully 
chosen as they are highly pathogenic, in order to set up the worst-case scenario of 
infection to look for initial marker profiles, and as previously mentioned are some of 
the most common causes of bacterial infections. Their ability to develop multi-drug 
resistant strains deems them ‘superbugs’ (Huang et al. 2013), and it is clear that there 
is a direct need for faster detection of these bacteria as a lack of early appropriate 
treatment is associated with high mortality and further increases the risk of 
resistance (Simor et al. 2016). 
 
Inappropriate treatment of patients with antibiotics when they are not infected with 
a bacterium has been shown to have an adverse effect on the patient and can lead 
to the emergence of antibiotic-resistant bacteria (Cassell & Mekalanos 2007). Failure 
to treat an individual with a bacterial infection also has dire consequences (Gauer 
2013). The types of antibiotics used to treat bacterial infections differ depending on 
their type i.e. Gram-positive versus Gram-negative and their antibiotic sensitivity. 
Normally, in cases such as sepsis, patients will be given type-specific, broad-spectrum 
treatment, thus the need to know what type of bacteria is responsible for the 
infection. In most hospitals in the UK clinicians will have information about the 
antibiotic susceptibility of the different classes of bacterial pathogens, therefore, if 
they know the nature of the infecting organism they can make an informed decision 
as to which antibiotics to use. Hence the desire to rapidly determine the nature of 
the infecting bacterium.  
  
   155 
Establishing profiles of inflammatory markers, such as eicosanoids and cytokines, 
specific to individual bacteria causing an infection could lead to faster treatment, 
increased patient survival rates and lower risk of bacteria becoming increasingly 
drug-resistant.    
To characterise the interaction between the different bacteria and macrophages, this 
chapter focuses on detecting distinct profiles of eicosanoids and cytokines generated 
by RAW 264.7 ALOX macrophages in response to the highly antibiotic-resistant 
bacterial species, MRSA, E. coli and Klebsiella.    
 
6.1.1 Aims of this chapter  
The first aim of this chapter was to analyse the cytokine generation between RAW 
264.7 Control and ALOX macrophages to determine if exposure to whole bacteria 
altered the cytokine generation. As the cells have been engineered to generate the 
12/15-LOX-derived lipids there should be no effect on the cytokine generation and 
thus be the same between the two cell types. 
The second aim of this chapter exposed the RAW 264.7 ALOX macrophages to live 
Gram-positive and Gram-negative bacteria in order to identify if varying eicosanoid 
and cytokine responses are induced with a view to identifying pathogen specific 
signatures.  
 
The specific objectives of the work in this chapter are therefore: 
1. To establish the cytokine profiles generated by the RAW 264.7 ALOX 
macrophages are not altered by the presence of the 12/15-LOX gene.  
2. To employ mass spectrometry to determine the eicosanoid profiles 
generated by RAW 264.7 Control and ALOX macrophages following exposure 
to bacteria.  
3. To employ an ELISA-based method to determine the cytokine profiles 
generated by RAW 264.7 Control and ALOX macrophages following exposure 
to bacteria.  
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6.2  Specific materials and methods 
The transfected murine RAW 264.7 macrophage cell lines used in this chapter of work 
are the same as those described in Chapter 5, section 5.2.1. Culture conditions and 
media (which will be referred to hereafter as RAW media) are also consistent with 
those described in Chapter 5, section 5.2.2.    
 
6.2.1 Bacteria strains and growth conditions 
The bacteria selected for this study were the Gram-positive methicillin-resistant 
Staphylococcus aureus (MRSA) National Collection of Type Cultures (NCTC) strain 
reference 12497, Gram-negative Escherichia coli (E. coli) extensively resistant NCTC 
strain reference 8003 and a multi-drug resistant Gram-negative Klebsiella 
pneumoniae (Klebsiella) 20 clinical isolate from Pakistan known to cause serious 
invasive disease. Bacteria were checked for purity using the streak plate method and 
grown on Luria-Berani (LB) agar (Fisher Scientifics, BP1425-500) at 37°C for 18 hours.   
 
6.2.2 Maintenance of stocks and cultures 
Bacteria were recovered from ceramic bead stocks (Fisher Scientifics, 12817755), 
which had been stored at -80°C since preparation from stocks received from NCTC 
or clinical isolate from Pakistan. After growth in LB broth for 18±2 hours at 37°C and 
120 rpm (shaking incubator; IKA®KS3000-i-control), purity was assessed by Gram 
staining and strain identity of colonies from LB agar sub-cultured and confirmed by 
matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-
TOF MS) (Public Heath Wales Microbiology Division), as standard protocol for Cardiff 
University stocks.        
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6.2.2.1 Preparation of initial glycerol stocks of bacteria  
Glycerol stocks of verified strains were prepared by streaking the bacteria onto LB 
agar plates and incubated at 37°C for 18-24 hours. Plates were checked visually for 
uncontaminated growth. Three to five morphologically identical colonies were 
suspended in 20 mL LB broth and incubated for 18±2 hours at 37°C and 120 rpm. The 
bacterial culture was mixed with an equal volume of sterile 20% v/v glycerol and 
stored in 1 mL aliquots at -80°C. 
 
Stock maintenance was confirmed after three days by inoculating LB broth with three 
random samples of each organism, before being checked for purity by sub-culture 
onto LB agar for 18±2 hours at 37°C. 
 
For use in this work, fresh working cultures of each organism were produced once 
monthly by reviving one rapidly thawed glycerol stock in LB broth incubated at 37°C 
and 120 rpm for 18±2 hours (shaking incubator; IKA®KS3000-i-control). A 10 μl 
loopful of bacterial culture were streaked onto LB agar plates, incubated at 37°C for 
18-24 hours and stored agar side up at 4°C for a maximum of 6 weeks. 
 
6.2.3 Experimental growth conditions 
Bacteria were picked from single colonies and grown in LB broth (Sigma Aldrich, 
L3022) at 37°C, 120 rpm (shaking incubator; IKA®KS3000-i-control) to exponential 
growth phase. They were then washed in sterile phosphate-buffered saline (PBS) 
twice before being resuspended in RPMI-1640. Suspensions were adjusted to optical 
density (OD) 0.329, 0.198 and 0.199 for MRSA, E. coli and Klebsiella, respectively at 
wavelength 625 nm, which gave approximately 101 colony forming units per millilitre 
(cfu/mL) (JENWAY 6305 Spectrophotometer). The adjusted bacteria suspension was 
then added to the cells in volumes shown in Table 5.1 to obtain a 10:1 bacterial:cell 
ratio. 
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Table 5.1 Volumes for bacterial exposure model 
Bacteria OD for 10:1 
bug cell ratio 
+/- 0.01 OD 
Volume of RPMI (μl) Volume of bacterial 
suspension (μl) 
1 hour  24 hours 1 hour  24 hours 
MRSA 0.329 900 3920 100 80 
E. coli 0.198 950 3960 50 40 
Klebsiella  0.199 950 3960 50 40 
 
Once the OD was reached, drop counts were used to determine the number of 
bacteria in each suspension. Drops of 10 μl were spotted onto LB agar to determine 
cfu/mL, according to the Miles and Misra method (Miles & Misra 1938). Bacteria 
were stored at 4°C prior to exposure to macrophages.  
 
6.2.4 RAW 264.7 ALOX macrophage infection model 
The RAW 264.7 ALOX murine macrophages were plated in 6-well culture plates with 
4 mL of RAW media (5 x 106 cells/well for 1 hour exposure, 4 x 106 cells/well for 24 
hour exposure), and allowed to adhere overnight (time points were determined 
during infection model optimisation). Once adhered the RAW media was replaced 
with 1 or 4 mL RPMI-1640 alone, for the 1 hour and 24 hour time points respectively, 
and stimulated with the bacteria (MRSA, E. coli or Klebsiella). Bacteria were prepared 
as described in section 6.2.3 to be added to the cells at a 10:1 bug/cell ratio. Cells 
were incubated at 37°C in a humidified 5% CO2 atmosphere for either 1 hour or 24 
hours. (I had previously optimised these timepoints during characterisation of the 
cells). Cells and supernatant were collected separately. Supernatants were filtered 
using a 0.2-micron filter to remove bacteria. Following incubation, both cell and 
supernatant samples had deuterated internal standard mix added (75 nM), 
preparation described in Appendix l. The cell samples went through a hexane lipid 
extraction (described in Chapter 2, section 2.6). Subsequently, all samples (cells and 
supernatant) underwent SPE, as detailed in Chapter 2, section 2.7.      
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6.2.5 Lipidomic profiling of fatty acids and eicosanoids 
Samples were analysed using the targeted lipidomic method described in Chapter 5, 
section 5.2.5. 
 
6.2.5.1 Heatmap correlation  
The heatmap was generated as described in Chapter 5, section 5.2.5.1. 
      
6.2.6 Proinflammatory cytokine analysis  
Protein concentration was measured using the double antibody sandwich enzyme-
linked immunosorbent assay (ELISA), as described in Chapter 5, section 5.2.6.     
 
6.2.7 Statistical analysis  
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6.3  Results  
6.3.1 Comparison of cytokine generation in RAW 264.7 Control and ALOX 
macrophages  
Chapter 5, section 5.3.1, defined the basal eicosanoid expression of RAW 264.7 
Control and ALOX macrophages. Initial experiments in this chapter aimed to show 
that insertion of the 12/15-LOX gene in the ALOX macrophages did not alter the 
cytokine expression compared to the Control macrophages.        
 
6.3.1.1 Gram-positive bacteria MRSA 
Untreated RAW 264.7 Control and ALOX macrophages showed basal levels of TNF-α 
at 1021 and 1130 pg/mL, respectively (Figure 6.1Ai). Generation of IL-1β and IL-6 for 
untreated RAW 264.7 Control and ALOX macrophages was below the limit of 
detection (Figure 6.1Aii-iii).  
 
Upon stimulation, there was a significant increase (P<0.05) in TNF-α generation in 
ALOX macrophages compared to the Control macrophages, where values showed 
79,095 and 50,479 pg/mL, respectively (Figure 6.1Ai). There were no significant 
differences (P>0.05) seen between the RAW 264.7 Control and ALOX macrophage 
generation of IL-1β (207 and 181 pg/mL, respectively) and IL-6 (178 and 228 pg/mL, 
respectively) when cells were exposed to MRSA (Figure 6.1Aii-iii). MRSA alone 
showed TNF-α, IL-1β and IL-6 to be below the limit of detection. 
 
6.3.1.2 Gram-negative bacteria E. coli 
Untreated RAW 264.7 Control and ALOX macrophages showed basal levels of TNF-α 
at 321 and 140 pg/mL, respectively (Figure 6.1Bi). Untreated RAW 264.7 Control and  
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ALOX macrophages showed basal levels of cytokine generation for IL-1β and IL-6 to 
be below the limit of detection (Figure 6.1Bii-iii).  
 
When cells were exposed to E. coli, there was no significant difference (P>0.05) in 
TNF-α generation between the RAW 264.7 Control and ALOX macrophage (Figure 
6.1Bi). Even though the average value for TNF-α detection from ALOX macrophages 
(22,856 pg/mL) was higher upon stimulation than the Control macrophages (9,118 
pg/mL), it was not significantly different due to the variation between the replicates 
(P>0.05). The RAW 264.7 Control and ALOX macrophages exhibited no detectable 
generation of IL-1β and IL-6 upon stimulation (Figure 6.1Bii-iii). E. coli alone showed 
TNF-α, IL-1β and IL-6 to be below the limit of detection. 
 
6.3.1.3 Gram-negative bacteria Klebsiella 
Untreated RAW 264.7 Control and ALOX macrophages showed basal levels of TNF-α 
at 1628 and 2675 pg/mL, respectively (Figure 6.1Bi). Generation of IL-1β and IL-6 for 
untreated RAW 264.7 Control and ALOX macrophages was negligible (Figure 6.1Cii-
iii). 
 
Upon stimulation, there was no significant increase (P>0.05) in TNF-α, IL-1β or IL-6 
generation in ALOX macrophages (48,305, 43, 104 pg/mL, respectively) compared to 
the Control macrophages (29,881, 51, 109 pg/mL, respectively). Klebsiella alone 
showed TNF-α, IL-1β and IL-6 to be below the limit of detection.  
 
Lipid analysis of basal eicosanoid levels in Chapter 5, section 5.3.1, determined that 
RAW 264.7 ALOX macrophages, containing the 12/15-LOX gene, generated 12/15-
LOX-derived lipids compared to the RAW 264.7 Control macrophages.  
In this chapter of work, both cell types gave similar responses in terms of the 
production of cytokines upon bacterial stimulation. The only significant difference 
between the two cell types was seen in TNF-α generation, upon treatment with 
MRSA (section 1.3.1.1). Given that these were such high levels compared to all other 
   163 
cytokine generation, and that both cell types gave similar levels of response for all of 
the other test conditions, the RAW 264.7 ALOX macrophages were used for all 
subsequent experiments to provide a suitable model similar to in vivo macrophages.     
 
6.3.2 Eicosanoid generation from RAW 264.7 ALOX macrophages upon stimulation 
with live bacteria 
Out of the 110 eicosanoid and fatty acid transitions (Appendix lll) 41 showed 
detectable levels of expression when exposed to whole bacteria (Figure 6.2). All 
subsequent analysis will only discuss lipids that showed the greatest difference 
between the untreated and activated cells out of the 41 that were detected (Table 
6.2). The greatest difference was defined as lipids that showed a significant 
difference or change in abundance between groups. Untreated cells provided a 
baseline of basal lipid mediators generated by RAW 264.7 ALOX macrophages (Figure 
6.2A). 
 
6.3.2.1 Gram-positive bacteria MRSA 
The highest levels of 12/15-LOX-derived lipids, such as 12-HETE, 12-HEPE and 8,15-
DiHETE were detected intracellularly at 1 hour showing values of 4993, 917 and 394 
pg/106cells, respectively (Figure 6.2B). Stimulation with MRSA resulted in increased 
detection of intracellular lipids derived from the LOX pathways at 24 hours, these 
included LOX-derived lipids 13-HODE (6,872 pg/106cells), 13-OxoODE (1,847 
pg/106cells) and 9-HODE (533 pg/106cells). Although an apparent increase was seen 
in 13-HODE detection from 1 hour to 24 hours, it was not found to be statistically 
significant (P>0.05) (Figure 6.3). At 24 hours, the level of expression was higher than 
that seen for the Gram-negative bacteria, but this difference was not statistically 
significant (P>0.05) (Figure 6.3). Negligible amounts of lipid were detected 
extracellularly from the cells   
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at 1 hour. Mainly COX-derived-lipids such as PGE2 and PGD2 were seen extracellularly 
at 24 hours, showing values of 193 and 1,190 pg/106cells, respectively (Figure 6.2B).  
 
6.3.2.2 Gram-negative bacteria E. coli          
A lower level of lipids were generated intracellularly at 1 hour, compared to 24 hours 
(Figure 6.2C). The majority of lipids detected were generated intracellularly at 24 
hours including 12/15-LOX-derived lipids 12-HETE (1,212 pg/106cells) and LTB4 (1,021 
pg/106cells) (Figure 6.2C). Negligible amounts of lipid were expressed extracellularly 
by the cells at 1 hour. 12/15-LOX-derived lipids such as 12-HETE, LTB4 and 15-HETrE 
were also detected extracellularly at 24 hours, showing levels of 2,649, 231 and 177 
pg/106cells (Figure 6.2C). Extracellular detection of 14-HDOHE, following exposure to 
E. coli, significantly increased over time (P<0.05) (Figure 6.4). 
 
6.3.2.3 Gram-negative bacteria Klebsiella 
The heatmap indicates that treatment with Klebsiella showed increased lipid 
generation at 24 hours, both intracellularly and extracellularly, compared to 1 hour 
(Figure 6.2D). Intracellular and extracellular 12/15-LOX-derived 12-HETE significantly 
increased (P<0.001) at 24 hours (10,078 and 6,224 pg/106cells, respectively) 
compared to 1 hour (1,951 pg/106cells and below the limit of detection, respectively) 
(Figure 6.2D). Negligible amounts of eicosanoids were expressed extracellularly by 
the cells at 1 hour. Abundance of 14-HDOHE significantly increased extracellularly 
over time (P<0.01) (Figure 6.4).  
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6.3.3 Comparison between the RAW 264.7 ALOX macrophage responses to 
individual bacteria  
The highest abundance of the lipids generated were seen intracellularly, at 24 hours 
cell exposure to the bacteria (Figure 6.2). Overall Gram-positive MRSA generated the 
highest abundance of lipids intracellularly compared to Gram-negative E. coli and 
Klebsiella at 24 hours (Figure 6.2B). RAW 264.7 ALOX macrophages stimulated with 
Klebsiella showed the highest overall abundance of extracellular lipid generation at 
24 hours, compared to MRSA and E. coli (Figure 6.2D). Cell exposure to E. coli showed 
the lowest overall generation of lipids compared to MRSA and Klebsiella (Figure 
6.2C). Some 12/15-LOX derived lipids were also seen extracellularly at 24 hours; both 
E. coli and Klebsiella showed that this was the case for 15-HETE (328 and 611 
pg/106cells, respectively), 12-HETE (2649 and 6224 pg/106cells receptively) and its 
downstream metabolite LTB4 (231 and 1124 pg/106cells, respectively) generation.  
 
6.3.3.1 12/15-LOX-derived lipid 12-HETE 
12-HETE was generated by all bacteria intracellularly at 1 hour, showing levels of 
4,993, 717 and 1,951 pg/106cells for MRSA, E. coli and Klebsiella, respectively (Figure 
6.5, Table 6.3A). MRSA treatment showed a significant increase (P<0.05) compared 
to the untreated cells (1,081 pg/106cells).  There was no significant difference 
(P>0.05) seen with either E. coli or Klebsiella intracellularly at 1 hour compared to 
the untreated cells. MRSA showed a significant increase (P<0.05) in 12-HETE 
compared to E. coli intracellularly at 1 hour. No other significant differences were 
seen within this group. There were no statistically significance observations seen 
extracellularly at 1 hour (P>0.05).      
 
Intracellularly at 24 hours, Klebsiella showed a significant increase (P<0.001) in 12-
HETE (10,178 pg/106cells) compared to the untreated (1,193 pg/106cells), MRSA- 
(not detected) and E. coli- (1,818 pg/106cells) treated cells (Figure 6.5, Table 6.3A).   
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Klebsiella also showed a significant increase in 12-HETE (6,224 pg/106cells) 
extracellularly at 24 hours compared to untreated (P<0.01), MRSA- (P<0.01) and E. 
coli- (P<0.05) treated cells; 12-HETE was not detected in untreated and MRSA-
treated samples and showed a value of 2,649 pg/106cells in E. coli treated cells. 
 
Generation of intracellular 12-HETE by MRSA showed a significant decrease over 
time (P<0.001), however, Klebsiella indicated a significant increase over time, from 1 
hour to 24 hours (P<0.001) (Figure 6.5). 
Generation of extracellular 12-HETE by E. coli and Klebsiella showed a significant 
increase over time, from 1 hour to 24 hours (P<0.05, P<0.001, respectively) (Figure 
6.5).  
      
6.3.3.2 COX-derived lipid PGD2 
There were increased levels of COX-derived lipids in the supernatant at 24 hours 
exposure to the bacteria, these included PGD2, PGF2α, PGE1 and 13, 14-dihydro-15-
keto PGD2 (Figure 6.2).  
 
PGD2 was generated by all bacteria intracellularly at 1 hour (Figure 6.6). Only MRSA 
treatment (917 pg/106cells) showed a significant increase (P<0.001) in PGD2 
compared to the untreated cells (340 pg/106cells) intracellularly at 1 hour. MRSA 
showed a significant increase (P<0.001) in PGD2 compared to E. coli and Klebsiella 
intracellularly at 1 hour, which showed values of 394 and 256 pg/106cells, 
respectively (Table 6.3A). There were no statistically significance observations seen 
extracellularly at 1 hour (P>0.05).      
 
Intracellularly at 24 hours, both Gram-negative bacteria, E. coli and Klebsiella showed 
a significant decrease (P<0.05) in PGD2 (not detected) compared to the untreated 
cells (694 pg/106cells) (Figure 6.6). MRSA showed a significant increase (1,190   
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pg/106cells) in PGD2 extracellularly at 24 hours compared to untreated (292 
pg/106cells), E. coli- (54 pg/106cells) and Klebsiella- (305 pg/106cells) treated cells 
(P’s<0.05) (Table 6.3B). 
 
There was a significant increase (P<0.05) in intracellular PGD2 seen in untreated cells 
over time. Generation of intracellular PGD2 by MRSA and E. coli showed a significant 
decrease over time (P<0.001, P<0.05, respectively) (Figure 6.6).  
Generation of extracellular PGD2 by MRSA showed a significant increase over time, 
from 1 hour to 24 hours (P<0.001) (Figure 6.6).  
 
The differences seen intracellularly at 24 hours between the lipid responses upon cell 
exposure to the different bacteria are summarised in Figure 6.7 (Table 6.3A). For 
MRSA and Klebsiella, data indicate that the overall pattern of response (excluding 12-
HETE) is similar, however, levels are approximately 3-fold higher in MRSA compared 
to Klebsiella stimulated cells. 12-HETE is shown to be significantly increased (P<0.01; 
P<0.05) (Figure 6.5) in response to Klebsiella compared to MRSA and E. coli, 
respectively. Gram-negative E. coli did not show a similar pattern of response to the 
MRSA or the other Gram-negative bacteria Klebsiella (Figure 6.7).     
 
6.3.4 Generation of proinflammatory cytokines by RAW 264.7 ALOX macrophages 
exposed to whole bacteria    
RAW 264.7 ALOX macrophage generated the proinflammatory cytokines TNF-α, IL-
1β and IL-6 (Figure 6.8). Earlier cytokine analysis (section 6.3.1) compared generation 
between RAW 264.7 Control and ALOX macrophages to confirm that the 12/15-LOX 
gene insertion had no effect on cytokine responses. This section will now focus on 
bacteria specific cytokine responses by RAW 264.7 ALOX macrophages.     
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6.3.4.1 Production of TNF-α 
There was a significant increase in TNF-α production when cells were exposed to 
MRSA (P<0.001; 79,096 pg/mL), E. coli (P<0.05; 22,856 pg/mL) and Klebsiella 
(P<0.001; 48,305 pg/mL) compared to the untreated cells (1,315 pg/mL) for 24 hours 
(Figure 6.8A). Gram-positive MRSA was shown to significantly increase TNF-α 
generation compared to the Gram-negative bacteria E. coli and Klebsiella (P<0.001, 
P<0.05, respectively) (Figure 6.8A, Table 6.3C).   
 
6.3.4.2 Production of IL-1β   
Treatment of RAW 264.7 ALOX macrophage with Gram-positive bacteria MRSA (181 
pg/mL) showed a significant increase in IL-1β generation compared to untreated, E. 
coli- and Klebsiella-treated cells (P’s<0.001) at 24 hours; untreated and E. coli-treated 
cells showed levels below the limit of detection and Klebsiella was 43 pg/mL (Figure 
6.8B, Table 6.3C). There were no other statistically significant observations between 
groups (P>0.05). 
 
6.3.4.3 Production of IL-6     
The RAW 264.7 ALOX macrophage generated a significantly increased amount of IL-
6 when treated with MRSA (228 pg/mL) compared to untreated, E. coli- and 
Klebsiella-treated cells (P’s<0.001); untreated and E. coli-treated cells showed levels 
below the limit of detection and Klebsiella was 104 pg/mL (Figure 6.8C, Table 6.3C). 
Upon stimulation with Klebsiella, the RAW 264.7 ALOX macrophage showed a 
significant increase in IL-6 compared to untreated and E. coli-treated cells (P<0.001, 
P<0.01, respectively) (Figure 6.8C). Treatment of cells with E. coli generated 
negligible levels of IL-6, below the limit of detection.  
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6.4 Discussion 
This chapter of work represents the first ever measure of a lipid and cytokine 
biomarker series studied in an infection model of macrophages. The initial aim in this 
chapter was to analyse the cytokine generation between RAW 264.7 Control and 
ALOX macrophages in order to determine if the cell transfection altered the cytokine 
generation. The next aim was to expose the RAW 264.7 ALOX macrophages to live 
Gram-positive and Gram-negative bacteria to identify if pathogen specific eicosanoid 
and cytokine responses were induced.   
 
6.4.1 Comparison of basal expression between RAW 264.7 Control and ALOX 
macrophages  
As previously demonstrated in Chapter 5, section 5.3.1.1.1, initial experiments were 
carried out to establish basal levels of eicosanoid and cytokine expression by the 
RAW 264.7 Control and ALOX macrophages. As mentioned, the activity of 12/15-LOX 
in the RAW 264.7 ALOX cells was measured by the formation of 12-HETE, which was 
not seen in the RAW 264.7 Control macrophages and therefore confirms the 
presence of the gene in the RAW 264.7 ALOX cells. 
 
6.4.1.1 Proinflammatory cytokine generation 
An initial comparison of the cytokine profile of both the RAW 264.7 Control and ALOX 
macrophages was established. As previously mentioned, it was expected that these 
cells would generate the same cytokine profile as each other because the 
introduction of the ALOX gene was not expected to effect cytokine production.  
Interestingly, this wasn’t the case in Chapter 5 (Figure 5.4), where data showed up to 
a 100-fold increase in TNF-α cytokine generation from TLR-stimulated RAW 264.7 
ALOX macrophages compared to the Control cells. However, in this body of work 
further investigation showed that there was no significant difference in the cytokine 
generation between the RAW 264.7 Control and ALOX macrophages when exposed 
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to E. coli and Klebsiella, both of which are Gram-negative bacteria. Treatment of cells 
with MRSA showed a significant increase in TNF-α generation in the RAW 264.7 ALOX 
macrophages compared to the Control. A potential explanation for this is that the 
LOX products generated by the MRSA-stimulated RAW 264.7 ALOX macrophages 
upregulated cytokine production compared to the MRSA-stimulated RAW 264.7 
Control macrophages (Professor Valerie O’Donnell, personal communication).  
 
The average basal levels of TNF-α generated by both the RAW 264.7 Control and 
ALOX macrophages (990 and 1,315 pg/mL, respectively) were shown to be similar to 
basal levels in native RAW 264.7 macrophages (~1,500 pg/mL) in work carried out by 
Berghaus et al. 2010. This implies that the transfection has not changed the cytokine 
generation of these cells.         
 
Both cell types generated the proinflammatory cytokines TNF-α, IL-1β and IL-6. 
Unlike TNF-α, basal levels of IL-1β and IL-6 produced by RAW 264.7 Control and ALOX 
cells were below the limits detectable by ELISA. This finding also matches that seen 
by Chamberlain et al. 2009, who showed only TNF-α expression at the mRNA level in 
untreated RAW 264.7 macrophages but not IL-1β and IL-6.      
 
The next step was to expose these cells to whole, live bacteria and establish any 
patterns in their responses with a view to identifying pathogen specific signatures.       
 
6.4.2 Lipid profiling of RAW 264.7 ALOX macrophage exposure to live bacteria  
The use of various eicosanoid species as biomarkers for disease and 
pathophysiological conditions has previously been reported (Higashi et al. 2010; 
Drozdovszky et al. 2014). For example, Mal et al., (2011) showed that endogenous 
levels of arachidonic acid, PGE2 and 12-HETE were significantly altered in cancerous 
mucosae; indicating inflammation is correlated with tumorigenesis. It was also 
reported by Rago & Fu, (2013) that it was possible to distinguish between three 
groups of patients (healthy individuals, hypertensive patients and severe 
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atherosclerotic patients) by quantities of several eicosanoids in human plasma. The 
results showed that lower levels of 8-HETE, LTB4, 9-HODE and 13-HODE are potential 
biomarkers of severe heart disease. The metabolism of eicosanoids may differ 
depending on biological samples and pathophysiological events (Lee et al. 2016).  
 
This chapter of work shows, with the use of a targeted lipidomic approach, that 
murine RAW 264.7 ALOX macrophages generate differing lipid profiles when co-
cultured with Gram-positive and Gram-negative bacteria. Of the 110 eicosanoids and 
fatty acids transitions analysed, 41 were detectable from the RAW 264.7 ALOX cells. 
Analysis of data in the heatmap showed that Gram-positive MRSA had increased 
levels of lipids compared to the Gram-negative bacteria E. coli and Klebsiella. This is 
interesting as the Gram-positive TLR2 agonist HKLM and TLR6/2 agonist FSL used in 
Chapter 5, which are ligands present on MRSA, also displayed a more intense 
abundance of lipids compared to TLRs associated with Gram-negative bacteria. These 
findings contradict data that suggest Gram-negative infections induce a greater 
magnitude of inflammatory response than Gram-positive infections (Abe et al. 2010).  
The difference seen between the bacterial responses may be due to the varying 
degree of pathogenicity between the Gram-positive and -negative bacteria (Hoerr et 
al. 2012). It may also be the case that the Gram-negative bacteria have developed 
ways to evade earlier detection by the host, for example, by modifying the structure 
of the endotoxin lipid A, unique to Gram-negative bacteria, leading to greater 
resistance to host antimicrobial peptides and altering TLR4 recognition 
(Ramachandran 2014). This means that initially the Gram-negative bacteria may have 
not been detected by the RAW 264.7 ALOX macrophages, creating a delayed or 
dampened host response compared to the Gram-positive bacteria. 
Another possible reason for the increased response to the Gram-positive compared 
to Gram-negative bacteria, may be due to the differences in their cell wall structure. 
This is because Gram-positive bacteria are bound by a single cell membrane 
containing peptidoglycan layers, which are approximately 50 times thicker than 
those of Gram-negative bacteria (Tietze et al. 2006). Peptidoglycans and lipoteichoic 
acid are two of the major components in Gram-positive bacteria, such as MRSA, and 
have been shown to stimulate inflammatory responses in a number of in vivo and in 
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vitro experimental models (Mattsson et al. 1993; Lawrence & Nauciel 1998) and 
therefore may be a reason why the increased cell response to MRSA is seen. In 
contrast to this, Gram-negative bacteria, including E. coli and Klebsiella, contain a 
thin peptidoglycan layer (i.e. cell wall) lying between two different cell membranes 
in addition to LPS, where the composition of LPS can vary depending on the bacterial 
origin (Tietze et al. 2006). 
 
Chapter 5 describes the uniformity between the lipid profiles generated in response 
to individual TLR agonists, however, the intensities between responses differed. In 
this chapter of work, the overall lipid profiles generated by the RAW 264.7 ALOX 
macrophages was more distinct depending on the bacteria, suggesting it is possible 
to determine signatures of lipids in response to individual bacteria. This finding is 
supported by work carried out by Hoerr et al., 2012, who described how there are 
increased metabolic changes seen in the serum of mice infected with the Gram-
postive bacteria S. aureus compared to the Gram-negative bacteria E. coli.       
 
At 1 hour, generation of 12/15-LOX-derived 12-HETE was seen to significantly 
increase in reponse to MRSA stimulation compared to untreated and E. coli-treated 
cells. However, at 24 hours Klebsiella significantly increased 12-HETE compared to 
untreated, MRSA- and E. coli-treated cells. The significant differences seen in the 
generation of 12-HETE suggest that this lipid is formed in disease, where there may 
be a time-dependent factor for increases in production upon specific bacterial 
stimulation. These results represent a potential marker of infection that can not only 
distingustish between Gram-positive and -negative bacteria but also species within 
these classes.       
 
The data also showed that generation of 12/15-LOX-derived 12-HETE was seen to 
increase >4- and 40-fold upon stimulation with MRSA and Klebsiella, respectively, 
compared to the Gram-positive and -negative TLR agonist treatments shown in 
Chapter 5. This suggests a possible synergistic effect induced by several pathogenic 
elements in the presence of whole bacteria (Tan et al. 2014), and emphasises the 
importance of looking at whole bacterial responses compared to individual 
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components. When relating whole bacterial responses to TLR agonists it is important 
to note that, whole bacteria is likely to have considerably higher levels of individual 
TLR agonists compared to the specific known amounts being delivered to the cells, 
shown in Chapter 5. It is also the case that multiple TLR agonists will be delivered 
with whole bacteria, which may interact with eachother in positive and negative way 
and thus the overall result is the sum of multiple stimulatory pathways.   
 
In general, persistent bacterial infections trigger and sustain locally long-lasting 
inflammatory responses able to mediate dramatic changes in tissue remodelling 
(Leone et al. 2016). This sustained response was not seen for 12-HETE in response to 
MRSA, which was significantly increased at 1 hour and subsequently not detected at 
24 hours. This may be due to metabolism of 12-HETE over time, as there was 
detection of its downstream metabolite LTB4 at 24 hours. It may also be the case that 
administration of MRSA significantly increased levels of 12-HETE for longer than 1 
hour before returning to baseline levels at 24 hours. To further explore this, a profile 
of product formation could be carried out over time for detected lipids, as shown by 
Clark et al. 2011, who examined in vivo generation of 5-HETE in a murine model of 
bacterial peritonitis induced by Gram-positive Staphylococcus epidermidis (S. 
epidermidis). It was found that administration of live S. epidermidis significantly 
increased levels of 5-HETE by 3 hours, peaking at 6 hours before returning to baseline 
at 18 hours.  These results show that it could be possible that levels of 12-HETE may 
have further increased between 1 and 24 hours; additional time course investigations 
would need to be carried out in order to examine this theory. 
 
When RAW 264.7 ALOX macrophages were exposed to live bacteria, the profiles 
were seen to be dominated by lipids derived from the LOX pathways. However, in 
most cases, such as 13-HODE, when looking at the actual amounts generated these 
data did not show significant differences. The increased products seen with the LOX-
pathway do not correlate with the results of Buczynski et al. 2007, and those seen in 
Chapter 5, where it was shown that upon stimulation with TLR agonists the native 
RAW 264.7 macrophage and the RAW 264.7 ALOX macrophage profiles were 
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dominated by COX products, namely PGD2. This again speaks to the importance of 
using whole bacteria to look at responses rather than individual components. 
Upon stimulation with MRSA, PGD2 was seen to be significantly increased compared 
to E. coli and Klebsiella treatments. Interestingly, levels of PGD2 detected during 
exposure to live bacteria were up to 60-fold lower than those seen upon stimulation 
with individual TLR agonists. This may suggest that synergy between receptors 
activated in the presence of whole, live bacteria decreases PGD2 generation. It may 
also be possible that the potent proinflammatory chemoattractant, PGD2, has a 
significantly faster rate of metabolism when initiating an immune response during 
exposure to live bacteria (Murata & Maehara 2016). This may be because after an 
initial proinflammatory response is mounted, PGD2 then undergoes rapid 
dehydration into PGs such as 15-deoxy-12,14-PGJ2, which have been suggested to 
exert anti-inflammatory effects (Shibata et al. 2002; Norris et al. 2011). This 
hypothesis is only true for Klebsiella-treated cells as they were the only group to 
show an increase in 15-deoxy-12,14-PGJ2 at 24 hours compared to PGD2. However, the 
quantities of 15-deoxy-12,14-PGJ2 were very small by comparison with conventional 
PGs (Bell-Parikh et al. 2003) and therefore may need to be detected using an 
alternative lipidomic method.  
 
Between the two Gram-negative bacteria, Klebsiella generated increased lipid 
detection compared to E. coli. This is interesting as the Klebsiella strain produces a 
capsule which one might expect to dampen innate responses due to inhibition of 
phagocytosis (Tomás et al. 2015). A possible explanation for this may be due to the 
heterogeneous lipopolysaccharide structures, which possess differences between 
and within bacterial species, in the length and position of the acyl chains in the lipid 
A portion of the lipopolysaccharide, the length and polarity of the polysaccharide tail, 
and the formation of supramolecular structures, (Lüderitz et al. 1984; Brandenburg 
1993). The differences detected between the responses of the Gram-negative 
bacteria suggest that the effect of interaction between the pathogen and the 
immune cells is not limited to just differences between Gram-positive and -negative 
bacteria but also incorporates differences between species within that group. These 
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results are interesting as they are the first steps in determining potential lipid 
signatures for specific bacterial infections.    
 
6.4.3 Proinflammatory cytokine generation following bacterial stimulation of RAW 
264.7 ALOX macrophages 
Bacterial stimulation of the cell initiates multiple changes, including gene expression 
and changes in protein levels (Leone et al. 2016). Cytokine expression is recognised 
as one of the early events following infection by a variety of pathogens (Kim et al. 
2007). It has been reported that cytokines, such as TNF-α, IL-1β and IL-6 are 
proinflammatory in vitro and in vivo (Feldmann et al. 1991). As well as looking for 
changes in eicosanoid generation, the induction of proinflammatory cytokines after 
a 24 hour treatment with live bacteria was also examined.      
 
The RAW 264.7 ALOX macrophages exposed to Gram-positive MRSA generated 
significantly increased expression of TNF-α, IL-1β and IL-6 compared to the Gram-
negative E. coli and Klebsiella treatments. Klebsiella also generated significantly 
increased levels of IL-6 compared to E. coli. These findings suggest that there are 
differences in host responses to pathogenic microorganisms and virulence 
mechanisms should be considered in the treatment of patients with bacterial 
infection (Abe et al. 2010). Overall cell stimulation with E. coli resulted in the lowest 
cytokine generation compared to the other bacteria, which may indicate that E. coli 
has a cytokine inhibitory response. 
 
Levels of TNF-α were shown to be increased compared to TLR agonist exposure in 
Chapter 5. Upon cell exposure to Gram-positive MRSA, levels of TNF-α detected were 
~4-fold more than those generated by the Gram-positive TLR agonists. Gram-
negative E. coli and Klebsiella generated levels that were similar or >2-fold greater, 
respectively, than those induced by the Gram-negative TLR agonists. This finding 
again suggest it is possible to establish a distinct pattern of response to different 
species of bacteria. It also further drives the idea of receptor synergy in the presence 
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of whole, live bacterial, emphasising the importance of using whole bacteria to 
generate a response (Tan et al. 2014). TNF-α is known to increase during 
inflammation and infection (Lv et al. 2014). Given that TNF-α generation was much 
higher than the other proinflammatory cytokines, with a significant difference 
between the Gram-positive and -negative bacteria, these results could indicate it is 
a possible marker to differentiate between bacterial infections.   
 
Interestingly, IL-6 generation showed levels of up to a 40-fold decrease when cells 
were stimulated with live bacteria compared to individual TLR agonists. IL-6 is 
induced by TNF-α, and appears in the circulation soon after the initial TNF-α response 
(Alexandraki & Palacio 2010). Therefore, it may be the case that increasing the time 
of exposure to greater than 24 hours would see an increase in IL-6 levels detected. 
This is possible as IL-6 has been seen to have a longer half-life than TNF-α and remains 
elevated in the presence of various diseases (Porter 1997; Alexandraki & Palacio 
2010). 
 
IL-1β and TNF-α are two cytokines primarily generated by activated macrophages in 
response to infection and injury (Dama et al. 1992). In this study, IL-1β was the lowest 
detected cytokine. Chapter 5 showed that IL-1β was below the limit of detection for 
the ELISA when cells were exposed to TLR agonists. These finding correlate with 
those seen by Dama et al., 1992, who looked at the cytokine levels of forty critically 
ill patients with documented infections and found that IL-1β was not detected in any 
patient serum samples.  
 
6.5  Conclusion 
MRSA, E. coli and Klebsiella are all important pathogens that can cause potentially 
lethal systemic infections of mammalian hosts. An important approach to dissect 
aspects of the infection process has been to characterise the interaction between 
these bacteria and cultured cells. This study investigated the consequences of co-
culture of RAW 264.7 ALOX macrophages with Gram-positive or -negative bacteria in 
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order to analyse the effects of eicosanoid and cytokines signalling molecules in 
response to this interaction.  
 
The results here suggest that there are distinctions not only between Gram-positive 
and -negative bacterial responses but also between species. Further investigation 
into these initial eicosanoids and cytokines profiles are required to improve and 
increase our understanding. This will require greater focus on factors such as specific 
pathogen assault and severity of trauma.  
 
Application of refined methodologies in lipidomics and other similar approaches are 
crucial to advance the understanding of the role of eicosanoids in health and disease 
(Dennis & Norris 2015). The immune response is a complex network. A key element 
in the survival rate in severe cases such as sepsis or bacterial meningitis is early 
therapy. Work here has initiated an investigation into the cytokine and eicosanoid 
storm that accompanies classic inflammation to provide a new insight into novel 
strategies for early detection of bacterial infection and inflammation. The next stage 
of this work would be to obtain patient samples with known infections to see if there 
is any correlation between the responses of infected patients and healthy individuals. 
The ability to now analyse over a hundred eicosanoids and fatty acids, alongside a 
handful of well-characterised cytokine responses, provides a wealth of possibilities 
for understanding the immune response to bacterial infections. This could prove to 
become an extremely valuable clinical tool to distinguish between bacterial 
infections to better inform physicians and aid with faster appropriate treatment 
ultimately leading to better clinical outcomes. 
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7 General discussion 
The work presented in this thesis has aimed to identify pathogen-specific signatures 
of eicosanoids and cytokines that may represent useful prognostic indicators of 
bacterial infection. This was done with a view to identifying bacteria-specific bio-
signatures which could be used to underpin the development of rapid diagnostics 
which would allow clinicians to administer the correct antibiotics for patients with 
bacterial infections at the earliest opportunity, therefore increasing positive patient 
outcomes and reducing antibiotic resistance. 
 
In order to understand the complex networks of eicosanoid metabolism and 
signalling at the physiological level, the examination of individual cell contributions 
is required, which can then be applied to whole tissues. Advanced lipidomics 
strategies can be used to exploit the cell-specific signalling of eicosanoid pathway 
enzymes in neutrophils, macrophages and other immune cells. The presence of 
specific leukocytes is commonly used as an indicator of disease and its severity. 
Determining lipidomic profiles can potentially be used in addition to cell-specific 
protein markers such as cytokines to create a more specific read-out of disease. The 
complexity of eicosanoid biosynthesis is characteristic of the dynamic expression and 
intracellular compartmentalisation of biosynthetic machinery, which is dependent 
on time, conditions and cell type (Dennis & Norris 2015). Creating predictive models 
of eicosanoid and cytokine signalling to bacterial infection can provide faster point 
of care treatment increasing the chances of positive therapeutic outcomes. 
 
The focus of this research was to employ a targeted lipidomic approach to investigate 
the profile of 5-LOX lipids from isolated human neutrophils when activated with each 
individual bacterial TLR agonist. The initial responses examined were those of 
primary human neutrophils, as they play a central role in the human immune 
response to infection. Earlier work carried out by Clark et al. 2011, identified that 
human neutrophils generated 5-HETE when exposed to various agonists including 
TLR1/2 and TLR4. Chapter 3 took this study a stage further by employing the whole 
array of bacterial TLR agonists to look at the neutrophil responses and establish 
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whether eicosanoid and cytokine responses varied between TLR components, with a 
view to determining which play a key role in early inflammatory signalling.  
 
Initial lipidomic methods used in Chapter 3 only looked for the 5-HETE transition, 
subsequent developments in methods during the course of the project meant that in 
later chapters (5 and 6) 110 transitions were observed. It was seen that the 
eicosanoid 5-HETE was generated upon stimulation of primary neutrophils with 
bacterial TLR agonists. The results indicated that components derived from different 
bacteria had varying effects on the neutrophil 5-LOX pathway, however, these were 
not statistically significant. This work also showed that all the TLR agonists induced 
neutrophils to secrete proinflammatory cytokines, supporting the concept that 
neutrophils form a link between the innate and adaptive immune systems as 
cytokines are mediators between various immune cells during an immune response.   
 
This body of work identified many factors that should be taken into consideration 
when interpreting data generated from isolated cells in an outbred human 
population. Namely, the diverse variability within the range of responses seen from 
individual donors following exposure of their neutrophils to TLR agonists. There are 
multiple factors that may have contributed to these innate immune differences seen 
across the host responses during treatment, including age, gender, diet, exercise, 
smoking status, any underlying comorbidities, circadian rhythm, stress and ethnicity. 
For example, in humans, one of the systems that responds to challenging 
circumstances is the immune system and several facets have been empirically 
associated with stress (Morey et al. 2016). During times of acute and chronic stress 
increases in blood levels of proinflammatory cytokines have been detected (Steptoe 
et al. 2007; Gouin et al. 2012). To try and overcome this, early morning blood draws 
were taken from donors as this was thought to be the least stressful time of day. 
However, this does not account for any underlying stresses they may be facing. 
Another study exploring the interaction of the host and pathogen factors on the 
innate immune response determined that both race/ethnicity and pathogen factors 
influenced the innate immune response (Nahid et al. 2018). This fuels the need to 
have access to donor characteristics, which may help explain the varied responses by 
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categorising the population used. Data presented in this thesis were obtained using 
a donor group that consisted of 20 volunteers. The retrospective power calculation 
for this study suggested that 724 donors would be needed to achieve a power of 80% 
to declare that the conditions have significantly different means. With such a limited 
group of donors used in this study, it is also not possible to speculate whether any 
outliers within the donor responses are in fact extreme outliers or are a genuine 
member of the population. This suggests that, as the donor cohort was extremely 
small, a much larger data set would need to be carried out to allow for the diverse 
variation between donors in a population and enable more significant comparisons 
between responses. 
 
Indeed, it is this diversity and the wide range of “normal” responses generated by 
the human race that represents the principal challenge when seeking to identify a 
specific response indicative of bacterial infection. Therefore, a limitation of this study 
was the small, undefined donor population cohort and a much larger pool of donors 
would need to be analysed to allow for the variability seen within a population. It is 
recognised that amendments to the ethics of the study would be beneficial to allow 
for collection of factors such as ethnicity, age and gender from donors and 
permission for these to be disclosed to enable them to be related to the responses 
seen. This is an important point as the human race is outbred and thus it would be 
expected to observe a wide range of responses. The challenge in terms of predicting 
infection is determining a ‘normal’ range. 
 
Primary scientific research with neutrophils presents a number of challenges due to 
their short half-life, tendency to become activated, and also their predisposition to 
spontaneously apoptose. This is coupled with donor variability in the number of 
neutrophils collected during a single blood draw; sometimes leading to inadequate 
amounts and therefore terminating subsequent experiments. All of these factors 
make conducting experiments to investigate the innate immune cell responses to 
infection challenging. As previously mentioned, however, their involvement in early 
inflammation and infection does make any advance in the understanding of their 
function very valuable, regardless of the magnitude.  
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In light of the issues surrounding the use of primary neutrophils, coupled with the 
need to markedly increase the donor cohort to account for the natural variation 
within the population, initial experiments lead to the employment of an 
immortalised cell line to characterise the responses to individual TLR agonists. Whilst 
going from primary human cells to an immortalised cell line is counterintuitive, it 
provided a more robust, reproducible model to look at the initial responses 
generated as they present with a homogenous genetic background, therefore 
eliminating this confounding factor seen using primary cells to gain an initial readout 
of responses to infection. It must be noted that cell lines may display fundamental 
differences compared to primary cells. This is due to their continuous growth in 
culture resulting in permanent alterations in their genes, which may have an effect 
on the signalling cascade (Hartley et al. 2008). However, the positives in this case 
outweigh the negatives, not only providing a better model, but also allowing faster 
establishment and optimisation for protocols that require large numbers of cells.    
 
As mentioned in Chapter 4, a possible model system for neutrophils is the human 
leukaemia cell line HL-60, which can be differentiated into neutrophil cell lines. 
However, conflicting data suggest that these differentiated cells are limited in their 
capacity to respond to stimuli such as formylated peptides, which also activate 
neutrophils, as seen in Chapter 3. For example, one study showed that fMLP has no 
effect on differentiated HL-60 cells in chemokinesis assays (Meyer & Howard 1987). 
Whilst another study found that fMLP induced chemotaxis in differentiated HL-60 
cells, but in much smaller numbers compared to neutrophils (Fontana et al. 1980). 
Therefore, the initial cell line used was the human THP-1 monocyte cell line. This 
myeloid cell line is the most widely employed to investigate the function and 
expression of primary human macrophages during disease (Lund et al. 2016). These 
cells were chosen as they could be differentiated into monocyte-derived 
macrophages, which work alongside neutrophils as first responders to infection, and 
are accepted as a model to study immune response because they closely resemble 
those of primary human macrophages. Alongside this, these cells were also reported 
to produce inflammatory markers in response to infectious and non-infectious 
disease.  
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As outlined in Chapter 1, macrophages express a large number of distinct TLRs, which 
when stimulated activates an eicosanoid response by distinctly different pathways. 
By employing an array of bacterial stimuli, it was anticipated that the macrophages 
would generate a number of different eicosanoid profiles in response to the TLR 
agonists with a view that they could indicate the presence of agonist-specific 
responses. Unlike using primary cells, seen in Chapter 3, this model eliminated the 
variability in donor responses due to the genetic background of the host and also 
enabled the use of a larger quantity of cells. 
 
Despite THP-1 cells being a widely accepted model for observing macrophage 
functions and responses to external stimulation in vitro, the first hurdle faced here 
was that there was no current standardised protocol for the differentiation of THP-1 
monocytes to macrophages using PMA. Through optimisation, cell differentiation 
was established and characterised through cell adhesion, however, the lack of a 
standardised protocol for differentiation would make it difficult to compare results 
between studies.  
The results in this chapter of work (Chapter 4) went on to show that PMA 
differentiated THP-1 monocyte-derived macrophages did not generate biologically 
relevant amounts of 15-HETE through the 15-LOX-enzyme pathway when exposed to 
the positive control calcium ionophore A23187. The anticipated quantity of lipid 
generated by calcium ionophore A23187 would be similar to that shown by Morgan 
et al., 2009, who demonstrated the formation of 12-HETE by murine macrophages in 
response to 10 µM A23187 to reach 12 ng/106 cells after 15 minutes stimulation. 
Calcium ionophore A23187 stimulus is routinely used in experimental conditions as 
a positive control to assess the maximal quantities of eicosanoids released from 
white blood cells, which is why it was selected to establish the overall capacity of 
THP-1 macrophages to release 15-HETE. However, the data did show calcium 
ionophore A23187 and LPS induced generation of proinflammatory cytokine TNF-α, 
IL-1β, IL-8 and IL-6. This confirmed that the cells had been activated, although the 
absence of 15-HETE generation by these cells supported the idea they were not a 
suitable macrophage model to carry forward and further explore eicosanoid 
responses to bacterial infection.  
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The use of a cell line was still considered advantageous over primary cells 
predominantly because they had a homogenous genetic background which 
minimises the degree of variability that can be seen in the cell phenotype, and they 
could also be generated in large quantities over a shorter period of time. For these 
reasons, an alternative macrophage cell line derived from mice was employed, RAW 
264.7. These cells represent an immortalized phenotype derived from peritoneal 
tumours induced in BALB/c male mice by the Abelson murine leukaemia virus (Norris 
& Dennis 2014). As mentioned in Chapter 5, the specific cells used had been 
developed by Professor Valerie O’Donnell’s Lipidomics Group at Cardiff University 
and were genetically engineered with the 12/15-LOX enzyme as native RAW 264.7 
macrophages do not possess the relevant enzymes to make these 12/15-LOX lipids. 
This cell line, known as RAW 264.7 ALOX macrophages, had been extensively 
characterised and were known to generate eicosanoids in response to stimuli and 
therefore represented a suitable model capable of generating 12/15-LOX-derived 
lipids to establish initial responses to TLR agonists and subsequently determine the 
profiles in response to whole, live bacteria.  
 
Work in this thesis showed the first ever measure of both lipids and cytokines 
generated from the same 12/15-LOX transfected RAW 264.7 murine macrophages 
exposed to an array of bacterial TLR agonists and live, pathogenic bacteria.  
Initially as a control cell type, RAW 264.7 Control macrophages were employed 
alongside the ALOX macrophages. This cell line had been engineered with an empty 
vector to determine if the vector alone played a part in the responses of these cells.  
Studies carried out by Buczynski et al., showed that when native RAW 264.7 
macrophages were stimulated with 16 different agonists, including TLR agonists, no 
significant differences were seen in the COX metabolite profiles. It was established 
that the RAW 264.7 Control cells behaved in the same way that Buczynski and 
colleagues demonstrated with the original RAW 264.7 cells when comparing their 
responses to TLR agonist exposure. Therefore, the RAW 264.7 Control cells are the 
same as the native RAW 264.7 cells.  
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As described in Chapter 5, the first part of the work carried out assessed the basal 
eicosanoid profile in RAW 264.7 Control and ALOX macrophages. As this is a murine 
cell line, 12-HETE was the lipid isoform generated by the 12/15-LOX enzyme and was 
used to measure its activity. Results showed that the RAW 264.7 Control 
macrophages generated basal levels of COX-derived lipids without the presence of 
any 12/15-LOX products. The profile of basal lipids detected in the RAW 264.7 
Control macrophages was also demonstrated in the native RAW cells by Buczynski et 
al. 2007. This confirmed that the insertion of the empty vector into the cells did not 
alter the lipid signalling and therefore the 12/15-LOX-derived lipids could be 
attributed to the expression of the 12/15-LOX enzyme.  
Subsequent analysis of basal lipid detection from RAW 264.7 ALOX macrophages 
showed that these cells significantly upregulated the generation of 12/15-LOX-
derived lipids compared to the RAW 264.7 Control macrophages, where no 12/15-
LOX-derived lipids were detected. There was also no significant difference seen in 
the detection of COX-derived lipid PGD2. These results were important as they 
confirmed that the transfected RAW 264.7 Control macrophages with the empty 
vector and the RAW 264.7 ALOX macrophages carrying the 12/15-LOX gene remain 
unaltered in terms of their innate lipid generation, as they behave the same as the 
standard RAW 264.7 cell line. 
 
Another control measure for the transfected cells was to compare the generation of 
proinflammatory cytokines, in response to TLR agonists and to whole bacteria, 
between the RAW 264.7 Control and ALOX macrophages. It was predicted that the 
profiles generated by the two cell lines would be comparable as the transfection 
shouldn’t alter the cytokine production. Interestingly, data presented in Chapter 5 
showed that upon TLR agonist exposure the RAW 264.7 Control macrophages 
generated cytokine levels that were between 50-100-fold less than those seen by the 
RAW 264.7 ALOX macrophages. It was speculated that a possible reason for this 
difference between the two cell lines may be that the LOX products generated by the 
RAW 264.7 ALOX cells could upregulate cytokine production compared to the RAW 
264.7 Control cells. However, a study by Berghaus et al. 2010, showed that original 
RAW 264.7 macrophages treated with TLR1/2 and TLR4 agonists generated cytokine 
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levels closer to values seen by the RAW 264.7 ALOX cells when treated with the same 
agonists. As the RAW 264.7 ALOX macrophages were closer in respones to the native 
RAW 264.7 cells and they had been seen to generate 12/15-LOX-derived lipids, it was 
justified that the RAW 264.7 ALOX macrophages could be used for all subsequent 
experiments to provide a suitable model similar to in vivo macrophages. 
Nevertheless, it is still noted that this set of data is an n of 1 and would need to be 
repeated in order to make further conclusions.  
Chapter 6 subsequently provided evidence that the cytokines generated by the RAW 
264.7 Control and ALOX cell types in response to whole bacteria did show a similar 
response to each other. The only significant difference between the two cell types 
was seen in TNF-α generation, upon treatment with MRSA. However, as these were 
such high levels compared to all other cytokine generation, and that both cell types 
gave similar levels of response for all of the other test conditions, it was again 
justified to employ the RAW 264.7 ALOX macrophages to determine cell responses 
to whole bacteria.       
 
Advanced methodologies developed within Professor Valerie O’Donnell’s Lipidomics 
Group enabled the application of a specifically designed method using a targeted 
lipidomics approach to analyse 110 eicosanoid and fatty acid transitions. Sample 
analysis saw 39 detectable analytes from the RAW 264.7 ALOX macrophages, and for 
the most part, the same eicosanoid profile was generated for the 6 bacterial agonists 
tested. The profiles seen were dominated by COX products, with PGD2 seen in the 
greatest amount, which was consistent with that demonstrated by Buczynski et al. 
2007. In the work presented in Chapter 6, the concentrations of TLR agonists used 
were based on the amounts seen to be used throughout other studies that were still 
within the optimal range indicated on the InvivoGen TLR agonist kit used (Buczynski 
et al. 2007; Clark et al. 2011; InvivoGen, Toulouse, France). It may be the case that 
carrying out a dose response for each TLR agonist, using a variety of concentrations 
within the appointed range to specifically identify the optimum concentration, e.g. 
the EC50, could prove to generate more comparative responses between cells.  
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Using this novel RAW 264.7 transfected cell line enabled me to generate an initial 
profile of mediators expressed when cells were exposed to different bacterial TLR 
agonists. However, no major differences were seen in the lipid and cytokine 
generation within these data sets when the RAW 264.7 ALOX cells were exposed to 
individual TLR agonists. Looking at the overall cell responses generated in response 
to the TLR agonists on the heatmap, it could be observed that the Gram-positive 
agonists TLR2 HKLM and TLR6/2 FSL displayed a higher abundance (change in the 
heatmap colour of intensity) of lipids compared to the other TLR agonists. However, 
when looking at the actual amounts generated these data didn’t appear to be 
suggestive of any substantial differences between the agonists.  
Other in vivo studies have demonstrated that macrophages yield different eicosanoid 
profiles during disease (Trebino et al. 2005; Wang et al. 2006; Ragolia et al. 2005). 
However, many of these profiles are determined looking at non-infectious diseases, 
therefore, it could be plausible that there aren’t distinct patterns generated during 
specific infectious insult. Notably, there are differences between the cells used in 
these studies such as the enviroment in which the in vivo macrophages differentiate 
is different to that of the RAW 264.7 cells, also the eicosanoid profile generated 
between human and mouse models are not directly comparable.  
It is also important to remember that TLR agonists represent only one bacterial 
component and in reality multiple factors will interlink in the presence of whole 
bacteria. This work showed that cell reponses to TLR agonists were alike and 
therefore it was not possible to distinguish between responses in this way. 
 
Alongside looking at eicosanoid release upon TLR agonist stimulation of RAW 264.7 
ALOX macrohages, the induction of proinflammatory cytokines was also examined. 
As cytokines have been extensively studied and characterised it was decided to select 
three of the most dominate cytokines during inflammation to look at in parallel to 
the eicosnaoind profile after 24 hour TLR agonist treatment of RAW 264.7 ALOX 
macrophages. Findings here showed that again there were no major differences seen 
in cytokine generation when the RAW 264.7 ALOX macrophages were exposed to 
individual TLR agonists. It may be possible that a longer time course of exposure is 
needed in order to see differences in cytokine generation between agonists or 
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combination treatment of several agonists at once is needed. However, experiments 
would need to be repeated in order to draw any further conclusions.   
 
Using the novel RAW 264.7 transfected cell line enabled the generation of an initial 
profile of mediator expression when cells were exposed to individual bacterial TLR 
components. Data indicated that it was not possible to identify profiles for individual 
TLR agonists. Another step to continue this work and further characterise the TLR 
agonists responses would be to expose the cells to combinations of the agonists, as 
during an infection multiple TLR agonists would be present at once. In fact, the 
presence of the whole bacteria during an infection would trigger a plethora of 
receptor-mediated responses in immune cells, as detailed in Chapter 1. To carry this 
investigation forward, it was decided that the natural next step was to expose the 
RAW 264.7 ALOX macrophages to whole, live bacteria, inevitably creating more 
pathophysiologically relevant conditions.  
 
Chapter 6 employed three highly pathogenic, clinically relevant strains of bacteria to 
determine if there are differences seen in the eicosanoid and cytokine signalling 
between species during infection. For a first look at these signalling profiles, it was 
important to pick multi-drug resistant and extremely virulent species in order to 
induce an immune response during a worst-case clinical scenario. The bacteria used 
were Gram-positive bacteria MRSA and Gram-negative bacteria E. coli and Klebsiella. 
Chapter 1 explains the differences within the cell wall that distinguish between the 
Gram-positive and -negative bacteria and how some of the unique components 
within the cell wall act as PAMPs that are recognised by receptors and activate the 
immune cells. 
 
Results showed that RAW 264.7 ALOX macrophages generated significantly different 
lipid and cytokine profiles when co-cultured with Gram-positive and Gram-negative 
bacteria. Overall, heatmap analysis showed Gram-positive MRSA had increased 
intracellular levels of lipids at 24 hour exposure compared to the Gram-negative 
bacteria E. coli and Klebsiella. These finding are interesting as they challenge data 
that suggest Gram-negative infections induce a greater inflammatory response 
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compared to Gram-positive infections (Abe et al. 2010). However, they do correlate 
with Chapter 5, which showed the Gram-positive TLR2 and TLR6/2 agonists, which 
are ligands present on MRSA, also had an increased level of lipids compared to the 
other TLRs. The possible reasons for the differences seen between the responses to 
the bacteria are discussed in more detail in Chapter 6.  
Chapter 5 also saw the lipid profiles generated upon cell treatment with the TLR 
agonists to be uniform in their pattern of response, differing only in their intensities. 
However, the profiles generated in response to cell stimulation with whole bacteria 
showed the profiles to be more distinct depending on the species used, indicating 
that the presence of whole bacteria may reveal defined lipid signatures. Again, this 
reinforces the point that a bacteria is the sum of its TLR agonists and other immune-
stimulatory factors.  
 
Data showed that MRSA had higher levels of lipids, some of which were significantly 
increased, after 1 hour exposure to the cells compared to the Gram-negative 
bacteria. For example, the 12/15-LOX-derived lipid, 12-HETE, was significantly 
increased with MRSA after one hour compared to E. coli-treated cells. However, 
Klebsiella-treated cells showed 12-HETE to be significantly increased at 24 hours 
bacterial exposure to the cells compared to MRSA and E. coli. The differences seen 
here represent a potential marker of infection that can not only distinguish between 
Gram-positive and -negative bacteria but also species within these classes. They also 
indicate that there may be a time-dependant factor for increases in production upon 
specific bacterial stimulation. Therefore, further studies could benefit from a longer 
time course of activation with several timepoint intervals in between. This would 
allow for a greater understanding into the generation and metabolism of the lipids 
during an infectious insult. It is also important to note that during an immune 
response cells are called to the sight of infection and generate signalling molecules. 
During this time cells are constantly replenished, sustaining the response, which is 
not the case in an in vitro model. Another point to note is that taking measurements 
at the earlier time points, such as 1 hour, are not feasible in a diseased state setting 
as the likelihood of recognising an infection at this time is unrealistic. It is however, 
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important to use such time points to gain an initial understanding of early signalling 
and how it changes over time.  
 
The importance of using whole bacteria was highlighted when comparing their 
generation of lipids and cytokines to that produced by TLR agonist stimulation. Data 
showed that 12-HETE, for example, was seen to increase >4- and 40-fold upon 
treatment with MRSA and Klebsiella, respectively, compared to TLR agonist 
exposure. Data also showed that TNF-α levels increased between 2-4-fold upon 
bacterial stimulation compared to the Gram-positive and -negative TLR agonists 
treatments. This is suggestive of a possible synergistic effect induced by several 
pathogenic elements in the presence of whole bacteria. 
Equally, the use of whole bacteria showed that upon stimulation with MRSA the COX-
derived lipid PGD2 was seen to be significantly increased compared to exposure to E. 
coli and Klebsiella treatments. Interestingly, levels of PGD2 detected during exposure 
to live bacteria were up to 60-fold lower than those seen upon stimulation with 
individual TLR agonists. This was also the case for the cytokine IL-6 which showed 
levels to be ~100-fold lower in bacteria-treated cells compared to the TLR agonists. 
These findings suggest that interactions between receptors activated in the presence 
of whole, live bacteria can lead to faster metabolism of mediators during an 
infectious insult. For examples, as suggested in Chapter 6, it may also be possible that 
the potent proinflammatory chemoattractant, PGD2, has a significantly faster rate of 
metabolism when initiating an immune response during exposure to live bacteria 
(Murata & Maehara 2016). This could be because PGD2 undergoes rapid dehydration 
into other PGs after an initial proinflammatory response is mounted. For IL-6, it may 
be that the time of exposure would need to be greater than 24 hours in order to see 
increased detection of IL-6 levels. This is because IL-6 is induced by TNF, and appears 
in circulation after the initial TNF response (Alexandraki & Palacio 2010). These data 
emphasise the significance of bacterial co-culture work compared to individual 
component analysis.       
 
Chapter 1 describes how eicosanoids are produced rapidly after the initiation of 
inflammation. They are not typically stored within cells but rather synthesised as 
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required and released by the cell by simple diffusion, driven by pH and the membrane 
potential to act in an autocrine or paracrine manor (Schuster 2002). Although 
considerable experimental effort has been expanded towards understanding 
mechanisms of eicosanoid synthesis and signalling, little attention has been paid to 
the mechanisms by which they traverse biological membranes (Schuster 2002). The 
data presented in this thesis show that upon examination, eicosanoid levels inside 
and outside the cell varied. Data showed elevated intracellular eicosanoid levels 
compared to the extracellular environment. For example, 12-HETE was only detected 
intracellularly at 1 hour and, surprisingly, not detected extracellularly in response to 
TLR agonist stimulation. It was also seen that 12-HETE was significantly increased 
intracellularly at 1 hour for MRSA, and 24 hours for E. coli and Klebsiella, compared 
to extracellular levels. It may be the case that the engineered RAW 264.7 ALOX 
macrophages retain these lipids inside the cell as they are not part of their normal 
processing and therefore lack the dedicated export pathways. This must be 
considered when assessing the data using this model as this would have an impact 
on the method used to assess inflammatory mediator profiles, be it with isolation of 
cells or more realistically in a patient setting from whole blood or plasma. Therefore, 
now that the infection model is established, and it is apparent that there are 
differences in profiles generated, the next step would be to employ primary human 
macrophages which should be able to release lipids and analyse their responses to 
whole bacteria.     
 
Work presented in Chapter 6 used refined methodologies to investigate the effect of 
co-culture of RAW 264.7 ALOX macrophages with highly pathogenic Gram-positive 
or -negative bacteria in order to analyse the effects of eicosanoid and cytokine 
signalling molecules in response to this interaction. Work here has taken the first 
step into investigating the eicosanoid and cytokine surge that accompanies classic 
inflammation to provide a new insight into novel strategies for early detection of 
bacterial infection and inflammation. It was apparent that the application of whole 
bacteria give differing mediator profiles not only between Gram-positive and -
negative bacteria but also between species within these classes and this warrants 
further studies.  
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7.1 Future work  
There are several lines of future research which could follow from the findings 
reported in this thesis. 
 
The buffy coat is the fraction of an anticoagulated blood sample that contains most 
of the white blood cells and platelets following density gradient centrifugation.  Using 
buffy coat is a means of obtaining human donors which can be used to isolate and 
culture primary human macrophages. Now that an established model of infection 
has been designed and implemented it can be applied to human macrophages to 
analyse the eicosanoid and cytokine profiles. The advantages of using buffy coats is 
that a large number of cells can be attained rapidly for use without the difficulty of 
recruiting individual donors. Using human cells also has the advantage of the data 
being more relatable to the human system and mechanisms of disease. Notably, the 
cells would have not been from a defined population and would not be genetically 
identical. Also, donor information would not be available when employing buffy 
coats from a bank and therefore may elude to similar issues raised when using 
primary human neutrophils in Chapter 3.         
 
The RAW 264.7 ALOX macrophages are an established cell line now confirmed to 
generate distinct profiles of signalling molecules under induced infection. Now that 
cell-specific signalling has been determined, a novel approach could be to use a 
mouse model to analyse the profiles generated in a whole system. This would involve 
using a wild type mouse, which inherently has the 12/15-LOX enzyme, and inducing 
bacterial infection. A 12/15-LOX knock-out mouse could be generated as a control. 
Employing a mouse model could shed light on the cell interactions of signalling during 
infection. Having the interaction of a whole system may cause the macrophages to 
release the lipids they generate into the extracellular environment as opposed to 
being kept within the cells, as seen with the RAW 264.7 ALOX cells. An advantage of 
using a mouse model where the whole system is involved will mean that responses 
can be sustained as cells would be continuously generating mediators in response to 
infection. This would allow for assessment of profiles over longer periods of time, 
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which is important as infectious agents may be present in the body for several days 
before symptoms of infection become apparent. Therefore, findings could ultimately 
allow for early detection and treatment of bacterial infections.        
 
Finally, the data in this thesis have provided evidence to show that profiles of 
eicosanoids and cytokines vary in response to infection. An additional step that could 
be looked at is using whole blood samples taken from patients with confirmed 
infection. Here, patient samples would be drawn, and cells could be isolated and/or 
whole blood used to analyse the signalling during a known infection. However, initial 
experiments would have to be run to make sure it is possible to isolate and analyse 
the required products using whole blood. With the appropriate ethics it may also be 
possible to gain access to patient records and correlate information (such as age, 
gender, comorbidities, ethnicity) to profiles seen. A disadvantage to using patient 
samples is that they may present with multiple comorbidities or infections at once. 
This would make it difficult to distinguish between individual profiles. In which case, 
the use of buffy coats would be more appealing as a first step and could be used as 
a model to look at infection with multiple bacteria at once. The use of patient 
samples also means that a healthy population of donors would need to be 
established. As previously mentioned it is the diversity and the broad range of 
‘normal’ responses produced by the outbred human race that represents the 
fundamental challenge when looking to identify a specific response indicative of 
infectious disease, as demonstrated by the aforementioned power calculation in 
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7.2 Conclusion 
The overall effects of eicosanoid and cytokine storms on host responses and survival 
are likely to be context-dependent, and further improvements in our understanding 
will require greater focus on factors such as age, diet, genetic variation and 
comorbidities, in addition to the specific pathogenic assault and severity of trauma. 
The refined application of lipidomics methodologies and similar approaches will be 
crucial to advance our understanding of the role of eicosanoids in health and disease. 
Work in this thesis has identified potential markers of bacterial infection, such as 12-
HETE, 14-HDOHE and TNF-α, which, along with future advances, could be used to 
develop novel strategies for clinicians, nurses and primary care staff to analyse 
patients suspected of bacterial infection at the bedside. Work here provides an 
insight of how the eicosanoid and cytokine storms are generated alongside each 
other to accompany classic inflammation during specific bacterial infection. The 
ability to distinguish between species of bacteria causing infection could prove 
invaluable, reducing the time taken to establish the cause of infection, ultimately 
leading to better patient outcomes. 
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Appendix lV. Participant information sheet. 
 
PARTICIPANT INFORMATION SHEET 
Name of Project: Eicosanoid and cytokine responses to bacterial infection 
 
Name of Researcher: Shayda Maleki-Toyserkani 
   School of Pharmacy & Pharmaceutical Sciences  
   Cardiff University 
   Redwood Building  
   King Edward Vll Avenue 
   Cardiff CF10 3NB 
 
Part 1 – Introduction 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through this information sheet with you and 
answer any questions you have. We suggest this should take about 10 minutes. Talk 
to others about the study if you wish.  
You are being asked to give blood samples of up to a 100 ml (20 teaspoons of blood). 
We need regular blood samples, but any help will be very useful; from just once to 
every few weeks (a maximum of 1000 ml may be donated each year).  
Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 of this information sheet gives you more detailed information about the 
conduct of the study. Ask us if there is anything that is not clear.  
What is the purpose of the study and why have I been invited?  
The group investigates how our immune defences in the blood (such as white blood 
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cells) protect us against invading micro-organisms. In this study, we use your blood 
samples to look at blood cells (such as neutrophils, monocytes or platelets) or other 
factors in the plasma – these blood components will then be mixed with bacteria or 
viruses (or related materials) and laboratory tests will be carried out. The 
investigations involve microscopy, immunological assays and biochemistry to study 
molecules on the surface of these cells, inside the cells and molecules released by the 
cells. If you wish to know more, full experimental details are available from the lead 
researcher. If you wish to see the results of this study, please request this and the lead 
researcher will provide you with them when the results are published.  
Do I have to take part?  
No. It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form 
(and you may have a copy). If you are a member of staff or a student at Cardiff 
University, your career or degree will not be affected by choosing not to participate. 
If you decide to take part you are still free to withdraw at any time and without giving 
a reason and without your legal rights being affected. If you have a concern about any 
aspect of this study, you should ask to speak to the researchers who will do their best 
to answer your questions (Contact Shayda Maleki-Toyserkani Maleki-
ToyserkaniSR@Cardiff.ac.uk). If you remain unhappy and wish to complain formally, 
you can do this. Details can be obtained from Cardiff Research Innovation and 
Enterprise Services,  029 2087 5834, 30-36 Newport Road Cardiff CF24 0DE.  
If you later withdraw your consent your tissue will not be used further in this study 
and will be destroyed according to locally approved practices. Any tissue, or results 
derived from the tissue, that has already been used prior to the withdrawal of consent 
will continue to be used in this study.  
Are there any risks?  
Blood samples will only be taken by trained phlebotomists or health care 
professionals, thereby minimising any risks. There may be minor irritation following 
blood donation, but this should pass after a few hours. There is a small risk that you 
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will faint during blood (reported as being 2%, but this is much lower in our experience) 
– we ask you to sit down during donation so that there is very little risk of injury after 
a faint.  
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision.  
Part 2 – Further details 
What will happen to me if I take part and what do I have to do? 
You are being requested to give blood samples for experiments in the laboratory. 
Once you have had time to read this information sheet and had answered to your 
satisfaction any questions that you might have, you will be asked to sign a consent 
form. At a later date, Shayda or a designated member of the laboratory team will 
contact you to arrange a donation. Times for donating a sample will be arranged with 
you personally and at your convenience. We will take blood in the Redwood building 
and this should not take more than 20 minutes.  
The volume of any single blood sample will be up to a max of 100 ml (20 teaspoons of 
blood). There will be a period of at least 2 weeks between requests for blood samples. 
A maximum of 1000 ml may be taken each year. This assumes that you are of average 
size and that you are not giving blood for any other reason. If you are under 65kg (10st 
3lb) and/or are under 168cm (5' 6") in height, we would use the National Blood 
Services Blood Volume Calculator to determine how much you can donate. 
http://www.blood.co.uk/giving-blood/who-can-give-blood/  
We request that if we have cells or material left after a planned experiment, you allow 
us to store this for subsequent use for this project. We also ask that we can store these 
samples after this study has ended, so we can repeat assays or for future projects 
relating to immune responses. There is a separate section of the consent form to 
indicate if you are happy that your tissue may be retained at the end of this study for 
up to 15 years for use in future research within the UK and abroad. Your tissue will 
not be sold. Any/all tissue will be supplied anonymously to researchers. The recipients 
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of the tissue will not be supplied with your name or any other identifiable information 
and will not be able to identify you from the tissue.  
Who can take part?  
We ask that you not give blood if you have consumed alcohol in the last 12 hours or if 
you are on any medication (you do not need to discuss what this medication might 
be). Please do not give blood if you have any health condition or disease, including 
anaemia. If you are under 65kg (10st 3lb) and are under 168cm (5' 6") in height, you 
might not be able to take part. You may refuse to give a blood sample at any time 
without giving a reason.  
What about confidentiality?  
All samples and data will be anonymised. To ensure you do not exceed the maximum 
donation volume, your name, date and volume of donation will be recorded in a 
password protected file accessible only to Shayda Maleki-Toyserkani and Dr Stephen 
Clark.  
We will not be performing any tests that could reveal information about your health 
and we will not be looking at any validated risk factors for disease (genetic or 
otherwise). It is very unlikely, but possible, that we might notice that someone has a 
very high or very low number of platelets or white cells or red cells. If this happened, 
we would let you know and suggest that you contact your GP for a blood count.  
What will happen to the results of the research study?  
If you wish to see the results of this study, they are available on request from the lead 
researcher. Ultimately, results of this research will be published as articles in peer-
reviewed scientific journals. If you are interested, the lead researcher will provide you 
with a copy of the manuscript. All results will be anonymous in any publication.  
If you have understood all the information above and wish to participate in this study, 
you will be asked to sign a CONSENT FORM. Thank you for considering taking part in 
this study and taking time to read this information sheet.  
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Appendix V. Consent form  




Name of Project: Eicosanoid Response to Infection in Sepsis 
 
Name of Researcher: Shayda Maleki-Toyserkani 
   School of Pharmacy & Pharmaceutical Sciences  
   Cardiff University 
   Redwood Building  
   King Edward Vll Avenue 
   Cardiff CF10 3NB 
 
Part A, The Current Project 
 
1. I confirm that I have read and understand the information sheet dated 1th June 
2015 (version 6) for the above study and have had the opportunity to ask 
questions and these have been answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason & without my legal rights being affected. 
 
3. I understand that, if I withdraw my consent, any tissue or results derived from 
the tissue that has already been used will continue to be used in this study.   
 
4. I confirm that as far as I am aware, I am healthy and have no underlying conditions. 
 
5. I agree to take part in the above study. 
  










You may contact me by email ____________________________________________  
to arrange a donation. 
 
______________________    ___________________ _____________________ 
Name of Participant     Date    Signature 
 
______________________    ___________________ _____________________ 
Name of person taking consent     Date    Signature 
(If different from researcher) 
 
 Shayda Maleki-Toyserkani        ___________________ _____________________ 




Part B, Future Use 
1. I agree that excess tissue can be stored for subsequent use for  
this project. 
2. I agree that excess tissue can be stored anonymously for up to 15 
 years for use in future research. 
 
 
